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1 Abstract 
Formins represent a protein family indispensable for many fundamental 
actin-dependent polarized processes including migration, vesicle trafficking, 
morphogenesis and cytokinesis (Faix and Grosse 2006). The hematopoietic 
lineage-restricted formin protein formin-like 1 (FMNL1) has been previously 
demonstrated to be overexpressed in chronic lymphocytic leukemia (CLL), 
other leukemias and lymphomas and in cell lines derived from solid tumors. In 
healthy tissue, it is almost exclusively expressed in hematopoietic cells. This 
restricted expression suggests FMNL1 to be an attractive target for novel 
immunotherapies in malignant and inflammatory diseases (Krackhardt, 
Witzens et al. 2002; Schuster, Busch et al. 2007). An allorestricted T-cell clone 
expressing a single defined T cell receptor recognizing a peptide derived from 
FMNL1 has been identified and showed potent antitumor activity against 
lymphoma and renal cell carcinoma cell lines, Epstein-Barr virus 
(EBV)-transformed B cells and primary tumor samples derived from patients 
with CLL (Schuster, Busch et al. 2007). However, the function and regulation of 
FMNL1 is recently not well understood which might be necessary for antigen 
validation. Previous work has shown involvement of FMNL1 in the 
reorientation of the microtubule organizing center (MTOC) towards the 
immunological synapse and cytotoxicity of T cells (Gomez, Kumar et al. 2007). 
In addition, the murine homologue FRL, which has 85% homology to the 
human counterpart, has been shown to be involved in cell adhesion and 
motility of macrophages as well as Fc receptor-mediated phagocytosis 
(Yayoshi-Yamamoto, Taniuchi et al. 2000; Seth, Otomo et al. 2006).  
 
The aim of this project is to investigate functional characteristics of FMNL1 for 
further validation of this protein as potential target for novel anti-tumor 
therapies. Moreover, we have identified a novel splice variant (FMNL1) 
containing an intron retention at the C-terminal end affecting the DAD and 
exhibiting a distinct membranous and cortical localization in diverse cell lines 
compared to the cytoplasma localization of other FMNL1 splice variants. 
Similar localization of FMNL1 was observed for a mutant lacking the DAD 
domain (FMNL1ΔDAD) indicating that deregulation of autoinhibition is 
effective in FMNL1which therefore represents a constitutively active form of 
FMNL1 potentially playing a role in cellular transformation. Both expression of 
FMNL1 and FMNL1ΔDAD could induce polarized non-apoptotic blebbing 
which is dependent on myosin, actin and tubulin integrity but independent of 
Src and ROCK activity. We have additionally confirmed FMNL1 as a 
myristoylated protein and identified the N-terminal myristoylation as an 
important regulatory tool for FMNL1 enabling fast and reversible membrane 
localization.
 
Moreover, FMNL1 located at the contractile ring and cortex of FMNL1 
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transfected mitotic cells and induced slightly accelerated cell proliferation. We 
have also observed colocalization of human endogenous FMNL1 with -tublin 
at the cortex and mitotic spindles of dividing T cells linking its role to mitosis 
and cell growth. FMNL1 could induce higher intracellular free calcium 
concentration suggesting its involvement in the calcium signaling pathway. 
 
Thus our results provide novel insights into the regulation and function of 
FMNL1 and point to its involvement in diverse polarized processes. The 
identification of interaction partners of FMNL1 in diverse hematopoietic-derived 
cells as well as the further characterization of splice variants will be highly 
interesting to identify key molecules regulating different FMNL1 functions 
potentially revealing possibilities for specific therapeutic interaction in 
malignant and inflammatory diseases. 
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1 Zusammenfassung  
 
Formine spielen eine wichtige Bedeutung bei der Regulierung polarisierter 
Aktin-gesteuerter Prozesse. Dies betrifft beispielsweise die Zellmigration, den 
Vesikeltransport, die Morphogenese und die Zytokinese (Faix und Grosse 
2006). In früheren Arbeiten konnte nachgewiesen werden, dass das Protein 
Formin-like 1 (FMNL1) in Zellen von Patienten mit chronischer lymphatischer 
Leukämie (CLL), anderen Leukämien und Lymphomen und in Zelllinien, die 
von soliden Tumoren stammen, überexprimiert wird. Im gesunden Gewebe 
wird es fast ausschließlich in hämatopoetischen Zellen exprimiert. Diese 
selektive Expression macht FMNL1 zu einem attraktiven Ziel für neuartige 
Immuntherapien bei malignen und entzündlichen Erkrankungen (Krackhardt, 
Witzens et al. 2002; Schuster, Busch et al. 2007). In Vorarbeiten der Gruppe 
wurde ein allorestringierter T-Zellklon mit einem definierten T-Zellrezeptor 
identifiziert, der ein Peptid von FMNL1 erkennt und eine starke 
Antitumor-Aktivität gegen Lymphom- und Nierenzellkarzinom-Zelllinien, 
Epstein-Barr-Virus (EBV)-transformierte B-Zellen und von CLL-Zellen zeigt 
(Schuster, Busch et al. 2007). Allerdings sind die Funktion und Regulation 
von FMNL1 – beide wichtig für die Validierung dieses Proteins als Antigen – 
noch nicht gut untersucht. Frühere Arbeiten haben eine Beteiligung von 
FMNL1 bei der Neuausrichtung des MTOC (Mikrotubulin-organisierendes 
Zentrum) in Richtung der immunologischen Synapse und zusätzlich bei der 
Zytotoxizität von T-Zellen beschrieben (Gomez, Kumar et al gezeigt. 2007). 
Darüber hinaus wurde gezeigt, dass das murine FRL, das zu 85% homolog 
zum menschlichen FMNL1 ist, an der Zelladhäsion und Motilität von 
Makrophagen sowie an der Fc-Rezeptor-vermittelten Phagozytose beteiligt 
ist (Yayoshi-Yamamoto, et al Taniuchi hat. 2000; Seth, Otomo et al. 2006).  
 
Das Ziel dieses Projekts war es, die Funktion von FMNL1 für die weitere 
Validierung dieses Proteins als mögliche Zielscheibe für neue 
Anti-Tumor-Therapien zu untersuchen. Wir haben eine neue Spleißvariante 
(FMNL1) identifiziert, die am C-terminalen Ende ein residuelles Intron 
aufweist, welches einen Einfluss auf die 
Diaphanous-autoinhibierende-Domäne (DAD) hat. Im Gegensatz zu anderen 
FMNL1-Spleißvarianten, die eine zytoplasmatischen Lokalisierung aufweisen, 
zeigt diese Speißvariante eine kortikale und membranständige Lokalisation in 
verschiedenen Zelllinien. Eine FMNL1 Mutante, bei der die DAD-Domäne 
fehlt (FMNL1ΔDAD), weist eine ähnliche Lokalisierung auf. Das weist darauf 
hin, dass es bei FMNL1 zu einer Deregulierung der Autoinhibition kommt, 
die zu einer konstitutiv aktiven Form von FMNL1 führt, die möglicherweise bei 
der zellulären Transformation eine Rolle spielen könnte. FMNL1 und 
FMNL1ΔDAD können eine polarisierte, nicht mit einer Apoptose-assoziierten 
Blasenbildung an der Membran hervorrufen, die von Myosin, Aktin und 
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Tubulin abhängig ist, aber unabhängig von Src und ROCK zu sein scheint. 
Wir haben außerdem nachgewiesen, dass FMNL1 als myristoyliertes Protein 
vorliegt und konnten zeigen, dass die N-terminale Myristoylierung wichtig für 
die Regulierung der Funktion von FMNL1 ist, indem sie eine schnelle und 
reversible Membran-Lokalisierung ermöglicht.  
 
Des Weiteren haben wir gezeigt, dass FMNL1, das auch am kontraktilen 
Ring und Kortex von FMNL1-transfizierten mitotischen Zellen lokalsiert ist, 
die Zellproliferation moderat verstärkt. Eine gemeinsame Lokalisierung von 
menschlichem endogenem FMNL1 und -Tubulin am Kortex und den 
mitotischenden Spindeln von sich teilenden T-Zellen weist ebenfalls auf eine 
Rolle von FMNL1 in der Mitose und dem Zellwachstum hin. Überexpression 
von FMNL1 konnte eine höhere Konzentration von intrazellulärem freiem 
Calcium nach Zell-Stimulation induzieren, was auf eine Beteiligung von 
FMNL1 am Calcium-Signalweg deutet.  
 
Unsere Ergebnisse eröffnen neue Einblicke in die Regulation und Funktion 
von FMNL1 und zeigen dessen Beteiligung an unterschiedlichen 
Polarisierungsprozessen. Die Identifizierung von Interaktionspartnern von 
FMNL1 in verschiedenen hämatopoetischen Zellen sowie die weitere 
funktionelle Charakterisierung der Spleißvarianten wird von besonderer 
Bedeutung sein, und möglicherweise zur Entwicklung einer spezifischen 
therapeutischen Beinflussung maligner und entzündlicher Erkrankungen 
beitragen. 
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2  Introduction 
 
2.1  Tumor antigens 
 
2.1.1  Identification of tumor antigens 
The immune system can respond to cancer cells by T cells recognizing tumor 
antigens (TA) on the cancer cells (Finn 2008). However, this mechanism 
remained in doubt until the development of methods for identifying and 
isolating tumor antigens. The first experimental evidence for the existence of 
human tumor antigens was obtained in the late 1960s, when it was found that 
lymphocytes from urinary bladder carcinomas patients other than from 
unrelated tumours patients or various normal tissues were cytotoxic for bladder 
carcinoma cells in vitro, and that serum of some patients contained antibodies 
specific to this tumor antigen (Bubenik, Perlmann et al. 1970). From then on, 
identifying potential tumor antigens has been essential in the progress towards 
the development of successful cancer immunotherapy (Graziano and Finn 
2005). 
 
Monoclonal antibodies derived from mice immunized with human tumors 
were used to detect potential human tumor antigens (Hellstrom, Hellstrom et 
al. 1982). However, it was not clear that if the human immune system could 
also recognize these tumor antigens identified by mice monoclonal antibodies 
(Finn 2008).  
 
Identification of tumor antigens by tumor-infiltrating lymphocytes (TILs) based 
methods 
A melanoma-specific antigen, MAGE-1, was the first human tumour antigen 
identified by being recognized in vitro by cytotoxic T cells derived from the 
tumor-bearing patient (van der Bruggen, Traversari et al. 1991), which proved 
that the human immune system could respond to tumor antigens. Furthermore, 
to identify the tumor antigens recognized by tumor-infiltrating lymphocytes 
(TILs), cDNA libraries prepared from tumor cells were transfected into target 
cells that expressed the appropriate major histocompatibility complex (MHC) 
molecule. These transfectants were then tested for their specific anti-tumor 
reactivity by using cytokine release or lysis by human T cells (Rosenberg 1996; 
Rosenberg 1999). Using this strategy, a number of tumor antigens from 
melanoma were successfully identified, such as MART-1, gp100, Tyrosinase, 
Tyrosinase-associated protein 1 (TRP1), p15 and Beta-Catenin (Rosenberg 
1996; Graziano and Finn 2005).  
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Identification of tumor antigens by biochemical methods 
By biochemical methods, peptides were eluted and fractionated from tumor 
cells or from MHC molecules purified from tumor cells and loaded onto 
antigen-presenting cells (APCs) to prime the tumor-reactive T cells. Fractions 
capable of inducing a T cell response are further analyzed using mass 
spectrometry (MS) analysis to identify the peptide sequence (Cox, Skipper et 
al. 1994). An alternative biochemical approach was performed without using 
known tumor-reactive T cells. After elution, peptides were analyzed by MS and 
tested for their ability to bind to MHC molecules. Peptides are identified 
depending on their natural processing and presentation on tumor cells, without 
known immunogenicity (Schirle, Keilholz et al. 2000). Although this approach 
allows for the rapid screening of large numbers of tumor genes, it is limited by 
the need of highly specialized equipment and the requirement of sufficient 
amounts of peptides present on the tumor cell surface (Rosenberg 1999; 
Graziano and Finn 2005). 
 
Identification of tumor antigens by dendritic cells (DCs) based method 
Tumor antigen proteins are broken down into small peptides by the 
proteasomes of normal and neoplastic cells. APCs could then present these 
peptides on the cell surface to cytotoxic CD8 T cells by MHC class I molecules. 
Dendritic cells (DC) are considered the most potent APCs, expressing high 
level of MHC molecules and costimulatory molecules, essential for capturing 
and presenting antigens to naive T cells (Banchereau, Briere et al. 2000).The 
biggest advantage of this approach is to load peptides extracted from tumors 
onto in vitro-generated DCs and prime naive T cells from healthy donors 
instead of T cell lines or clones from cancer patients. Peptides which 
successfully prime tumor-specific T cells have been sequenced in search for 
tumor-specific antigens. This approach has led to the identification of the tumor 
antigen cyclin B1 (Kao, Amoscato et al. 2001). Beside peptides derived from 
tumors, DCs could also be loaded with proteins or even whole tumor cells and 
prime T cells, mimicking what occurs in vivo (Finn 2008). This approach of 
identifying new tumor antigens is different from others which relied on the 
availability of T cell lines or clones from cancer patients. 
 
Identification of tumor antigens by serological analysis of recombinant cDNA 
expression libraries (SEREX) 
Another technique for the identification of tumor antigens which also does not 
dependent on the prior availability of antitumor T cells is based on the humoral 
immune response to an antigen. This approach is used by serological analysis 
of recombinant cDNA expression libraries, or SEREX. In this approach, a 
cDNA library is constructed from a fresh tumor specimen, packaged into a 
lambda-phage vector and expressed in E. coli. The recombinant proteins are 
transferred onto nitrocellulose membranes and screened for recognition by 
high-titer IgG antibodies present in the patient‟s serum. Any positive clones are 
2 Introduction 
                                                                           7 
subcloned further to monoclonality, and the sequence of the inserted cDNA is 
determined (Sahin, Tureci et al. 1997). Proteins recognized by antibodies in 
serum samples from patients with a particular tumor, and not from healthy 
controls, were tagged as candidate tumor antigens. This approach is based on 
the assumption that antibody production implies that a helper T cell reaction 
exists against the detected antigen (Rosenberg 1999). Several new tumor 
antigens were identified by SEREX, among which NY-ESO-1 is one of the 
most actively studied tumor antigens (Chen, Stockert et al. 1996). NY-ESO-1 
belongs to a family of cancer–testis antigens that are expressed by a variety of 
human tumors but not by any normal cells or tissues, except for the testis.  
 
2.1.2  Characterization of tumor antigens 
To date a number of tumor antigens have been identified through the 
previously described approaches. Among several criteria for selecting 
particular ones for clinical development, safety is of primary concern. It means 
the immune responses against tumor antigens would only destroy tumor cells 
but no normal cells (Finn 2008). Beside, the expression of tumor antigens 
should be present at the very earliest stages of tumorigenesis, or even during 
a pre-malignant stage. In addition to the primary tumor, a specific tumor 
antigen should be expressed on metastatic lesions in able to prevent 
metastatic growth and recurrence of the tumor after removing the primary 
tumor surgically (Graziano and Finn 2005). However, one important issue at 
least reagarding adoptive T cell therapies is the question if antigen expression 
correlates with peptide ligand presentation which seems not always to be the 
case (Weinzierl, Lemmel et al. 2007). 
 
Perfect target tumor antigens would be unique mutant antigens which are 
expressed in the malignant but not the normal cell type. An additional 
important feature of unique antigens is that the mutated protein may be crucial 
to the oncogenic process and indispensable for maintaining the neoplastic 
state or required for tumor cell survival. This kind of antigen would overcome 
the immunoselection, either by further mutation or loss of expression (Ho, 
Blattman et al. 2003; Parmiani, De Filippo et al. 2007). Moreover, since the 
majority of human tumor antigens described so far are self-proteins, mutant 
proteins which differ from normal self proteins have the advantage to 
potentially overcome peripheral tolerance (Theobald, Biggs et al. 1997). The 
first description of such a unique antigen was a human melanoma antigen, 
resulting from a point mutation of cyclin-dependent kinase (CDK4) in 1995 
(Wolfel, Hauer et al. 1995). After that, a series of tumor-specific mutant 
proteins have be identified which are encoded by oncogenes or suppressor 
genes that have undergone structural mutations resulting from point mutations 
(e.g: p21/ras mutations found in multiple malignancies), chromosomal 
translocations (e.g: BCR/ABL translocation in chronic myelogenous leukemia), 
internal deletions (e.g: the epidermal growth factor receptor gene deletion in 
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human primary brain tumor) and viral insertional mutagenesis (e.g: HPV 
proteins in cervical cancer and EBV proteins in Hodgkin‟s disease and 
nasopharyngeal carcinoma) (Urban and Schreiber 1992).  
 
However, most tumor antigens are nonmutated proteins which are over- 
expressed or aberrantly expressed by the tumor. These antigens are named 
tumor-associated antigens (TAA). Compared to tumor unique antigens, a large 
number of peptides from tumor associated antigens which are also produced 
from normal cells are much more successfully presented on the cell surface. 
That is the reason that the majority of tumor antigens identified as cytotoxic 
T-lymphocyte (CTL) targets in cancer patients are tumor associated antigen 
(Morris, Bendle et al. 2003). 
 
The tumor-associated antigens which are important for maintaining the 
malignant phenotype are considered as the second choice beside the unique 
tumor antigens. Because higher expression of such proteins in malignant cells 
than in normal tissues may make it possible for immune system to recognize 
and eliminate tumors while ignoring the low levels of antigen expressed by 
normal tissues. Overexpressed protein antigens associated with tumorigenicity 
include the WT1 (Wilms‟ tumor) gene in leukemias and various solid tumors as 
well as HER-2/neu in breast and ovarian cancer (Ho, Blattman et al. 2003). 
The cancer testis antigens, such as NY-ESO-1, which have unknown functions 
are expressed by a variety of human tumors such as ovarian cancer and 
melanoma but not by any normal tissues, except for the testis (Chen, Stockert 
et al. 1996). The melanoma antigen MAGE-1 also belongs to this category. 
The family of cancer testis antigens provides nearly unique potential target 
antigens. 
 
Many tumor-associated antigens are derived from malignant melanomas and 
have been found not only on melanomas but also on other tumor types. These 
normal, non-mutated genes are differentiation antigens which are limited to 
melanomas as well as melanocytes, the cell of origin of this tumor, and 
pigment-producing cells in retina (Rosenberg 1999). In this category, 
MART-1/MelanA antigen which have an unknown function are targets of 
tumor-reactive T cells in melanoma patients (Coulie, Brichard et al. 1994). 
gp100 antigen encodes an enzyme involved in melatonin synthesis (Kawakami, 
Eliyahu et al. 1994) and tyrosinase is an enzyme critical for the synthesis of 
melatonin (Brichard, Van Pel et al. 1993). 
 
In conclusion, the classification of tumor antigens was reviewed by Daniel F. 
Graziano and Olivera J. Finn as follows: 
 
1. Cancer testis antigens: These antigens are expressed only in tumors and 
germ cells of the testes. This group includes a large number of MAGE antigens, 
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GAGE and the more recently discovered NY-ESO-1. 
2. Melanocyte differentiation antigens: This group of antigens is expressed 
during melanocyte differentiation, in normal melanocytes and in melanomas. 
Included in this group are MART-1/MelanA, tyrosinase and gp100. 
3. Tumor-specific mutated gene products: This group includes antigens that 
are products of mutated normal genes. These mutations are usually 
responsible for oncogenic properties of the tumor cell. CDK-4, β-catenin, 
MUM-1, mutated p53 and ras (H- and K-ras) all belong to this group. 
4. Overexpressed or widely expressed self-antigens: This class of TA is 
encoded by genes that are widely expressed in normal tissues but are also 
selectively expressed on tumor cells. This group includes PRAME, SART-1, 
P15, wild type p53, MUC1, cyclin B1, Her2-neu and CEA. 
5. Viral antigens. Examples are the products of the E6 and E7 genes of the 
human papillomavirus and EBNA-1, the Epstein–Barr virus nuclear antigen. 
 
2.1.3  Cancer immunotherapies based on tumor antigens 
To date, continuous efforts have been made to improve the conventional 
cancer therapy such as chemotherapy and radiotherapy to obtain a long-term 
eradication of tumour cells without any side effects. However, the conventional 
approaches are limited by both their lack of specificity and toxicity (Morris, 
Bendle et al. 2003). The development of immunotherapies based on the 
identification of tumor antigens has supplied a promise option of cancer 
therapy (Rosenberg 1995). Cancer immunotherapies can be categorized as 
passive and active approaches. In passive immunotherapy, immune cells or 
monoclonal antibodies with anti-tumor abilities are generated and adoptively 
transferred to the patients. In active immunizations, patients are directly 
immunized the with the therapeutic cancer vaccines which could induce 
endogenous immune responses against tumors (Rosenberg 1996). 
 
Passive immunotherapy: 
After the development of monoclonal antibodies in 1975, monoclonal 
antibodies against cancer cells have been investigated as an immunotherapy 
(Chapman 2004). The infusion of manufactured monoclonal antibodies can 
generate an immediate immune response which is independent of MHC 
molecules restriction bypassing many of the limitations that impede 
endogenous immunity. However, the lack of monoclonal antibodies to 
penetrate tissues and the extracellular matrix to reach their target cells limits 
the efficiency of the treatment, especially for solid tumors which are 
characterized by heterogeneous and tortuous vasculature, high interstitial fluid 
pressure and high viscosity of the tumour blood supply. (Chames, Van 
Regenmortel et al. 2009). Therefore, although melanoma antigens were the 
first targets chosen by investigators, most successfully developed 
immunotherapeutic monoclonal antibodies are against haematological 
antigens and surface antigens or tumor mediator of other types of tumors. For 
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example, alemtuzumab anti-CD52 for CLL, gemtuzumab anti-CD33 for AML, 
rituximab anti-CD20 for B-cell lymphoma, More recently, antibodies are more 
successful also in solid tumors as trastuzumab anti-HER2/neu for breast 
cancer, cetuximab anti-epidermal growth factor receptor for colon cancer and 
bevacizumab anti-vascular endothelial growth factor for colon cancer (Adams 
and Weiner 2005).  
 
Another passive cancer immunotherapy is based on the tumor-specific T-cell 
responses which have several advantages over monoclonal antibody therapy. 
Specific T cells can penetrate the tissue barriers and home in to 
antigen-expressing tumors despite of their location. In addition, T cells can 
continue to proliferate in response to tumor antigens until all the tumour cells 
are eradicated. Moreover, memorial T cells with specificity for tumor antigens 
can be generated in able to eliminate antigen-bearing tumors when they 
relapse (Disis, Bernhard et al. 2009). However, there are also some 
drawbacks of T-cell immunotherapy such as the restriction of MHC molecules 
and undesirable toxicity induced by unspecific reaction. Furthermore, the 
majority of T cell-recognized tumour antigens in humans are encoded by 
genes that are also present in normal tissues. Low levels of gene expression in 
normal cells can lead to the inactivation of high avidity T cells by 
immunological tolerance mechanisms. 
 
Recently, a number of novel approaches have been developed to circumvent 
the tolerance mechanisms to generate high-avidity cytotoxic T cells or 
monoclonal antibodies specific for tumour-associated antigens (Figure 2.1). 
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Figure 2.1 Novel approaches for the generation of high-avidity CTL specific for 
tumor-associated antigens. (a) and (b) take advantage of the TCR repertoire of 
healthy individuals or transgenic mice that are not tolerant to A2-presented peptide 
epitopes of tumor-associated antigens. (c) and (d) take advantage of in vitro 
mutagenesis and selection of high affinity TCRs (c) or high-affinity single chain 
antibodies specific for the peptide/HLA combination. (e) Strategies to transfer high 
avidity HLA-restricted receptors into patient T cells or stem cells to produce 
tumor-reactive T cells. (Morris, Bendle et al. 2003) 
 
A tumor associated antigen, p53, has been reported to be an attractive 
immunotherapy target, because it is only expressed in normal tissues of low 
amounts. However, p53 turns may be not suitable to be targeted by 
immunotherapeutic approaches since the low expression of p53 in normal 
cells could still sufficiently stimulate T cells activation (Theoret, Cohen et al. 
2008). Therefore, the functional characterizations of tumor antigens which are 
selected as targets are critical for the development of cancer immunotherapy. 
 
Active immunotherapy: 
The active immunotherapy refers to cancer therapeutic vaccines which could 
elicit or boost similar tumor antibodies and T cells in the patients other than 
infusion of antibodies or T cells (Finn 2008). These strategies are usually 
directed against tumor associated antigens, or against an unidentified number 
of antigens such as whole tumour cells, cell lysates or heat shock proteins and 
RNA isolated from tumour cells. Although vaccines based on multiple 
unidentified antigens have shown promise in the experimental setting, it is 
difficult to monitor vaccine-induced immune responses without knowing the 
specific target antigens (Morris, Bendle et al. 2003). The progressive 
improvement of vaccines is more probable with defined antigens, including 
immunodominant peptides, peptides modified to increase immunogenicity, 
proteins, "naked" DNA encoding cancer antigens, antigen-presenting cells 
expressing the antigen or recombinant viruses or bacteria containing the 
genes encoding tumor antigens (Rosenberg 1996; Morris, Bendle et al. 2003). 
Some examples are vaccines against breast cancer (the HER2 antigen), B-cell 
lymphoma (the tumor immunoglobulin idiotype), lung cancer (the MUC1 
antigen), melanoma (dendritic cells loaded with tumor peptides or killed tumor 
cells), pancreatic cancer (telomerase peptides), and prostate cancer (dendritic 
cells loaded with prostatic acid phosphatase).  
 
A predominant limiting factor of therapeutic vaccines is the 
immunosuppressive microenvironment both during the induction of immunity 
and in the effector phase of the response. One approach to improve the 
induction phase is by using antibodies against a negative regulator of the 
activation of effector T cells named cytotoxic T-lymphocyte–associated antigen 
4 (CTLA-4) (Korman, Peggs et al. 2006; Ribas, Hanson et al. 2007). 
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Unfortunately, the enhancing tumor immunity induced by anti-CTLA 4 antibody 
is accompanied by serious autoimmunity. Combination of therapeutic vaccine 
with chemotherapy could also induce the synergistic action of immunotherapy 
probably because of the elimination of regulatory T cells by chemotherapy 
(Emens and Jaffee 2005).  
 
2.2  FMNL1 as a tumor associated antigens 
 
2.2.1  Identification of FMNL1 
The formin-like 1 (FMNL1) protein is a lymphoma-associated antigen identified 
by using the SEREX approach in patients with chronic lymphocytic leukemia 
(CLL) (Krackhardt, Witzens et al. 2002). It belongs to the formin protein family 
indispensable for many fundamental actin-dependent processes including 
migration, endocytosis, vesicle trafficking, morphogenesis and cytokinesis 
(Faix and Grosse 2006). FMNL1 is restrictedly expressed in 
hematopoietic-lineage derived cells and overexpressed in malignant cells of 
different origins (Figure 2.2). Detailed expression analysis was performed on 
mRNA level. FMNL1 is most highly expressed in peripheral blood leukocytes 
(PBL) and seldom expressed in normal tissues with the exception of bone 
marrow, thymus and lung where hematopoietic cells accumulate. Moreover, 
FMNL1 expression is up-regulated in PBLs derived from patient with CLL and 
acute leukemia. This restricted expression suggests FMNL1 to be an attractive 
target for novel immunotherapies in malignant and inflammatory diseases 
(Krackhardt, Witzens et al. 2002; Schuster, Busch et al. 2007). 
 
However, function and regulation of FMNL1 is less well characterized. 
Previous work has shown involvement of FMNL1 in the reorientation of the 
microtubule organizing center (MTOC) towards the immunological synapse 
and cytotoxicity of T cells (Gomez, Kumar et al. 2007). It demonstrated a 
fringe-like localization of FMNL1 at the leading edge of the lamellipod in 
spreading T cells. This FMNL1 accumulation was also apparent at the edge of 
F-actin structures, which formed during APC recognition, along with a distinct, 
„„ring-like‟‟ localization of FMNL1 around the centrosome within the T cell. 
Moreover, this FMNL1 ring reoriented along with the MTOC to face stimulating 
APCs and regulate centrosome polarization in T cell as the absence of FMNL1 
negatively effects MTOC polarization and cytotoxic T cell function. Additionally, 
the murine homologue FRL, which has 85% homology to the human 
counterpart, has been shown to be involved in cell adhesion and motility of 
macrophages as well as Fc receptor-mediated phagocytosis 
(Yayoshi-Yamamoto, Taniuchi et al. 2000; Seth, Otomo et al. 2006).  
 
 
2 Introduction 
                                                                           13 
 
 
Figure 2.2 Expression of FMNL1 in normal and malignant tissue. (a) Relative 
quantitative mRNA expression of FMNL1 in different tissues pooled from different 
healthy donors was measured using quantitative real-time PCR. The relative 
quantitative expression compared to skeletal muscle was calculated using the 
delta-delta Ct method. (b) Relative quantitative mRNA expression of FMNL1 in CLL 
samples and tumor cells derived from patients with acute B- and T-ALL as well as 
AML is shown in comparison to normal PBMC. 
 
2.2.2  Formin protein family 
Formin proteins are a widely expressed family of proteins, generally more than 
1000 amino acids in size, and contain a series of domains and functional 
motifs which associate with a variety of other cellular proteins. Formins are 
defined by a unique and highly conserved C-terminal formin homology (FH) 2 
domain containing around 400 amino residues that mediates the actin 
assembly (Higgs 2005; Faix and Grosse 2006; Goode and Eck 2007). 
Bioinformatics studies show that eukaryotic species have multiple formin 
genes, including S. cerevisiae (2 formins), S. pombe (3 formins), Drosophila 
melangastor (6 formins), Caenorhabditis elegans (6 formins), Dictyostelium 
discoideum (10 formins), and mammals (15 formins) (Higgs and Peterson 
2005; Rivero, Muramoto et al. 2005). Phylogenetic analyses of the FH2 
domain have led to the classification of the 15 mammalian formin genes into 
seven group (Higgs and Peterson 2005): 
 
1. the Diaphanous formins (Dia1); 
2. the formin-related proteins identified in leucocytes (FRL1); 
(a) (b) 
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3. the disheveled-associated activators of morphogenesis (DAAM1); 
4. Delphilin (Delphilin); 
5. the “inverted” formins (INF1); 
6. the formin homology domain containing proteins (FHOD); 
7. the original “namesake” formins (FMN). 
 
Most eukaryotes have multiple formin isoforms, suggesting diverse cellular 
roles. The FH2 core domain and the intervening linker region between the FH1 
and FH2 domains are necessary and sufficient to nucleate actin polymerization 
from G-actin in vitro (Pruyne, Evangelista et al. 2002; Kovar, Kuhn et al. 2003). 
Before FH2 domain is a proline-rich FH1 domain which binds with low 
micromolar affinity to profilin (Evangelista, Blundell et al. 1997; Watanabe, 
Madaule et al. 1997). 
 
Figure 2.3 Filament polymerization by actin assembly factors. (a) Actin filaments 
are polar structures, with the barbed end (B) being the only site of elongation in 
non-muscle cells. (b) The Arp2/3 complex (multi-coloured) nucleates a new filament 
from the side of an existing filament. The Arp2/3 complex remains at the branch point 
between the pointed end of the new filament and the side of the existing filament. 
Repeated branching results in the assembly of a dendritic network. The formin FH2 
domain (semi-circles) nucleates a filament, and then moves processively with the 
barbed end as it elongates. Some formins can also bundle filaments. Spire (circles 
with black connectors) nucleates a filament by stabilizing a longitudinal tetramer and 
dissociates from filaments soon after nucleation. (Chhabra and Higgs 2007) 
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Eukaryotic cells nucleate actin filaments from a large pool of monomeric actin 
bound to profilin in order to elicit temporal and spatial remodeling of the actin 
cytoskeleton. This process underlies several cellular functions such as the 
establishment of cell shape, cytokinesis, or cell motility (Faix and Grosse 2006). 
The actin filament is a polar structure with a „barbed‟ and a „pointed‟ end, since 
all the actin subunits face the same direction. Monomers can add to or 
depolymerize from either end, but both processes are much more efficient at 
the barbed end (Goode and Eck 2007). The step to assemble dimeric and 
trimeric actin complexes limits the rate of actin filament nucleation. So far, 
three major classes of actin nucleators are known to nucleate actin filaments in 
vivo: the Arp2/3 complex, Spire, and the formin-homology proteins with 
different mechanisms to accomplish their tasks (Figure 2.3).  
 
The first identified actin nucleator was the Arp2/3 complex, which binds to the 
side of pre-existing actin filaments, and nucleates a branched filament 
structure with an angle of 70° between the filaments. The Arp2/3 complex 
remains at the branch point between two filaments. Repeated branching leads 
to a „dendritic network‟. Therefore, the Arp2/3 complex functions not only as a 
nucleation factor, but also provides structure to the network. Spire nucleates 
the assembly of unbranched actin filaments and, like the Arp2/3 complex, 
remains bound to the pointed ends of the nucleated filaments. Pointed-end 
nucleators, such as Arp2/3 and Spire, will experience only limited growth 
before being capped at their barbed ends by capping proteins (Faix and 
Grosse 2006; Chhabra and Higgs 2007). 
 
Formins were identified more recently as an additional family of actin assembly 
factors. All formins studied to date are dimeric because of their FH2 domain, 
which initiates actin filament assembly and remains persistently associated 
with the fast-growing barbed end, enabling rapid insertion of actin subunits 
while protecting the end from capping proteins (Higgs 2005). Central function 
of FH2 domain is to nucleate new actin filaments through binding tightly to the 
barbed end of the filaments with low nanomolar affinity (Moseley, Sagot et al. 
2004). Meanwhile, the FH2 domain moves processively with this elongating 
actin filament barbed end. It means, the FH2 domain remains contacting with 
actin filaments barbed ends when adding new actin monomers without 
dissociation and reassociation. Related to processive barbed-end movement, 
FH2 domains antagonize the effects of barbed-end capping proteins which 
could completely block monomer addition to barbed ends. Therefore, the 
barbed ends of actin filaments retain the ability to elongate even in the 
presence of capping protein (Higgs 2005). Formin-mediated elongation is 
further enhanced by the association of profilin with the FH1 domain of formin. 
The adjacent FH1 domain recruits profilin-actin complexes and accelerates 
filament elongation. The profilin–actin complex participates in actin assembly 
at the barbed end as fast as free actin monomers do, whereas profilin 
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interferes with actin nucleation. Normally, free actin monomers exist only at a 
submicromolar concentration in cells, and thus profilin prevents spontaneous 
actin nucleation while it allows fast actin elongation (Watanabe and Higashida 
2004). 
 
Vavylonis et al. suggested a model of formin-associated actin filament 
elongation. They assumed that FH1 domains capture profilin-actin complex 
from the bulk solution and transfer the captured subunit to the barbed end of 
the filament (Figure 2.4a). The FH1 domains vary in the length and number of 
proline-rich stretches, separated by proline-poor „„linker‟‟ stretches. Both of 
them serve as the profilin binding sites but differ in affinity. If the profilin binding 
sites were immobile at fixed locations relative to the barbed end, an actin unit 
would be released and to diffuse to the barbed end. Otomo et al. proposed that 
the FH2 dimer exists in equilibrium between two states (Figure 2.4b): the 
closed (or blocked) configuration that prevents polymerization and the open (or 
accessible) state that allows actin subunit addition. The transition from the 
closed to the open state involves movement of the FH2 dimer toward the 
barbed end (Otomo, Tomchick et al. 2005; Vavylonis, Kovar et al. 2006). 
 
 
 
 
Figure 2.4 Model of actin filament growth mediated by formin dimer. FH2 
domains (red) are shown as a dimer encircling the barbed end of the filament (blue). 
The FH1 domain (black, green) is shown unstructured with three profilin binding sites 
(green). (a) FH1-mediated polymerization: (1) assembly of profilin-actin to FH1; (2) 
transfer of actin from FH1 to the barbed end; (3) detachment of profilin. (b) 
Mechanism of FH2 processivity: FH2 in states preventing or allowing actin subunit 
incorporation. (Otomo, Tomchick et al. 2005) 
 
2.2.3  Diaphanous-related formins (DRFs)  
In a conserved and widely expressed subfamily of formins known as 
(a) 
(b) 
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Diaphanous-related formins (DRFs), the FH1 and FH2 domains are flanked by 
an array of regulatory domains at the N-terminus and by a single C-terminal 
Diaphanous autoregulatory domain (DAD) (Alberts 2001). The large N-terminal 
regulatory region includes the GTPase binding domain (GBD) followed by an 
adjacent Diaphanous-inhibitory domain (DID) and a dimerization domain (DD) 
(Rose, Weyand et al. 2005; Faix and Grosse 2006; Nezami, Poy et al. 2006) 
(Figure 2.5a). In the basal state, DRFs exist as autoinhibited proteins via 
intramolecular interactions between DID and DAD (Figure 2.5b) (Alberts, 2001; 
Li and Higgs, 2003; Watanabe et al., 1999). As revealed by the mDia1 crystal 
structure, the DID domain is composed of five armadillo repeats, a structural 
motif of three helices arrayed in a superhelical coil. The DAD polypeptide binds 
along the entire length of the domain, roughly perpendicular to the B helices, 
and establishes an extensive interface through numerous mainly hydrophobic 
contacts (Figure 2.5c) (Otomo, Otomo et al. 2005; Rose, Weyand et al. 2005; 
Nezami, Poy et al. 2006).  
 
 
 
Figure 2.5 Domain organization and molecular regulation of diaphanous- 
related formins. (a) Schematic representation of the domain organization of a 
representative DRF. GBD: GTPase binding domain; DID: Diaphanous-inhibitory 
(a) 
(b) 
(c) 
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domain; DD: dimerization domain; CC: coiled coil; FH1: formin homology 1 domain; 
FH2: formin homology 2 domain; FH3: formin homology 3 domain; ARR: 
armadillo-repeat region. Based on its structure, DID is also referred to as ARR. (b) 
Autoinhibition of DRFs caused by the interaction of DAD with DID is relieved by 
binding a Rho GTPase to GBD, which releases DAD and lead to a partial activation of 
the DRF. An unknown additional signal(s) is required to fully activate the DRF. (c) 
Ribbon diagram showing the overall structure of the DID/DAD complex. The DID 
domain is shown in blue, and the DAD domain is shown in yellow. The B helices of 
armadillo repeats 1–5 are labeled from left to right, and the N and C termini of the 
DAD domain are indicated. (Faix and Grosse 2006; Nezami, Poy et al. 2006) 
 
This autoinhibition is relieved after binding of an active Rho GTPase to the 
GBD domain. The binding induces displacement of the DAD, because the 
GTPase binds to the GBD/DID fragment more tightly than does the DAD 
segment (Faix and Grosse 2006; Nezami, Poy et al. 2006). The mammalian 
diaphanous 1 (Dia1) as well as the macrophage-enriched murine Formin-like 
protein 1 (FRL) are both regulated by autoinhibition in a DAD-dependent 
manner (Yayoshi-Yamamoto, Taniuchi et al. 2000; Li and Higgs 2003; Harris, Li 
et al. 2004; Seth, Otomo et al. 2006).  
 
In addition to the domain specific functions, formin proteins seem to be 
intensively regulated by splicing. Splicing at the N-terminus of human Dia2 has 
been demonstrated to be involved in a novel signal transduction pathway, in 
which hDia2C and c-Src are sequentially activated by RhoD to regulate the 
motility of early endosomes through interactions with the actin cytoskeleton 
(Gasman, Kalaidzidis et al. 2003). The DAD domain is also a hotspot of 
splicing. Within this area, two splice variants have been characterized for FRL 
although functional differences have not been observed (Harris, Li et al. 2004). 
In contrast, abrogation of autoinhibition in mutants lacking the C-terminal end 
in Dia1 and FRL specifically induces peripheral and plasma membrane 
localization (Seth, Otomo et al. 2006; Copeland, Green et al. 2007). The exact 
mechanism how DRFs locate to the plasma membrane is, however, currently 
unknown.  
 
2.3  Non-Hodgkin's lymphoma (NHL)  
FMNL1 has been reported as a tumor-associated antigen in chronic 
lymphocytic leukemia and overexpressed in various lymphomas (Krackhardt 
et al, 2002b, Schuster et al, 2007). Malignant lymphoma is a group of 
malignant neoplasms characterized by accumulation of cells native to the 
lymphoid tissues, such as lymphocytes, histiocytes, and their precursors and 
derivatives. The group is divided into two major categories: Hodgkin disease 
(HD) and non-Hodgkin lymphoma (NHL), with subtypes, classified according 
to predominant cell type and degree of differentiation. Hodgkin's disease was 
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named after Thomas Hodgkin, who first described abnormalities in the lymph 
system in 1832. It has a histological feature of the Reed-Sternberg giant cells, 
which emerge from the so-called Hodgkin cells. Non-Hodgkin's lymphomas 
are defined by the absence of these giant cells of Hodgkin's lymphoma. The 
NHL is a group of malignant clonal neoplasms, originating from the B-(80 to 
85% of cases) or T-lymphocytes (15 to 20% of cases). They arise from 
different lymphoid components of the immune system (Kuppers 2009). One 
widely used classification is based on two criteria: cytologic characteristics of 
the constituent cells and type of cell growth pattern (defined as either follicular 
or diffuse). Another system of classification is based on the cell type of origin: 
T- or B-lymphocytes or histiocytes. FMNL1 has been demonstrated to be 
expressed in all these subtypes of NHL as follicular NHL, diffuse large B cell 
NHL and T cell NHL, and most highly expressed in T cell NHL (Favaro, Traina 
et al. 2006) although partially at low levels. The most recent lymphoma 
classifications, the 1994 Revised European-American Lymphoma (REAL) 
classification and the 2001 WHO classification, abandoned the HD vs. NHL 
grouping. Instead, 43 different forms of lymphoma are listed and discussed 
separately. 
 
2.3.1  Chronic lymphocytic leukemia (CLL)  
Chronic lymphocytic leukemia is the most frequent leukemia in adults in 
western countries, accounting for 25% of all leukemias, but fewer than 5% of 
the cases in the eastern hemisphere (Kalil and Cheson 1999). It is 
characterized by the clonal proliferation and accumulation of neoplastic B 
lymphocytes in the blood, bone marrow, lymph nodes, and spleen. The normal 
counterpart of CLL cells is a subpopulation of mature CD5+ B lymphocytes 
(also known as B-1 cells) present in the mantle zone of lymph nodes and also 
in small numbers in blood. These CD5+ B cells are increased in diseases with 
an autoimmune basis, such as rheumatoid arthritis, systemic lupus 
erythematosus, and Sjoeren‟s syndrome (Rozman and Montserrat 1995). The 
median age of patients at diagnosis is 65 years, with only 10 to 15 percent 
under 50 years of age. In most series, more men than women are affected. 
The course of the disease is variable. Whereas some patients with CLL have a 
normal life span, others die within five years after diagnosis. The etiology of 
CLL is unknown. Several lines of evidence suggest a genetic component, such 
as the increased prevalence of CLL among first-degree relatives. 
Environmental factors, such as ionizing radiation, chemicals, and drugs have 
shown no apparent relationship (Rozman and Montserrat 1995; Kalil and 
Cheson 1999; Montserrat and Moreno 2008). 
 
Patients with CLL have progressive immunodeficiency, which chiefly manifests 
as hypogammaglobulinaemia (up to 60% of CLL patients), but involves all 
elements of the immune system. Compared with normal peripheral blood B 
cells, CLL B cells express relatively low levels of surface-membrane 
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immunoglobulin, mostly IgM and IgD with a single light chain (kappa or lambda) 
(Rozman and Montserrat 1995). Only 15% of patients with CLL have 
completely normal serum immunoglobulins. The extent of hypogamma- 
globulinaemia depends on the stage and duration of the disease and lead to 
bacterial infections of the respiratory tract, skin or urinary tract. They are the 
major causes of death in between a quarter and a half of patients with CLL 
(Hamblin and Hamblin 2008). The mechanisms of immune defects in CLL 
have not been completely elucidated, although several explanations have 
been proposed, including abnormalities in T regulatory cells and 
non-neoplastic B cells (Montserrat and Moreno 2008). One critical step for the 
immune response to antigen is the expression of the CD40 ligand on the 
surface of activated T cells. Downregulation of this ligand induced by CLL 
lymphocytes results in severe immunodeficiency states. Gene transfer of  
CD40 ligand into B cells of CLL patients has been reported to induce cytotoxic 
T lymphocytes against autologous leukemic cells (Cantwell, Hua et al. 1997; 
Kato, Cantwell et al. 1998). B-CLL cells are resistant to most currently 
available gene transfer systems. Several virus vectors such as replication 
defective adenovirus vector and recombinant adeno-associated virus (rAAV) 
vector have been used to enable efficient transduction of CD40 ligand to 
primary B-CLL cells and already entered the clinical trial (Wendtner, Kofler et al. 
2004). However, the specificity and safety need to be further confirmed.  
 
2.3.2  Therapies for CLL 
CLL is generally considered not curable. The former standard treatment, 
chlorambucil only leads to a very low level of complete response (10%). The 
more effective agent fludarabine results in a much higher complete response 
rate (20–40%) and a longer disease-free interval, however, survival is not 
prolonged (Montserrat and Moreno 2008). The target therapy using 
monoclonal antibodies rituximab (anti-CD20) and alemtuzumab (anti-CD52) 
has brought great improvement in the treatment of CLL. It has dramatically 
improved complete response rates and progression-free survival in patients 
with both newly-diagnosed and relapsed CLL when incorporating of these 
monoclonal antibodies with chemoimmunotherapy, however, the overall 
survival has not been changed (Quintas-Cardama and O'Brien 2009). Stem 
cell transplants have been performed in an increasing number of subjects with 
CLL. Autologous stem cell transplants do not cure CLL but could prolong 
survival in extremely selected patients (Dreger, Stilgenbauer et al. 2004). 
However, the necessary condition for the success of an autologous transplant 
is to achieve complete remission before the procedure, which is rare in 
patients failed in chemo or chemo-immunotherapy (Dreger and Montserrat 
2002). An additional problem with autotransplant is the risk of secondary 
myelodysplasia/acute myeloid leukaemia, particularly in patients having 
performed with total body irradiation. In contrast, allogeneic transplants can 
cure about 40% of the patients, but leads to a high toxicity and mortality 
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(Moreno, Villamor et al. 2005; Dreger, Corradini et al. 2007).  
 
Since the beneficial effects of allogeneic stem cell transplantation partly 
depend on the graft-versus-leukaemia effects, one promising strategy consists 
of the genetic manipulation of effector T lymphocytes with tumor specific T-cell 
receptors or chimeric antigen receptors on the surface directed against surface 
antigens on the CLL cells. This strategy may produce therapeutic benefits 
without the adverse effects of more generalized allo-reactivity (Foster, Brenner 
et al. 2008). A number of tumour-associated antigens overexpressed on CLL 
cells can be selected as the target of specific CTL responses, including 
fibromodulin, MDM2 (murine double minute 2), survivin, oncofetal 
antigen-immature laminin receptor protein (OFAiLRP), FMNL1, preferentially 
expressed antigen of melanoma (PRAME) and receptor for hyaluronic-acid 
mediated motility (RHAMM/CD168) (Giannopoulos and Schmitt 2006). 
Moreover, the idiotypic determinants of the unique monoclonal immunoglobulin 
on CLL cells may serve as tumour-specific antigens (Trojan, Schultze et al. 
2000). It has been already reported that an allorestricted T-cell clone, SK22, 
expressing a single defined T cell receptor recognizing a peptide derived from 
FMNL1 shows potent antitumor activity against lymphoma and renal cell 
carcinoma cell lines, Epstein-Barr virus (EBV)-transformed B cells and primary 
tumor samples derived from patients with CLL. SK22 recognizes preferentially 
malignant cells and has only limited reaction against normal hematopoietic 
cells. (Schuster, Busch et al. 2007). This suggests FMNL1 to be a highly 
attractive target antigen in CLL patients and gene-modified TCR-transgenic T 
cells might be suitable therapeutic tools in the autologous setting. However, 
functional investigation of FMNL1 might be highly important in order to identify 
FMNL1-dependent processes of diverse hematopoietic-lineage derived cells 
which may be associated with enhanced FMNL1 ligand presentation and 
therefore affected by FMNL1-specific immunotherapeutic approaches. 
 
2.4  Aim of the project 
The aim of this project is to investigate functional role of FMNL1 in order to 
evaluate and validate FMNL1 as potential target antigen for novel 
immunotherapies： 
1. Testing of novel FMNL1-specific antibodies for potential application in 
immunofluorescence analysis and investigation of the localization of 
native FMNL1 in diverse hematopoietic-lineage derived cells, especially 
focusing on the function-associated localization with the help of confocal 
microscopy. 
2.  Functional analysis of different splice variants of FMNL1 using diverse 
cell biochemical and biological assays. 
3. Investigation of functional aspects of FMNL1, associated with the newly 
identified interaction partners.  
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3  Materials  
 
3.1  Equipments and supplies 
•  Cell culture bottles, Becton Dickinson, Heidelbuerg 
•  Centrifuge, Hettich, Kirchlengern, Germany 
•  Centrifuge 4K15, Sigma Laborzentrifugen GmbH, Osterode an Herz, 
Germany 
•  Centrifuge 5417R , Eppendorf-Netheler-Hinz-GmbH, Hamburg, Germany 
•  Counting chamber, Brand GmbH & Co., Wertheim, Germany 
•  Confocal microscopy, LEICA TCS SP2/405, Leica Microsystems GmbH, 
Wetzlar, Germany 
•  Coverslip 10 mm X 10 mm, Josef Peske, Aindling, Germany 
•  FACS Calibur cell sorter, Becton Dickinson, Heidelbuerg 
•  Fluorescence Microscope, Leica Microsystems GmbH, Wetzlar, Germany 
•  Gloves latex, Rösner-Mautby Meditrade GmbH, Kiefersfelden, Germany 
•  Gloves nitrile, Kimberly-Clark Corporation, Neenah, USA 
•  Hyperfilm MP, Amersham Bioscience, Freiburg, Germany 
•  Incubator, Heraeus Holding GmbH, Hanau, Germany 
•  Incubator for bacteria, Bachofer, Reutlingen, Germany 
•  Incubator shaker, INFORS AG, Bottmingen, Switzerland 
•  InGenius gel documentation (gel doc) system, Synoptics Ltd, Cambridge, 
England 
•  Irradiation facility Gammacell 40, Atomic Energy of Canada Limited, 
Ottawa, Canada 
•  Microplate reader ELISA Reader, SLT Labinstruments, Crailsheim, 
Germany 
•  Microscope, Zeiss AG, Jena, Germany 
•  Midi Electrophoresis chamber, Harnischmacher, Labor- und 
Kuststofftechnick, Kassel, Germany 
•  MilliQ System, Millipore GmbH, Schwalbach, Germany 
•  MoFlowTM, Dako, Hamburg, Germany 
•  Multichannel pipets, Eppendorf-Netheler-Hinz-GmbH, Hamburg, Germany 
•  PCR thermocycler, Biometra Biomedizinische Analytik GmbH, Göttingen, 
Germany 
•  PH-meter 766, Knick Elektronische Messgeräte GmbH & CO. KG, Berlin, 
Germany 
•  Pipets, Stripette 5 ml, 10 ml, 25 ml, Corning, New York, USA 
•  Pipet boy, Integra Biosciences, Fernwald, Germany 
•  Pipets, Eppendorf-Netheler-Hinz-GmbH, Hamburg, Germany 
•  Polystyrene round bottom FACS tubes, Becton Dickinson, Heidelbuerg 
•  Power supply, Pharmacia GmbH, Erlangen, Germany 
•  Pursep-A Xpress disinfection agent, Metz Consumer Care GmbH, Frankfurt, 
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Germany 
•  Slides, Glaswarenfabrik Karl Hecht KG, Sondheim, Germany 
•  Sterile bench, BDK, Sonnenbühl-Genkingen, Germany 
•  Sterile polypropylene round bottom FACS tubes with cap, Becton Dickinson, 
Heidelbuerg 
•  Sterile filters, Techno Plastic Products AG, Trasadingen, Switzerland 
•  Syringes 10ml, 50 ml, BD Perfusion, Becton Dickinson, Heidelbuerg 
•  Thermomixer, Eppendorf-Netheler-Hinz-GmbH, Hamburg, Germany 
•  Tips 1–10 μl, 10–200 μl, 100–1000 μl, Greiner Bio-One International AG, 
Kremsmünster, Austria 
•  Ultraspec 1100 pro UV/ vis Spectrophotometer, Biochrom Ltd, Cambridge, 
England 
•  Vortexer, Bender & Hobei AG, Switzerland 
•  Water bath, Memmert, Schwab Bach 
•  XCell SureLockTM Mini-Cell, Invitrogen Cooperation, Karlsruhe 
•  XCell IITM Blot Module, Invitrogen Cooperation, Karlsruhe 
•  X-ray film, valmex, Augsburg, Germany 
•  12-, 24- well tissue culture plates, Becton Dickinson, Heidelbuerg 
•  96 well U-bottom tissue culture plates, Becton Dickinson, Heidelbuerg 
•  96 well flat-bottom tissue culture plates, Becton Dickinson, Heidelbuerg 
•  50 ml, 15ml Falcons, Becton Dickinson, Heidelbuerg 
•  1.5 ml, 0.5 ml tubes, Eppendorf-Netheler-Hinz-GmbH, Hamburg, Germany 
 
3.2   Chemicals, enzymes and cytokines 
•  Ampicillin sodium salt, Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
•  A23187, Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 
•  Agarose, Bio & Sell Nürnberg, Germany 
•  CaCl2, Merck KGaA, Darmstadt, Germany 
•  CD40 ligand, Peprotech, London, UK 
•  Chloroform (1 Bromo-3-choloro-prapan), Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany 
•  Chloroform: Isoamyl alcohol (CIA) 24:1, Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany 
•  Ciprofloxacin, Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 
•  Cyclosporin A, Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 
•  Complete (25 X), Roche, Basel, Switzerland 
•  4`,6-Diamidino-2-phenylindole dihydrochloride (DAPI), Sigma-Aldrich 
Chemie GmbH, Taufkirchen, Germany 
•  Diethylpyrocarbonat (DEPC) H2O, Invitrogen Corporation, Karlsruhe, 
Germany 
•  Dulbecco‟s modified Eagle‟s medium (DMEM), Gibco, Invitrogen 
Corporation, Karlsruhe, Germany 
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•  Dimethyl Sulfoxide (DMSO), Merck KGaA, Darmstadt, Germany 
•  Desoxinucleosidtriphosphate (dNTP) (2mM/10mM), Fermentas GmbH, 
St.Leon-Rot, Germany 
•  Dithiothreitol (DTT), 0.1M, Fermentas GmbH, St.Leon-Rot, Germany 
•  EcoR I enzyme, Fermentas GmbH, St.Leon-Rot, Germany 
•  Ethanol, Merck KGaA, Darmstadt, Germany 
•  Ethidium Bromide, Invitrogen Corporation, Karlsruhe, Germany 
•  Fetal calf serum (FCS), PAA Laboratories GmbH, Pasching, Austria 
•  Ficoll, Biochrom, Berlin, Germany 
•  First strand buffer (5×), Fermentas GmbH, St.Leon-Rot, Germany 
•  G418, PAA Laboratories GmbH, Pasching, Austria 
•  Glucose, Merck KGaA, Darmstadt, Germany 
•  Granulocyte Macrophage Colony Stimulating Factory (GM-CSF)，Peprotech, 
London, UK 
•  [3H]-myristic acid, PerkinElmer, Boston, U.S.A 
•  HEPES (1M), Gibco, Invitrogen Corporation, Karlsruhe, Germany 
•  HEPES (powder), Biochrom KG, Berlin, Germany 
•  HPLC H2O, Fisher Scientific Corporation, UK 
•  Human serum, Helmholtz Zentrum Munich, healthy male donors 
•  HyperLadder I, Bioline GmbH, Luckenwalde, Germany 
•  IL-1β, Peprotech, London, UK 
•  IL-2, Chiron Vaccines International, Marburg, Germany 
•  IL-4, Peprotech, London, UK 
•  IL-6, Peprotech, London, UK 
•  Iscove‟s Modified Dulbecco‟s Medium (IMDM), Gibco, Invitrogen 
Corporation, Karlsruhe, Germany 
•  Indo-1 AM, Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 
•  Ionomycine, Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany  
•  Isopropyl alcohol, Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 
•  Kanamycin, Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 
•  KCl, Merck KGaA, Darmstadt, Germany 
•  Kpn I enzyme, New England BioLabs GmbH, Frankfurt am Main, Germany 
•  100bp ladder, New England BioLabs Incorporation 
•  Lusogeny broth (LB) agar, Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
•  L-Glutamine, Gibco, Invitrogen Corporation, Karlsruhe, Germany 
•  Lipopolysoccharide (LPS), Sigma Aldrich Chemie GmbH, Taufkirchen, 
Germany 
•  6× loading Dye Solution, Fermentas GmbH, St.Leon-Rot, Germany 
•  LURIA Broth Base, Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 
•  Methanol, Merck KGaA, Darmstadt, Germany 
•  Mfe I enzyme, New England BioLabs GmbH, Frankfurt am Main, Germany 
•  Milk powder, Frema, Lueneburg, Germany 
•  Mounting medium, Vector Laboratories, Burlingame, U.S.A 
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•  3-(4,5)-dimethylthiahiazo (-z-y1)-3,5-di- phenytetrazoliumromide (MTT), 
Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 
•  Na-Acetate, Merck KGaA, Darmstadt, Germany 
•  Na2HPO4·2H2O, Merck KGaA, Darmstadt, Germany 
•  NaN3, Merck KGaA, Darmstadt, Germany 
•  NEB buffer, New England BioLabs GmbH, Frankfurt am Main, Germany 
•  Nhe I enzyme, New England BioLabs GmbH, Frankfurt am Main, Germany 
•  Non Essential Amino Acids, Gibco, Invitrogen Corporation, Karlsruhe, 
Germany 
•  NP-40, Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 
•  Okt-3, kindly provided by Elisabeth Kremmer 
•  Olig(dt)15 Primer, Promega Corporation Madison, USA 
•  Penicilline Streptomycin, Gibco, Invitrogen Corporation, Karlsruhe, 
Germany 
•  Paraformaldehyd (PFA), Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
•  Phenol, Carl Roth GmbH, Karlsruhe, Germany 
•  Pluronic, Peprotech, Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 
•  Phorbol 12-myristate 13-acetate (PMA) , Sigma-Aldrich Chemie GmbH, 
Taufkirchen, Germany 
•  Prostaglandin (PG) E-2, Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
•  Pheylmethanesulfonyl (PMSF), Sigma-Aldrich Chemie GmbH, Taufkirchen, 
Germany 
•  Poly-L-lysin, Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 
•  Ponceau, Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 
•  Prodium Iodide (PI), Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany 
•  RNaseOUT Recombinant Ribonuclease Inhibitor, Invitrogen Corporation, 
Karlsruhe, Germany 
•  RPMI 1640 (-L-Glutamin), Gibco, Invitrogen Corporation, Karlsruhe, 
Germany 
•  Seminaphtorhodafluor-1 carboxylic acid, acetate and succinimidyl ester 
(SNARF-1), Invitrogen Corporation, Karlsruhe, Germany 
•  Sbf I enzyme, New England BioLabs GmbH, Frankfurt am Main, Germany 
•  Sodium Carbonate, Sigma Aldrich Chemie GmbH, Taufkirchen, Germany 
•  Sodium Pyruvate, Gibco, Invitrogen Corporation, Karlsruhe, Germany 
•  Sodium Chloride, Sigma Aldrich Chemie GmbH, Taufkirchen, Germany 
•  SuperScript II Reverse Transcriptase, Invitrogen Corporation, Karlsruhe, 
Germany 
•  T4 DNA ligase (10× ligation buffer), Fermentas GmbH, St.Leon-Rot, 
Germany 
•  TAE buffer (10×), Invitrogen Corporation, Karlsruhe, Germany 
•  Tumor necrosis factor α (TNF α), Peprotech, London, UK 
•  Trypsin EDTA 0,5 %, Gibco, Invitrogen Corporation, Karlsruhe, Germany 
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•  Trypan blue, Gibco, Invitrogen Corporation, Karlsruhe, Germany 
•  Tri Reagent, Sigma Aldrich Chemie GmbH, Taufkirchen, Germany 
•  Tween 20, Sigma Aldrich Chemie GmbH, Taufkirchen, Germany 
•  Western LightingTM Plus-ECL, Amersham Bioscience, Freiburg, Germany 
•  Xba I enzyme, New England BioLabs GmbH, Frankfurt am Main, Germany 
•  Xho I enzyme, Fermentas GmbH, St.Leon-Rot, Germany 
•  ß2-Microglobulin, EMD Biosciences, Darmstadt, Germany 
 
3.3 Kits 
•  BCATM Protein Assay kit, Pierce, Rockfold, U.S.A 
•  B cell negative isolation kit, Dynal, Invitrogen Corporation, Karlsruhe, 
Germany 
•  BrdU flow kit, Becton Dickinson, Heidelbuerg, Germany 
•  KOD Hot Start DNA Polymerase kit, Novagen, EMD Biosciences, 
Darmstadt, Germany  
•  LightCycler® - FastStart DNA MasterPLUS SYBR Green I kit, Roche, Basel, 
Schweiz 
•  Venor®GeM-Mykoplasmen Detektions Kit, MinervaBiolabs, Berlin, 
Germany 
•  NucleoSpin® Extract II kit for PCR gel extraction, Macherey-Nagel 
Corporation, Düren, Germany 
•  Jetstar 2.0 kit for plasmid purification, Genomed GmbH, Löhne, Germany 
 
3.4 Buffers and Solutions 
•   Dulbecco's Phosphate-Buffered Saline (DPBS), Gibco, Invitrogen 
Corporation, Karlsruhe, Germany 
•   Phosphate buffered saline (PBS), Dulbecco‟s Biochrom AG, Berlin, 
Germany 
•   Binding Buffer (10 X), Becton Dickinson, Heidelbuerg, Germany 
•   MOPS buffer (20 X), Invitrogen Corporation, Karlsruhe, Germany 
•   NuPAGE® Transfer Buffer (20 X), Invitrogen Corporation, Karlsruhe, 
Germany 
•   NuPAGE® LDS Sample Buffer (4 X), Invitrogen Corporation, Karlsruhe, 
Germany  
•   Protein G–Sepharose 4 Fast Flow, Amersham Bioscience, Freiburg, 
Germany 
•   AmplifyTM Fluorographic Reagent, Amersham Bioscience, Freiburg, 
Germany 
•   FACS buffer 
o  PBS 
o  1 % Δ FCS 
•   Ripa Buffer (stock solution):  
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o  10 mM Tris-Cl 
o  10 mM NaCl 
o  1 % SDS 
o  0.5 % Deoxycholic  
o  1 % NP-40 
•   Ripa Buffer (working solution):  
o  Ripa Buffer (stock solution) 
o  1 mM PMSF 
o  1 X complete 
•   Lysate Buffer for immunoprecipitation (stock solution):  
o  20 mM Tris-Cl 
o  150 mM NaCl 
o  pH 7.4 
•   Lysate Buffer for immunoprecipitation (working solution):  
o  Lysate Buffer (stock solution) 
o  150 mM Chaps 
o  1 mM Na3VO4 
o  1 mM NaF 
o  1 mM PMSF 
o  1 X complete 
•   Fixation buffer for SDS/PAGE gel: 
o  25% volume isoproponal 
o  65% volume water 
o  10% volume acetic acid 
•   Tris buffered saline (TBS) buffer (10 X) pH 8.0: 
o  10 mM Tris-base 
o  150 mM NaCl 
o  H2O 
•   TBST buffer: 
o  1 X TBS buffer 
o  0.05% Tween 20 
•   Western blot washing buffer: 
o  1 X TBS buffer 
o  0.05 % Tween 20 
•   5 % or 1 % milk powder in TBST 
•   Immunofluoresence washing buffer: 
o  PBS 
o  0.5 % NP-40 
o  0.01 % NaN3 
•   Fixation buffer for Immunofluoresence staining: 
o  PBS 
o  10 % PFA 
•   Saline-sodium citrate (SSC) buffer (20 X) pH 7.0: 
o  H2O 
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o  0.3 M Na Citrat 2 H2O 
o  3 M NaCl 
•   DAPI solution: 
o  1 X SSC buffer 
o  5 μg/ul DAPI 
•   2× Hanks Balanced Salt Solution (HBSS) Buffer pH 7.06: 
o  280 mM NaCl 
o  10 mM KCl 
o  12 mM Glucose 
o  50 mM HEPES 
o  1.5 mM Na2HPO4·2H20 
 
3.5 Cell culture medium 
•   Complete DMEM/ RPMI 
o   DMEM/RPMI1640 
o   10% Δ FCS 
o   2 mM L-Glutamine 
o   Penicillin (100 U/ml)-Streptomycin (100 μg/ml) 
o   10 mM Non essential amino acid 
o   1 mM Sodium-Pyruvate 
•   DMEM hunger medium 
o   DMEM 
o   3 % Δ FCS 
o   2 mM L-Glutamine 
o   Penicillin (100 U/ml)-Streptomycin (100 μg/ml) 
o   10 mM Non essential amino acid 
o   1 mM Sodium-Pyruvate 
•   T cell medium 
o   RPMI1640 
o   10 % Δ human serum 
o   2 mM L-Glutamine 
o   Penicillin (100 U/ml)-Streptomycin (100 μg/ml) 
o   10 mM Non essential amino acid 
o   1 mM Sodium-Pyruvate 
o   10 mM HEPES (pH 7.4) 
o   Gentamycin (16.6 μg/ml) 
•   B cell medium 
o   IMDM 
o   10 % Δ FCS 
o   2 mM L-Glutamine 
o   Insulin-Transferrin (50 μg/ml) 
o   Gentamycin (16.6 μg/ml) 
•   AIM-V medium 
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o   AIM-V Medium 
o   0.1 % Natriumacid 
o   0.1 % BSA 
•   Medium for CD40-Fibroblasts 
o   F12 + DMEM medium 
o   2 mM L-Glutamine 
o   10 mM Non essential amino acid 
o   10 mM HEPES (pH 7.4) 
o   Gentamycin (16.6 μg/ml) 
o   G418 (400 μg/ml) 
 
3.6 Cell lines and bacteria 
 
Table 3.1: Cell lines and bacteria 
Cell lines Decription Culture medium Qwelle/Reference 
BJAB 
EBV-negative 
lymphoma cell line 
RPMI (10% FCS) 
Joseph Mautner, 
Helmholtz Zentrum 
Muenchen 
DG75 
EBV-negative Burkitt 
lymphoma cell line, 
(ATCC CRL-2625) 
RPMI (10% FCS) 
Joseph Mautner, 
Helmholtz Zentrum 
Muenchen 
T2 
TAP-deficient hybrid of 
T-and B- 
Lympho-blastoiden 
cell line, HLA-A2 +, 
(ATCC CRL-1992) 
RPMI (10% FCS) 
IMI, Helmholtz 
Zentrum Muenchen 
(Salter and Cresswell, 
1986) 
Namalwa 
Burkitt lymphoma 
B-lymphoblasts,  
(ATCC CRL-1432) 
RPMI (10% FCS) 
Helmholtz Zentrum 
Muenchen 
Daudi 
Burkitt lymphoma 
B-lymphoblasts,  
(ATCC CCL-213) 
RPMI (10% FCS) 
Helmholtz Zentrum 
Muenchen 
Raji 
Burkitt's lymphoma 
cell line, EBV + (ATCC 
CCL-86) 
RPMI (10% FCS) 
Helmholtz Zentrum 
Muenchen 
Ramos 
Human Burkitt's 
lymphoma cell line 
(ATCC CRL-1596) 
RPMI (10% FCS) 
Helmholtz Zentrum 
Muenchen 
AK-EBV-B 
Epstein-Barr 
virus-transformed 
lymphoblastoid cell 
line 
RPMI (10% FCS) 
Helmholtz Zentrum 
Muenchen 
G361 Human melanoma cell RPMI (10% FCS) Helmholtz Zentrum 
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line Muenchen 
RCC26 
Human renal cell 
carcinoma cell line 
RPMI (10% FCS) 
IMI, Helmholtz 
Zentrum Muenchen 
RCC53 
Human renal cell 
carcinoma cell line 
RPMI (10% FCS) 
IMI, Helmholtz 
Zentrum Muenchen 
KT195 
Human renal cell 
carcinoma cell line 
RPMI (10% FCS) 
Helmholtz Zentrum 
Muenchen 
NN26 Human renal cell RPMI (10% FCS) 
Helmholtz Zentrum 
Muenchen 
293T 
Human embryonic 
kidney cell line, 
(ATCC CRL-1573) 
DMEM (10% FCS) 
Joseph Mautner, 
Helmholtz Zentrum 
Muenchen 
293A 
Human embryonic 
kidney cells 
transformed with 
sheared human 
adenovirus type 5 
DNA 
DMEM (10% FCS) Invitrogen 
Molt4 
Human acute 
lymphoblastic 
leukemia 
T lymphoblast. 
(ATCC CRL-1582) 
RPMI (10% FCS) 
Helmholtz Zentrum 
Muenchen 
K562 
Humane Chronic 
myeloid leukemia 
(CML)-cell line, (ATCC 
CCL-243) 
RPMI (10% FCS) 
Helmholtz Zentrum 
Muenchen 
MDA-MB 231 
Human 
adenocacinoma 
epithelial cells 
(ATCC HTB-26) 
DMEM (10% FCS) Cell Line Service 
HT1080 
human fibrosarcoma 
cell line 
DMEM (10% FCS) 
Helmholtz Zentrum 
Muenchen 
CD40L-fibrobla
sts 
NIH3T3 fibroblasts, 
expressing CD40L 
CD40L-medium with 
400 g / ml G418 
Boston, USA  
(Cracking Hardt et al, 
2002a) 
TOP10 
Chemically competent 
E. coli bacteria 
LB-Broth medium Invitrogen, Karlsruhe 
 
3.7 Antibodies and peptides 
 
Table 3.2: Primary antibodies 
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Antibodies Host Conjugation Dilution Manufacturer 
anti-FMNL1 
6F2 
Rat   
Elisabeth Kremmer, 
Helmholtz Zentrum 
Muenchen 
anti-FMNL1 
8A8 
Rat   
Elisabeth Kremmer, 
Helmholtz Zentrum 
Muenchen 
anti-hCD3 Rabbit  1:50 Dako, Glostrup, Denmark 
anti- tubulin Mouse  1:100 
Santa Cruz Biotechology, 
Heidelberg 
anti- tubulin Mouse  1:100 Sigma, Taufkirchen 
anti-ezrin Rabbit  1:100 Sigma, Taufkirchen 
anti-myosin IIa Rabbit  1:100 Sigma, Taufkirchen 
anti-myosin IIb Rabbit  1:100 Sigma, Taufkirchen 
 
Phalloidine 
 
 
Alexa 
Fluor 488 
 
1:100 
 
Invitrogen, Karlsruhe 
anti-annexin V  Apc 1:20 
Becton,Dickinson, 
Heidelberg 
 
Table 3.3: Secondary antibodies 
Antibosies Conjugation Dilution Manufacturer 
anti-Rat Cy3 1:200 Jackoson, Suffolk, UK 
Cy5 1:100 Jackoson, Suffolk, UK 
Peroxidase 1:2000 Jackoson, Suffolk, UK 
anti-Mouse Alexa Fluor 488 1:100 Invitrogen, Karlsruhe 
Cy5 1:100 Jackoson, Suffolk, UK 
Peroxidase 1:5000 Jackoson, Suffolk, UK 
anti-Rabbit Cy5 1:100 Jackoson, Suffolk, UK 
 
Table 3.4: Peptide 
Peptide Sequence Description Manufacturer 
FMNL1-PP2 RLPERMTTL Predict, binding to HLA-A2 
BIOSYNTAN 
GmbH, berlin 
 
3.8 DNA-Material 
3.8.1 Vectors 
 
Table 3.5: Vectors 
Vector Description Resistance Manufacturer 
pcDNA3.1 
Vector for high-level 
expression in mammalian 
host controlled by 
Ampicillin Invitrogen, Karlsruhe 
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CMV promotor 
pACDC 
entry clone 
Entry clone containing GFP 
for recombination with 
adenovirus expression clone 
Kanamycin 
Vigo Heissmeyer, 
Helmholtz Zentrum 
Muenchen 
pAd/PL-DEST 
Adenovirus expression 
clone 
Ampicillin Invitrogen, Karlsruhe 
 
3.8.2 Primers 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.9  Software and website 
•   Edition of DNA sequence: 
o  Sequencher 4.5  
o  Clone Manager 7  
•   Analysis of FACS data: 
o  BD CellQuestTM Pro 
o  FlowJo  
•   Analysis of immunofluorescence data: LCS Lite  
•   Primer synthesis corporations: 
o  MWG-Biotech AG, Ebersberg, Germany 
o  Sigma-Aldrich Chemie GmbH, Steinheim, Germany 
•   Search restricted enzyme and reaction condition: 
http://www.neb.com/nebecomm/default.asp
5`C5B6 Sbf I: 
3`C5B6 Xba I:  
5`pCD-F-NheI KL2:  
 
3`FMNL1-Ins-Xho I:  
5`Adeno-FMNL1-F:  
 
3`Adeno-FMNL1-C5B6:  
 
G2TA4T:  
 
G2TA4T anti:  
 
5`G2TA4T-Nhe I:  
 
3`pCD-F-C-Xba I 2: 
  
5`-G2TA4T-BamH I 2:  
 
3`FMNL1-C-BamH I 2:  
GAC CTG CAG GCT CTG GGC CTG G 
TAT CTA GAC TAG AGG GGC ATC TCT TC 
ATT GCT AGC CAC CAT GGG CAA CGC GGC CGG 
CAG CGC CGA GC 
TAC TCG AGC AGC ACA TCC AGG CCA CGG TTC TC 
ATG GAT CCC ACC ATG GGC AAC GCG GCC GGC 
AGC GCC GAG CAG C 
TAG GAT CCC TAG AGG GGC ATC TCT TCT CCC 
AGG CTG GCC TC 
AGA TCC CAC CAT GAC CAA CAC GGC CGG CAG 
CGC 
GCG CTG CCG GCC GTG TTG GTC ATG GTG GGA 
TCT 
ATT GCT AGC CAC CAT GAC CAA CAC GGC CGG 
CAG CGC CGA G 
ATT CTA GAC TAG CTC TCA TAA ATG AGT GGC TCC 
TTC TGC TG 
ATT GGA TCC CAC CAT GAC CAA CAC GGC CGG 
CAG CCG CCG A  
AAG GAT CCC TAG CTC TCA TAA ATG AGT GGC TCC 
TTC TGC TG 
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4  Methods  
 
4.1  Cell culture method 
 
4.1.1  General cell culture methods  
All cells were incubated at 37 °C and in an incubator with 5 to 6% CO2 and 
95% humidity. Cell culture was performed under sterile conditions. Working 
with adenoviruses or untested blood (testing for HIV, hepatitis B and C) were 
performed under the genetic conditions of the security level S2 and biological 
safety conditions L2. 
 
4.1.1.1  Freezing and thawing of cells  
Cells were frozen in 1.8ml of 90% FCS and 10% DMSO per tube first at -80 ° 
C for at least 24 h and then in liquid nitrogen for permanent storage.  
 
For thawing, the cells were first briefly incubated at 37 °C in a water bath and 
immediately transferred into medium, washed and cultured in medium 
depending on the cell line.  
 
4.1.1.2  Culture of cell lines  
Suspension cells were cultured by replacing old medium with fresh medium 
every 3-4 days. Adherent cells were placed in new bottles and added with 
fresh medium every 3-4 days. To do this, they were washed once with PBS in 
the bottle, incubated with trypsin for several minutes and harvested from the 
bottle within complete medium into 50 ml tubes. After centrifugation (1800 
rpm, 5 min), cells were resuspended in fresh medium and transferred 1:2 to 
1:40 split to new culture bottles according to cell types. 
 
4.1.1.3  Determination of cell number  
To determine cell numbers, the cells were diluted in trypan blue for living-dead 
distinction. Trypan blue can only penetrate dead cells and dye them blue. 
Unstained living cells were conducted using a Neubauer-counting chamber 
and counted in two to four large squares under microscope, the dead cells 
were excluded. The cell number was determined by the following formula:  
 
c [cells / ml] = number of cells / number of large squares X dilution factor X 
104 
 
4.1.1.4  Mycoplasma contamination test 
Mycoplasma contamination was tested by using Venor®GeM- Mykoplasmen 
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Detektions Kit (Minerva Biolabs). Samples were derived from cell cultures 
which are at 90-100 % confluence. Cell culture supernatant or cell pellets 
following DNA extraction were tested for mycoplasma C infection according to 
the manufacturer. After gel running, the internal control of 191 bp should be 
seen in every samples and a 265-278 bp band could be seen only in the 
mycoplasma-contaminated samples. 
 
When culturing mycoplasma-contaminated cells, 6-10μg/ml ciprofioxaxin was 
added to the cell culture medium. 
 
4.1.2  Isolation of PBL from whole blood 
Peripheral blood leukocytes (PBLs) were obtained from donors by ficoll 
gradient. Blood samples with heparin were firstly diluted 1:1 with RPMI. Each 
25-35 ml mixture was then carefully transferred on the top of 15ml pre-warmed 
ficoll and centrifuged at 2000 rpm for 30 min with slow acceleration and brake. 
The middle layer buffy coat was carefully taken out and washed with RPMI 
with centrifugation (1800 rpm, 5 min). Finally, the PBL were resuspended in 
T-cell medium and counted.  
 
4.1.3  Unspecific stimulation of T cells  
For unspecific stimulation, T cells were cultured in T-cell medium with IL2 (50 
U/ml) and OKT3 (100 ng/ml) for 3-5 days. In some cases, T cells were also 
unspecifically stimulated by LPS (1 μg/ml), TNFα (1000 U/ml) or PMA (50 
ng/ml) combined with ionomycine (250 ng/ml) for about 16 hours.  
 
4.1.4  Peptide pulsing of T2 cells  
T2 cells were washed twice in serum-free RPMI (centrifugation at 1800 rpm 5 
min) and then pulsed in AIM-V medium with a concentration of 2 Mio cells/ml 
containing 5 μg/ml β2-microglobulin and 100 μM peptide. After 2 hours 
incubation at 37 °C, they were washed once in T-cell medium. 
 
4.1.5  Isolation of B cells from PBL using magnetic beads 
B cells were isolated from PBLs of healthy donors using B cell negative 
isolation kit (Dynal). The cells were incubated with a mixture of monoclonal 
antibodies against T cells, NK cells, monocytes, granulocytes and 
erythrothytes to mark all the PBLs with the exception of B cells. Magnetic 
beads coupled with secondary antibodies binding to the constant part of 
primary antibodies could separate the B cells with the help of a magnet to all 
other cells in the PBLs. The magnetic beads were washed twice with PBS 
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containing 1% FCS. PBLs were incubated with antibodies for 30 min at 4°C 
under rotation, and washed once. Subsequently, the PBLs were gently mixed 
and incubated with magnetic beads for another 30 min at 4°C under rotation 
and placed in the magnet. B cells in supernatants were collected, washed 
and resuspended in B cell medium. Isolated B cells were investigated using 
flow cytometry and were about 90% pure. 
 
4.1.6  Unspecific stimulation of B cells and CLL cells  
Isolated or thawed B cells or chronic lymphatic leukemia (CLL) cells were 
added to irradiated (90 Gy) CD40 ligand expressing fibroblasts which were 
cultured in 6-well plates with the addition of IL-4 (5 ng / ml) and cyclosporin A 
(0.66 g / ml). After 3-4 days B cells were transferred onto fresh plates 
containing CD40 ligand expressing fibroblasts. The CD40 ligand-activated 
CLL cells were tested after 3-7 days. B-cells were tested after approximately 
14 days, when the purity of the cells was at least 70%. The purity was 
determined with an anti-CD19 antibody binding to the surface of B cells. 
 
4.1.7  Isolation and maturation of dendritic cells from PBL 
PBLs suspended in B-cell medium (5 Mio/ml) were placed into 6-well plate (3 
ml per well). After 2 hours incubation at 37℃ , the medium containing 
non-adherent cells were removed and the adherent immature dendritic cells 
were stimulated by B-cell medium (3 ml per well) with IL 4 (20 ng/ml) and 
GM-CSF (100 ng/ml) and incubated at 37℃. Three days later, the immature 
dendritic cells were restimulated under the same condition. After another 3 
days, the immature dendritic cells were matured by either CD40 ligand (1 
μg/ml) combined with LPS (1 μg/ml) or a cocktail containing GM-CSF (50 
μg/ml), IL-4 (20 ng/ml), IL-1β (10 ng/ml), TNF α (10 ng/ml), PGE-2 (1 μg/ML) 
and IL-6 (15 ng/ml) for about 7 days. 
 
4.2  Protein biochemical methods  
 
4.2.1  Western blot 
 
4.2.1.1  Cell lysis and protein concentration measurement 
The cell pellets of different cell lines were incubated in Ripa lysis buffer for 30 
min on ice and vortex 3 times during incubation. The cell lysates were 
centrifuged (5000rpm, 10min, 4℃) and the supernatants were taken to 
measure the protein concentration with BCATM Protein Assay Kit (Pierce).  
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4.2.1.2  Electrophoresis and transfer 
To prepare loading samples, 65μl protein supernatants were mixed with 25μl 
4X NuPAGE® LDS Sample Buffer (Invitrogen) and 10μl 0.5mM DTT. These 
samples were heated at 95°C for 5 min and loaded equally of the protein 
concentration into the NuPAGE® Novex Bis-Tris Gel (Invitrogen). The 
electrophoresis was progressed in XCell SureLockTM Mini-Cell (Invitrogen) 
using 500 ml MOPS buffer (Invitrogen) under 200V constant for 50 min.  
 
Transfer was performed in the XCell IITM Blot Module (Invitrogen). Briefly, 500 
ml of 1X NuPAGE® Transfer Buffer was prepared by adding 25 ml 20X 
NuPAGE® Transfer Buffer (Invitrogen) and 50 ml methanol to 425 ml 
deionized water for transferring one gel in one blot module. Two buffer 
pre-soaked blotting pads were placed into the cathode (-) core of the blot 
module. A gel/membrane sandwich was prepared by a pre-soaked filter paper, 
the gel, a pre-soaked nitrocellulose or PVDF membrane and another 
pre-soaked filter paper. The gel/membrane sandwich was placed on the 
blotting pads in the correct orientation, so the gel was closest to the cathode 
core. Finally, enough pre-soaked blotting pads were added to rise to 0.5 cm 
over rim of cathode core. The anode (+) core was placed on the top of the 
pads. Transfer was performed under 30V constant for 1 hour.  
 
If two gels need to be transferred in one blot module, 1X NuPAGE® Transfer 
Buffer was prepared by adding 25 ml 20X NuPAGE® Transfer Buffer 
(Invitrogen) and 100 ml methanol to 375 ml deionized water. Another 
pre-soaked blotting pad need to be placed between two gel/membrane 
sandwiches. Other steps were the same as transferring one gel in one blot 
module. 
 
4.2.1.3 Blotting 
The membrane was stained by ponceau for 1 min and washed by deionized 
water to analyse the efficiency of protein transfer. The membrane was then 
blocked in 5% fat-free milk for 1 to 2 hours at room temperature. After 
washing with TBST buffer, the membrane was incubated with primary 
antibodies diluted in 1% fat-free milk for 1 hour at room temperature. The 
membrane was washed with TBST buffer for 3 times (10 min for each time) 
and incubated with secondary antibodies diluted in 1% fat-free milk for 
another 1 hour at room temperature. After another 3 washing steps with TBST 
buffer (10 min for each time), the membrane was incubated with Western 
LightingTM Plus-ECL buffer (Amersham) for 1 min and exposed to an X-ray 
film for half to several minutes. The film was developed using a developing 
machine. 
 
4.2.2  [3H]- myristic acid uptake assay 
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293T cells were transfected with FMNL1 and G2TA4T. 1 day later, the cells 
were biosynthetically labelled for 16 h with [3H]myristic acid (0.2 mCi/ml) 
(PerkinElmer) in DMEM supplemented with 5% heat-inactivated FCS.  
 
4.2.2.1  Immunoprecipitation 
[3H]myristic acid -labelled cells were washed with PBS and lysed in lysis buffer. 
Probes were centrifuged at 12000 g for 10 min. 1 ml protein supernatants were 
cleared by incubation with 50 μl Protein G–Sepharose 4 Fast Flow (Amersham 
Biosciences) for 1 hour at 4°C. Meanwhile, the Protein G–Sepharose 4 Fast 
Flow was bound to FMNL1 specific antibody 8A8 and isotype control by 
coincubation for 1 hour at 4°C. The specific proteins were immunoprecipitated 
by mixing precleared supernatants and antibodies coupled to Protein 
G–Sepharose 4 Fast Flow while rotating at 4°C for 3 hours. After that, 
immunoprecipitated proteins were eluted in LDS buffer through Pall filters 
(6000 rpm, 2 min, 3 times) and analyzed by western blot. 
 
4.2.2.2  Autoradiography 
Immunoprecipitated proteins were resolved by SDS/PAGE. The gel was 
treated first with fixation solution for 30 min and then with AmplifyTM 
Fluorographic Reagent (Amersham Biosciences) for another 30 min. After 
drying, the gel was exposed for 12 days to Hyperfilm MP (Amersham 
Biosciences) at −80°C using an intensifying screen. 
 
4.3  Cell biological assays 
 
4.3.1  Immunofluorescence staining 
Adherent cells were settled on sterilized coverslips (1 cm X 1 cm) in 12-well 
plate overnight (0.2 Mio cells/well). For non-adherent cells, coverslips were 
treated with poly-L-lysine for 15 min at room temperature, washed with 
deionized water and then dried in air. Non-adherent cells were then seeded 
on the coverslips (0.5 Mio cells/well) and incubated for 40 min at room 
temperature. Cells were fixed by fresh prepared 3% PFA and washed with 
immunofluoresence washing buffer. After blocking by washing buffer 
containing 10% FCS, the coverslips were stained with the primary antibody 
for 1 hour at room temperature. The coverslips were washed by washing 
buffer containing 10% FCS and incubated with the secondary antibody diluted 
in washing buffer containing 10% FCS for 30 min at room temperature. After 2 
washing steps with immunofluoresence washing buffer, the coverslips were 
stained with DAPI for 1-2 min and washed again with washing buffer. During 
fixation, blocking and staining the 12-well plate was kept shaking slowly. The 
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coverslips were dried and put on the slide prepared with a drop of mounting 
medium. The edges were sealed with nail polish and stored at -20℃ in dark. 
Slides were investigated by the Leica TCS SP20/405 confocal microscopy. 
 
4.3.2  Apoptosis assay 
K562 cells were adenovirally transduced with FMNL1 isoforms as well as 
vector control. Meanwhile, K562 cells were incubated with vincristine for 48 
hours to induce cell apoptosis as a positive control. The cells were washed 
twice with cold PBS and resuspended in 1x Binding Buffer (BD) at a 
concentration of ~1 Mio cells/ml. 100 μl of the solution (~0.1 Mio cells) were 
transferred to a 5 ml culture tube and then gently mixed with 5 μl APC 
conjugated annexin V antibody together with 2 μl propidium iodide (PI) and 
incubated for 15 min at room temperature. After that, 400 μl 1x Binding Buffer 
was added into the tube and the cells were analyzed by flow cytometry using 
FACS Calibur (BD) as soon as possible (within 1 hour). The annexin V 
positive cells represented apoptotic cells.   
                                                                         
 
4.3.3  Proliferation assay 
 
4.3.3.1  SNARF-1 staining 
The cells were stained with SNARF-1 at a working concentration of 5 μM for 
15 minutes at 37°C. After removing SNARF-1, cells were incubated in 
medium at 37°C for 30 minutes and then adenovirally transduced with 
different splice variants of FMNL1 and GFP vector control (Charpter 4.3.2) 
and cultured for three additional days. Cells were analyzed by flow cytometry 
using a FACS Calibur (BD).  
 
4.3.3.2  BrdU uptake assay 
A BrdU flow kit (BD) was used to determine the cell cycle kinetics by  
measuring the incorporation of 5`-bromo-2`-deoxyuridine (BrdU) into DNA of 
proliferating cells and therefore coupling cell cycle and cell proliferation. 
HT1080 cells were seeded overnight and transduced with different FMNL1 
splice variants and GFP vector control on the next day (Chapter 4.3.2). After 
24 hours 10 μM BrdU was added. 48 hours later, cells were harvested, fixed 
and permeabilized followed by DNAse incubation. After washing, 
APC-conjugated anti-BrdU antibody was added for 20 min at room 
temperature. Cells were then washed and stained with 7- amino-actinomycin 
D (7-AAD) followed by flow cytometric analysis using the FACS Calibur (BD). 
 
4.3.4  Analysis of free intracellular Calcium  
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Cells were harvested and adjusted to 1 Mio/ml in prewarmed RPMI 
containing 10% FCS in round bottom tubes. Indo-1 AM stain was prepared by 
adding 40 μl prewarmed 10% pluronic solution (prepared in DMSO) and 1 ml 
prewarmed RPMI containing 10% FCS to an indo-1 AM stock aliquot (1 μg/ul, 
20 ul, dried, store in the dark at -20°C). To stain 1 Mio cells in a round bottom 
tube, 250 μl indo-1 AM stain was added and the final volume was adjusted to 
1 ml with prewarmed RPMI containing 10% FCS. Cells were then incubated 
for 30 min at 37°C and mixed every 10 min during incubation. Stained cells 
were diluted to 0.1 Mio/ml and kept in the dark until analysis. The free 
intracellular calcium was analyzed by flow cytometry at the MoFlow (Dako). 
The FL7 channel of violet fluorescence (405 nm) represents the 
calcium-bound dye and the FL8 channel of green fluorescence (530 nm) 
represents the calscium-free dye. Therefore the ratio FL8/FL7 indicates the 
free intracellular calcium concentration. Stained cells were measured within 
2-3 hours after labeling. 
 
4.4  Protein overexpression 
 
4.4.1  Calcium-phosphate transfection 
293T cells or 293A cells were seeded overnight in 6-well plate (5x105 per 3ml 
medium per well). 300 μl 2x HBSS buffer were mixed with 300 μl plasmid 
mixture containing 200 mM CaCl2, 253.4 μM chloroquine and 6 μg plasmid. 
The plasmid mixture was dropped into 2x HBSS buffer while generating 
bubbles with the pipetboy. After 30 min incubation at room temperature, the 
slightly turbid mixture (300 μl per well) was transferred drop by drop to cells 
incubated in DMEM hunger medium for about 30-60 min before the 
transfection. At last, the transfected cells were incubated for another 6 hours 
at 37°C, washed 1 time with DPBS and finally cultured in complete DMEM.  
 
4.4.2  Adenoviral transduction 
4.4.2.1  LR recombination reaction  
pAd/PL-DESTTM Gateway® vector (Invitrogen) was used to induce high-level, 
transient protein expression in mammalian cells by the ViraPowerTM 
Adenoviral Expression System. 2 μl LR ClonaseTM II enzyme (Invitrogen) was 
added to a mixture containing entry clone (50-150 ng/reaction), 
pAd/PL-DESTTM Gateway® vector (300 ng/reaction) and TE buffer (pH 8.0, 
adjust the total volume to 8μl) and mixed well by pipetting up and down. After 
incubation at 25°C for 18 hours followed by another incubation with 1 μl of the 
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Proteinase K solution (Invitrogen) in each reaction for 10 min at 37°C, the 
reaction mixture transformed into E.coli host (Chapter 4.4.1.5) and selected 
on LB plates containing ampicillin for expression clones. 
 
4.4.2.2  Generation and amplification of adenoviral stocks 
The selected pAd/PL-DEST expression clones were digested by Pac I 
enzyme for 16 hours at 37°C, purified by phenol-chroloform extraction 
(Chapter 4.4.1.3) and then transfected to 293A cell line (Invitrogen) by 
calcium-phosphate transfection (Chapter 4.3.1). After around 10-13 days 
post-transfection during which culture medium were replaced with fresh, 
complete culture medium every 2-3 days, approximately 80% of cells showed 
a cytopathic effect (CPE) which is characterized by formation of plaques. The 
adenovirus-containing cells were then harvested. To prepare a crude viral 
lysate, the harvested cells were frozen at -80°C for at least 30 min and 
thawed at 37°C in water bath for 15 min. After repeating freezing and thawing 
twice, the cell lysates were centrifuged (3000rpm, 15 min, room temperature) 
and the supernatants were taken and stored at -80°C as adenoviral stock 
passage one. 
 
The andenoviral stocks were amplified by infecting 293A cells. The infected 
cells were harvested 2-3 days after infection when 80-90% cells had rounded 
up or were floating. After repeating freezing-thawing, the cell lysates were 
centrifuged and the supernatants were collected and stored at -80°C as 
adenoviral stock passage two. 
 
4.4.2.3  Titeration of adenoviral stocks 
293A cells were seeded in 6-well plate at 37°C overnight (1 Mio cells per well). 
Adenoviral stocks were thawed and diluted ranging from 10-4 to 10-9 with 
complete culture medium to a final volume of 1 ml. The adenoviral dilutions 
were added to cells and incubated at 37°C overnight. The following day, the 
medium containing virus was gently replaced with agarose overlay (2 ml per 
well). After another 2 days, the cells were gently overlayed with an additional  
1 ml of agarose overlay solution per well. Generally 8-12 days post-infection, 
MTT solution (5 mg/ml, 1/10 the volume of the agarose overlay) was layered 
the on top of the solidified agar and incubated for 3 hours at 37°C. 
Plaques were counted to determine the titer of adenoviral stocks. Titers 
ranging from 1 x 108 to 1 x 109 pfu/ml are generally suitable for use in most 
applications. 
 
4.4.2.4  Cell transduction with adenoviral stocks 
The mammalian cells of choice were plated in appropriate complete media. On 
the day of transduction, the adenoviral stocks of passage 2 were thawed and 
mixed gently by pipetting. The culture medium of the cells were replaced with 
the supernatant of passge 2 of diverse adenoviral stocks. The plate was 
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swirled gently to disperse the medium and incubated at 37°C overnight. The 
following day, the medium containing viruses were replaced with fresh, 
complete culture medium. The cells were harvested 2 days post transduction 
and analyzed for the presence of the specific protein. 
 
4.5  Molecular biology methods 
 
4.5.1  Cloning of FMNL1 and FMNL1 into pcDNA 3.1 vector 
The plasmid pcDNA 3.1 containing FMNL1 and the FMNL1 and FMNL1 
DNA fragments were prepared by Elfriede Eppinger (in the research group of 
Angela Krackhardt). As decribed in Chapter 5.2, the three FMNL1 splice 
variants are only different at C-terminus of the amino acid sequence (Figure 
5.7b). To prepare plasmids, pcDNA 3.1-FMNL1and pcDNA 
3.1-FMNL1pcDNA 3.1-FMNL1was digested by restrict enzyme Sbf I in 
the middle of FMNL1 inserts and Xba I at the 3` cloning site and exchanged 
the 3` terminus with FMNL1 and FMNL1(Figure 4.1)

 
Figure 4.1:  FMNL1 in the pcDNA3.1 vector. Sbf I restrict enzyme site is in 
the middle of FMNL1 inserts and Xba I is at the 3` cloning site. 
 
4.5.1.1  Amplification of 3` terminuses of FMNL1 and FMNL1
Although FMNL1 and FMNL1are different at the C terminus, the last 30 
amino acids are exact the same (Figure 5.7b). Therefore, the same primers 
5`C5B6 Sbf I and 3`C5B6 XbaI were used to amplify 3` terminuses of 
FMNL1 and FMNL1The KOD Hot Start DNA Polymerase kit (Novagen) 
was used for the amplification. PCR products were amplified in 10 separated 
reaction tubes. 
 
PCR mixture: 
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FMNL1  3` terminus                 FMNL1  3` terminus               
 
 
 
 
 
 
           
 
 
 
 
 
 
 
 
 
 
 
4.5.1.2  Gel electrophoresis and gel-extraction of the PCR production 
The PCR products were diluted in a ratio of 5:1 with 6-fold Ladebuffer, loaded 
in a 1.5% agarose gel (with 0.7 g / ml ethidium bromide) and run in a gel 
electrophoresis chamber at a voltage of 120 mV over a period of 
approximately 50 min. The DNA ladder HyperLadder I (Bioline) was served 
as a size control. Amplified DNA products were visualized under a UV 
transilluminator. Appropriate bands were cut with a scalpel and eluted from 
the gel by using the NucleoSpin gel extraction kit (Macherey-Nagel Company), 
according to the manufacturer. The DNA quantity was measured on the 
spectrometer. 
 
4.5.1.3  Digestion and purification of the inserts and vector 
Both of the inserts (FMNL1 and FMNL13` termini) and the vector (pcDNA 
3.1-FMNL1) were digested with Sbf I and Xba I at 37°C for 3-4 hours and 
inactivated at 65°C for 20 minutes. 
 
Digestion: 
 
 
 
 
 
 
 
 
P-5` (100 pmol/ul) 
P-3` (100 pmol/ul) 
dNTP (2 mM) 
MgSO4 (25 mM) 
PCR buffer (10X) 
KOD-Polymerase (1U/μl) 
FMNL1  (263 ng/μl) 
DEPC-H2O 
1 μl 
1 μl 
5 μl 
3 μl 
5 μl 
1 μl 
2 μl 
to 50 μl 
P-5` (100 pmol/ul) 
P-3` (100 pmol/ul) 
dNTP (2 mM) 
MgSO4 (25 mM) 
PCR buffer (10X) 
KOD-Polymerase (1U/μl) 
FMNL1  (524 ng/μl) 
DEPC-H2O 
1 μl 
1 μl 
5 μl 
3 μl 
5 μl 
1 μl 
1 μl 
to 50 μl 
PCR-program;   1. initial denaturation 
2. denaturation 
3. annealing l 
4. elongation 
5. terminal elongation 
6. cooling 
 
35 cycles form step 2 to step4 
 
94°C  2 min 
94°C  30 sec 
58°C  30 sec 
68°C  1 min 
72°C  10 min 
4°C 
4
. elongation 
5
. terminal 
elongation 
6
. cooling 
3` terminus of FMNL1 or pCDNA 3.1-FMNL1 
Buffer NEB4 (10X) 
BSA (10X) 
Sbf I (10 U/ml) 
Xba I (20 U/ml) 
DEPC-H2O 
100 μg 
10 μl 
10 μl 
3 μl 
4 μl 
add to 100 μl 
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For purification, the digested vector were diluted in a ratio of 5:1 with loading 
buffer, loaded in a 1% agarose gel (with 0.7 g / ml ethidium bromide) and run 
in a gel electrophoresis chamber at a voltage of 120 mV over a period of 
approximately 50 min. The DNA ladder HyperLadder I (Bioline) was served 
as a size control. The appropriate band was eluted from the gel by using the 
NucleoSpin gel extraction kit (Macherey-Nagel Company), according to the 
manufacturer. The DNA quantity was measured on the spectrometer. 
 
The digested inserts were purified by using phenol-chloroform extraction to 
remove enzymes and small DNA fragments. Each insert digestion was very 
well mixed with 500 μl of equilibrated phenol. After centrifugation (2 min, 
14000 rpm), the upper aqueous phase was transferred into a new tube and 
added with 500 μl chloroform-isoamyl alcohol. After mixing and centrifugation 
(2 min, 14 000 rpm), the upper phase was again transferred into a new tube 
and mixed with 10 μl sodium acetate (3 M) and 1 ml ethanol (99%). After 
centrifugation (20 min, 14 000 rpm, 4 °C) the supernatant was discarded and 
the DNA sediment was solved in DEPC-H2O after air drying. The DNA 
quantity was measured on the spectrometer. 
 
4.5.1.4  Ligation  
Digested and purified inserts and vectors were ligated in a ratio of insert : 
vector = 6 : 1. The DNA amount is calculated as follows:  
Insert [ng] = 6 X (insert [bp]) X (vector [ng]) / (vector [bp]) 
 
Ligation mixture: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pcDNA 3.1-FMNL1 
3` terminus of FMNL1 
pcDNA 3.1-FMNL1(Sbf I / Xba I) 
Ligation buffer (10X) 
T4 ligase 
DEPC-H2O 
 
 
1 μl (562 ng/μl 1:5 diluted) 
1 ul (99.5 ng/μl) 
1 μl 
1 μl 
to 10 μl 
 
 
pcDNA 3.1-FMNL1 
3` terminus of FMNL1 
pcDNA 3.1-FMNL1(Sbf I / Xba I) 
Ligation buffer (10X) 
T4 ligase 
DEPC-H2O 
 
Reaction: 
Inactivation: 
Cooling: 
Stock: 
 
 
1 μl (105 ng/μl) 
1 ul (99.5 ng/μl) 
1 μl 
1 μl 
to 10 μl 
 
16°C  overnight 
65°C  20 min 
4°C 
-20°C 
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4.5.1.5  Transformation to bacteria 
Ligation products were transformed by heat shock into chemically competent 
E. coli , Escherichia coli One Shot TOP10 (Invitrogen). These bacteria were 
thawed on ice and 2 μl ligation products were added and stirred with a tip. 
After 30 min incubation on ice, the bacteria were incubated for 45 s at 42°C 
and immediately transferred on ice to cool. After the addition of 250 μl S.O.C 
medium (Invitrogen) the bacteria were shaked at 225 rpm for 1 h at 37°C, and 
placed on preheated LB agar plates with appropriate antibiotic additives (eg: 
Ampicilllin: Cend = 100 μg / ml) in two different volumes (50 μl, 100 μl). The 
plates were incubated at 37°C overnight and stocked at 4°C for maximum 
one week. 
 
4.5.1.6  Selection of the transformed bacteria 
Only the bacteria successfully transformed with the ligation products could 
grow on the agar plates since the ligation products contains antibiotic 
resistance. Individual colonies were picked with tips and transferred in 5 ml 
LB medium containing the same antibiotic, shaked overnight at 37 °C.  
 
4.5.1.7  Plasmid-DNA-extraction and digestion  
To check whether the ligation products were properly incorporated into the 
vector, plasmid DNA of 5-10 starter cultures were purified by using the 
"Jetstar Plasmid Purification Mini Kit" (Genomed) according to the 
manufacturer. After determining the DNA quantity, these mini-preparations 
were tested by digestion with specific restriction enzymes targeting a specific 
sequence within the insert (Sbf I and Xba I). Two bands of 7701 bp and 1079 
bp should be visible after digestion of pcDNA 3.1-FMNL1two bands of 7701 
bp and 1253 bp should be visible after digestion of pcDNA 3.1-FMNL1 
 
4.5.1.8  Plasmid sequencing and maxi-preparation 
Plasmid with the fragments of the correct size had been sequenced by the 
company Sequiserve or MWG.  
 
The corresponding starter culture, from which the plasmid of right sequence 
was obtained, was used to provide plasmid DNA of greater quantity. For this, 
300 μl of starter cultures was transferred in 300 ml LB-medium (with antibiotic) 
and the bacteria were shacked overnight at 37 ° C for expanding. The Maxi 
preparation was performed with the "Jetstar Plasmid Purification Maxi Kit" 
(Genomed) according to the manufacturer. The DNA quantity was measured 
on the spectrometer and the plasmid was stocked at -20°C. 
 
4.5.2  Cloning of Kozak sequence into pcDNA 3.1-FMNL1
To enhance the expression, a kozak sequence (CACC) was added before the 
5` start coden of FMNL1in pcDNA 3.1 vector. To do this, pcDNA 
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3.1-FMNL1were digested by restrict enzyme Nhe I at the 5` cloning site 
and Xho I in the middle of FMNL1 inserts and exchanged the 5` terminus of 
FMNL1containing kozak sequence (Figure 4.2)since the three FMNL1 
splice variants are same at N-terminus of the amino acid sequence. 
 
Figure 4.2:  FMNL1 containing Kozak sequencein the pcDNA3.1 vector. 
Restrict enzyme Nhe I is at the 5` cloning site and Xho I site is in the middle of 
FMNL1 inserts. 
 
4.5.2.1  Amplification of 5` terminuse of FMNL1containing kozak 
sequence 
The pEntr11-derived entry clone pACDC-FMNL1 including the kozak 
sequence was prepared by Elfriede Eppinger (in the research group of 
Angela Krackhardt). The primers 5`pCD-F-NheI KL2 and 3`FMNL1-Ins-Xho I 
and the KOD Hot Start DNA Polymerase kit (Novagen) were used to amplify 
5` termini of FMNL1containing kozak sequence. PCR products were 
amplified in 10 separated reaction tubes. 
 
PCR mixture: 
 
5` terminus of FMNL1 + Kozak 
 
 
 
 
 
 
 
 
 
 
 
 
 
P-5` (15 pmol/ul) 
P-3` (15 pmol/ul) 
dNTP (2 mM) 
MgSO4 (25 mM) 
PCR buffer (10X) 
KOD-Polymerase (1U/μl) 
pACDC-Kozak-FMNL1
DMSO 
DEPC-H2O 
1 μl 
1 μl 
5 μl 
3 μl 
5 μl 
1 μl 
1 μg 
2.5μl 
to 50 μl 
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The PCR products were used for gel electrophoresis and eluted from the gel 
as described before (Chapter 4.5.1.2). The DNA quantity was measured on 
the spectrometer. 
 
4.5.2.2  Digestion and purification of the inserts and vector 
Both of the inserts (5` terminus of FMNL1+ Kozak) and the vector (pcDNA 
3.1-FMNL1) were digested with Nhe I and Xho I at 37°C for 3-4 hours and 
inactivated at 65°C for 20 minutes. 
 
Digestion: 
 
 
 
 
 
 
 
Purification of the digested insert and vectors was performed as described 
before (Chapter 4.5.1.3). DNA quantity was measured on the spectrometer. 
 
4.5.2.3  Ligation  
Digested and purified inserts and vectors were ligated in a ratio of insert: 
vector = 6 : 1.  
 
Ligation mixture: 
 
 
 
 
 
 
 
 
 
 
PCR-program;   1. initial denaturation 
2. denaturation 
3. annealing l 
4. elongation 
5. terminal elongation 
6. cooling 
 
35 cycles form step 2 to step 4 
 
94°C  2 min 
94°C  30 sec 
68°C  30 sec 
68°C  1 min 
72°C  10 min 
4°C 
4
. elongation 
5
. terminal 
elongation 
6
. cooling 
5` terminus of FMNL1+ Kozak or pcDNA 3.1-FMNL1 
Buffer NEB2 (10X) 
BSA (10X) 
Nhe I (10 U/ml) 
Xho I (20 U/ml) 
DEPC-H2O 
100 μg 
10 μl 
10 μl 
2 μl 
2 μl 
add to 100 μl 
pcDNA 3.1-Kozak-FMNL1 
5` terminus of FMNL1 + Kozak 
pcDNA 3.1-FMNL1(Nhe I / Xho I) 
Ligation buffer (10X) 
T4 ligase 
DEPC-H2O 
 
 
 
1 μl (52.24 ng/μl) 
1.5 ul (64.29 ng/μl) 
1 μl 
1 μl 
to 10 μl 
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Bacteria are transformed by ligation products as described before (Chapter 
4.5.1.5). On the second day, 5-10 clones of each ligation were select to make  
start cultures. 
 
4.5.2.4  Plasmid-DNA-extraction and digestion  
Starter cultures were purified by using the "Jetstar Plasmid Purification Mini 
Kit" (Genomed). After determining the DNA quantity, these mini-preparations 
were tested by digestion with Nhe I and Xho I. Two bands of 8353 bp and 431 
bp should be visible after digestion of pcDNA 3.1-Kozak-FMNL1two bands 
of 8527 bp and 431 bp should be visible after digestion of pcDNA 
3.1-Kozak-FMNL1. 
 
Plasmid with the fragments of the correct size had been sequenced by the 
company Sequiserve or MWG.  
 
The corresponding starter culture was expanded and the maxi preparation 
was performed with the "Jetstar Plasmid Purification Maxi Kit" (Chapter 
4.5.1.8). The DNA quantity was measured on the spectrometer and the 
plasmid was stocked at -20°C. 
 
4.5.3  Cloning of FMNL1 /  into pACDC entry clone vector
To clone FMNL1/ from pcDNA 3.1 vector into pACDC entry clone vector, 
the restrict enzyme Bgl II site in pACDC entry clone vector was selected as 
the cloning site, which is however in the FMNL1 sequence. Therefore, 
BamH I was added at the 5` and 3` ends of FMNL1which has the 
compatible end of Bgl II (Figure 4.3). 
pcDNA 3.1-Kozak-FMNL1 
5` terminus of FMNL1 + Kozak 
pcDNA 3.1-FMNL1(Nhe I / Xho I) 
Ligation buffer (10X) 
T4 ligase 
DEPC-H2O 
 
Reaction: 
Inactivation: 
Cooling: 
Stock: 
 
1 μl (52.24 ng/μl) 
1.2 ul (80.42 ng/μl) 
1 μl 
1 μl 
to 10 μl 
 
16°C  overnight 
65°C  10 min 
4°C     
-20°C 
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Figure 4.3:  FMNL1 in the pACDC entry clone vector. Restrict enzyme BamH 
I at the 5` and 3` ends of FMNL1 was ligated with Bgl II in poly cloning site of 
pACDC entry clone.  
 
4.5.3.1  Amplification of FMNL1 
The primers 5`Adeno-FMNL1-F and 3`Adeno-FMNL1-C5B6 and the KOD Hot 
Start DNA Polymerase kit (Novagen) were used to amplify FMNL1using 
pcDNA 3.1-Kozak-FMNL1 as templates. PCR products were amplified in 
10 separated reaction tubes. 
 
PCR mixture: 
 
FMNL1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The PCR products were used for gel electrophoresis and eluted from the gel 
as described before (Chapter 4.5.1.2). The DNA quantity was measured on 
the spectrometer. 
P-5` (100 pmol/ul) 
P-3` (100 pmol/ul) 
dNTP (2 mM) 
MgSO4 (25 mM) 
PCR buffer (10X) 
KOD-Polymerase (1U/μl) 
pcDNA 3.1-Kozak-FMNL1
DMSO 
DEPC-H2O 
1 μl 
1 μl 
5 μl 
3 μl 
5 μl 
1 μl 
1 μg 
2.5 μl 
to 50 μl 
PCR-program;   1. initial denaturation 
2. denaturation 
3. annealing l 
4. elongation 
5. terminal elongation 
6. cooling 
35 cycles form step 2 to step4 
 
94°C  2 min 
94°C  30 sec 
72°C  30 sec 
72°C  4 min 
72°C  10 min 
4°C 
4
. elongation 
5
. terminal 
elongation 
6
. cooling 
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4.5.3.2  Digestion and purification of the inserts and vector 
The inserts (FMNL1+ Kozak) was digested by BamH I at 37°C for 3-4 
hours and inactivated at 65°C for 20 minutes.  
 
Digestion: 
 
 
 
 
 
Purification of the digested insert was performed as described before 
(Chapter 4.5.1.3). DNA quantity was measured on the spectrometer. The Bgl 
II digestion and purification of vector (pACDC) was done by Elfriede Eppinger 
(in the research group of Angela Krackhardt). 
 
4.5.3.3  Ligation  
Digested and purified inserts and vectors were ligated in a ratio of insert: 
vector = 5 : 1.  
 
Ligation mixture: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Ligation products were transformed to bacteria as described before (Chapter 
4.5.1.5). On the second day, 5-10 clones of each ligation were select to make 
starter cultures. 
 
4.5.3.4  Plasmid-DNA-extraction and digestion  
FMNL1  
BamH I buffer with BSA (10X) 
BamH I (10 U/ml) 
DEPC-H2O 
100 μg 
10 μl 
3 μl 
to 100 μl 
pACDC-FMNL1 
FMNL1 (BamH I) 
pACDC(Bgl II) 
Ligation buffer (10X) 
T4 ligase 
DEPC-H2O 
 
 
 
2.6 μl (117 ng/μl) 
0.5 ul (220 ng/μl) 
1 μl 
1 μl 
to 10 μl 
 
 pACDC-FMNL1 
FMNL1 (BamH I) 
pACDC(Bgl II) 
Ligation buffer (10X) 
T4 ligase 
DEPC-H2O 
 
Reaction: 
Inactivation: 
Cooling: 
Stock: 
3 μl (104 ng/μl) 
0.5 ul (220 ng/μl) 
1 μl 
1 μl 
to 10 μl 
 
16°C  overnight 
65°C  10 min 
4°C     
-20°C 
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Starter cultures were purified by using the "Jetstar Plasmid Purification Mini 
Kit" (Genomed). After determining the DNA quantity, these mini-preparations 
were tested by digestion with EcoR I (in insert) and Kpn I (in vector). Two 
bands of 5302 bp and 3165 bp should be visible after digestion of 
pACDC-Kozak-FMNL1two bands of 5302 bp and 3339 bp should be visible 
after digestion of pACDC-Kozak-FMNL1. 
 
Plasmid with the fragments of the correct size had been sequenced by the 
company Sequiserve or MWG.  
 
The corresponding starter culture was expanded and the maxi preparation 
was performed with the "Jetstar Plasmid Purification Maxi Kit" (Chapter 
4.5.1.8). The DNA quantity was measured on the spectrometer and the 
plasmid was stocked at -20°C. 
 
4.5.4  Mutagenesis 
Mutagenesis was performed by QuikChange® Site-Directed Mutagenesis Kit 
(STRATAGENE) which allows site-specific mutation in virtually any 
double-stranded plasmid. The QuikChange® site-directed mutagenesis 
method is performed using PfuTurbo DNA polymerase and a temperature 
cycler. The basic principle is that PfuTurbo DNA polymerase replicates both 
plasmid strands with high fidelity and without displacing the mutant 
oligonucleotide primers. The oligonucleotide primers, each complementary to 
opposite strands of the plasmid, are extended during temperature cycling to 
generate a mutated plasmid containing staggered nicks. Following 
temperature cycling, the product is treated with Dpn I (target sequence: 
5 -´Gm6ATC-3 )´ which is specific for methylated and hemimethylated DNA and 
is used to digest the parental DNA template and to select for 
mutation-containing synthesized DNA. DNA isolated from almost all E. coli 
strains is dam methylated and therefore susceptible to Dpn I digestion. The 
nicked vector DNA containing the desired mutations is then transformed into 
XL1-Blue supercompetent cells.  
 
4.5.4.1  Mutagenesis of N-terminal myristoylation site in pACDC-FMNL1 
To mutate the N-terminal myristoylation site (Chapter 5.4, Figure 5.15), the 
oligonucleotide primers G2TA4T and G2TA4T anti were designed using 
QuikChange® Primer Design Program available online 
(http://www.stratagene.com/qcprimerdesign). A four-step procedure to 
generate mutants was performed according to the introduction manual.  
 
Reaction mixture: 
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After cycling, 1 μl of the Dpn I restriction enzyme (10 U/μl) was directly added 
to the amplified product and incubated at 37°C for 1 hour to digest the parental 
supercoiled dsDNA. After that, reaction was transformed into XL1-Blue 
supercompetent cells.  
 
DNA was extracted from selected bacteria clones and digested by EcoR I and 
Kpn I. Plasmids with the fragments of the correct size were sent for 
sequencing by the company Sequiserve or MWG to check if correct mutants 
were obtained. The plasmid containing the correct mutant was named 
pACDC-G2TA4T. 
 
4.5.4.2  Cloning of the N-terminal myristoylation site mutant into 
pcDNA 3.1-FMNL1
In order to clone the mutated N-terminal myristoylation site into pcDNA 
3.1-FMNL1, pcNDA 3.1-FMNL1was digested by restrict enzyme Nhe I at 
the 5` cloning site and Xho I in the middle of FMNL1 inserts and exchanged 
the 5` terminus with G2TA4T containing the mutant N-terminal myristoylation 
site (Figure 4.2). 
 
The primers 5`G2TA4T-Nhe I and 3`FMNL1-Ins-Xho I and the KOD Hot Start 
DNA Polymerase kit (Novagen) were used to amplify the 5` terminus  
sequence of G2TA4T using pACDC-G2TA4T as template. PCR products 
were amplified in 10 separated reaction tubes. 
 
PCR mixture: 
 
 
 
 
 
P-G2TA4T (100 ng/ul) 
P-G2TA4T anti (100 ng/ul) 
dNTP mix 
Reacton buffer (10X) 
PfuTurbo DNA polymerase 
pACDC-FMNL1
DMSO 
DEPC-H2O 
1.25 μl 
1.25 μl 
1 μl 
5 μl 
1 μl 
1.925 μl (25ng) 
4 μl (Cend=8%) 
to 50 μl 
Cycling-program; 1. initial denaturation 
2. denaturation 
3. annealing l 
4. elongation 
18 cycles form step 2 to step4 
 
95°C  2 min 
95°C  1 min 
68°C  1 min 
68°C  9 min 
5 
6
. cooling 
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5` terminus of G2TA4T 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The PCR products were used for gel electrophoresis and eluted from the gel. 
After digestion with Nhe I and Xho I, the PCR products were ligated with 
pcDNA 3.1-FMNL1digested with the same enzymes in a ratio of 6:1.  
 
Bacteria were transformed by ligation products. After DNA extraction, the 
plasmids with correct insert were selected by digestion with Nhe I and Xho I 
and sequencing. Maxi preparation was performed with the "Jetstar Plasmid 
Purification Maxi Kit" (Chapter 4.5.2). The DNA quantity was measured on the 
spectrometer and the plasmid was stocked at -20°C. 
 
4.5.5  Cloning of FMNL1ΔDAD and G2TA4TΔDAD into pcDNA 
3.1 vector and pACDC entry clone vector 
 
4.5.5.1  Cloning of FMNL1ΔDAD and G2TA4TΔDAD into pcDNA 3.1 
To Clone FMNL1ΔDAD into pcDNA 3.1, the restrict enzyme Nhe I and Xba I 
were selected as the cloning sites in pcDNA 3.1 vector (Figure 4.4). The 
primers 5`pcD-F-NheI KL2 and 3`pcD-F-C-Xba I 2 were used to amplify 
FMNL1ΔDAD sequence using pcDNA 3.1-Kozak-FMNL1 as template. The 
amplification was performed by KOD Hot Start DNA Polymerase kit 
(Novagen). The gel-purified PCR production was used as template for further 
PCR reaction to obtain more product. PCR products were amplified in 10 
separated reaction tubes. 
P-5` (15 pmol/ul) 
P-3` (15 pmol/ul) 
dNTP (2 mM) 
MgSO4 (25 mM) 
PCR buffer (10X) 
KOD-Polymerase (1U/μl) 
pACDC-FMNL1
DMSO 
DEPC-H2O 
PCR-program;   1. initial denaturation 
2. denaturation 
3. annealing l 
4. elongation 
5. terminal elongation 
6. cooling 
 
35 cycles form step 2 to step4 
 
94°C  2 min 
94°C  30 sec 
68°C  30 sec 
68°C  1 min 
68°C  10 min 
4°C 
4
. elongation 
5
. terminal 
elongation 
6
. cooling 
1 μl 
1 μl 
5 μl 
3 μl 
5 μl 
1 μl 
1 μg 
2.5 μl 
to 50 μl 
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PCR mixture: 
 
FMNL1ΔDAD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCR products were used for gel electrophoresis and eluted from the gel. After 
digestion with Nhe I and Xba I, the PCR products were ligated with pcNDA 3.1 
vectordigested with the same enzymes in a ratio of 6:1.  
 
             
 
Figure 4.4:  Cloning of FMNL1ΔDAD and G2TA4TΔDAD in the pcDNA 3.1 
vector. a: FMNL1ΔDAD# containing mutants were cloned into pcDNA 3.1 vector by 
Nhe I at 5` and Xba I at 3` end. b: FMNL1ΔDAD and G2TA4TΔDAD were cloned into 
pcDNA 3.1 vector by using Sbf I to exchange the 3`terminus with FMNL1ΔDAD#.  
 
Bacteria were transformed by ligation products. After DNA extraction, the 
plasmids with correct insert were selected by digestion with Nhe I and Xba I. 
P-5` (100 pmol/ul) 
P-3` (100 pmol/ul) 
dNTP (2 mM) 
MgSO4 (25 mM) 
PCR buffer (10X) 
KOD-Polymerase (1U/μl) 
pcDNA3.1-FMNL1
DMSO 
DEPC-H2O 
PCR-program;   1. initial denaturation 
2. denaturation 
3. annealing l 
4. elongation 
5. terminal elongation 
6. cooling 
 
35 cycles form step 2 to step4 
 
94°C  2 min 
94°C  30 sec 
72°C  30 sec 
72°C  4 min 
72°C  10 min 
4°C 
4
. elongation 
5
. terminal 
elongation 
6
. cooling 
1 μl 
1 μl 
5 μl 
3 μl 
5 μl 
1 μl 
1 μg 
2.5 μl 
to 50 μl 
a b 
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However, several mutatations were found in the FMNL1ΔDAD sequence 
before Sbf I restriction site by sequencing. Maxi preparation of pcDNA 3.1- 
FMNL1ΔDAD containing mutatations (pcDNA 3.1-FMNL1ΔDAD#) was 
performed with the "Jetstar Plasmid Purification Maxi Kit". The 3` terminus 
lacking DAD was cut out from FMNL1ΔDAD# by Sbf I and Xba I and 
exchanged with the 3`terminuses of FMNL1 and G2TA3T in pcDNA 3.1 
vector (Figure 4.4). 
 
Digestion1: 
 
 
 
 
 
 
 
The small fragment of 956 bp was extracted from the gel and used as insert 
for ligation (3`terminus of FMNL1ΔDAD).  
 
Digestion2: 
 
 
 
 
 
 
 
The big fragments of 7705 bp were extracted from the gel and used as cut 
vector for ligation (pcDNA 3.1-FMNL1 / G2TA4T (Sbf I / Xba I)). 
 
Ligation (insert : vector = 6 : 1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
pcDNA 3.1-FMNL1ΔDAD# 
Buffer NEB4 (10X) 
BSA (10X) 
Sbf I (10 U/ml) 
Xba I (20 U/ml) 
DEPC-H2O 
10 μg 
10 μl 
10 μl 
3 μl 
3 μl 
to 100 μl 
pcDNA 3.1-FMNL1 / G2TA4T  
Buffer NEB4 (10X) 
BSA (10X) 
Sbf I (10 U/ml) 
Xba I (20 U/ml) 
DEPC-H2O 
20 μg 
10 μl 
10 μl 
3 μl 
3 μl 
add to 100 μl 
pcDNA 3.1-FMNL1ΔDAD: 
3`terminus of FMNL1ΔDAD 
pcDNA 3.1-FMNL1 (Sbf I / Xba I) 
Ligation buffer (10X) 
T4 ligase 
DEPC-H2O 
 
 
 
0.83 μl (90.9 ng/μl) 
1.55 ul (64.4 ng/μl) 
1 μl 
1 μl 
to 10 μl 
 
 
pcDNA 3.1-GTA4TΔDAD: 
3`terminus of FMNL1ΔDAD 
pcDNA 3.1-G2TA4T (Sbf I / Xba I) 
Ligation buffer (10X) 
T4 ligase 
DEPC-H2O 
 
 
 
0.83 μl (90.9 ng/μl) 
0.67 ul (148.5 ng/μl) 
1 μl 
1 μl 
to 10 μl 
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Bacteria were transformed by ligation products. After DNA extraction, the 
plasmids with correct insert were selected by digestion with Sbf I (in insert) 
and Mfe I (in vector). Two bands of 5723 bp and 2938 bp should be visible 
after digestion and gel-electrophoresis of both pcDNA 3.1-FMNL1ΔDAD and 
pcDNA 3.1-G2TA4TΔDAD. 
 
Plasmids with the fragments of the correct size had been sequenced by the 
company Sequiserve or MWG.  
 
The corresponding starter culture was expanded and the maxi preparation 
was performed with the "Jetstar Plasmid Purification Maxi Kit". The DNA 
quantity was measured on the spectrometer and the plasmid was stocked at 
-20°C. 
 
4.5.5.2  Cloning of FMNL1ΔDAD and G2TA4TΔDAD into pACDC entry 
clone vector 
To clone FMNL1ΔDAD and G2TA4TΔDAD from pcDNA 3.1 vector into 
pACDC entry clone vector, similar procedures have been performed as 
described in chapter 4.5.3.  
 
The primers 5`Adeno-FMNL1-F and 3`FMNL1-C-BamH I 2 were used to 
amplify the FMNL1ΔDAD, while the FMNL1ΔDAD fragment was used as 
template which was cut out from pcDNA 3.1-FMNL1ΔDAD by Nhe I and Xba I 
and purified by gel extraction. The primers 5`-G2TA4T-BamH I 2 and 
3`FMNL1-C-BamH I 2 were used to amplify G2TA4TΔDAD while the 
G2TA4TΔDAD fragment was used as template which was cut out from 
pcDNA 3.1- G2TA4TΔDAD by Nhe I and Xba I and purified by gel extraction. 
The amplification was performed by using the KOD Hot Start DNA 
Polymerase kit (Novagen). The product was amplified in 10 separated 
reaction tubes. 
 
PCR mixture: 
 
 
 
 
 
 
 
 
Reaction: 
Inactivation: 
Cooling: 
 
16°C  overnight 
65°C  10 min 
4°C 
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FMNL1ΔDAD:                       G2TA4TΔDAD: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The PCR products were used for gel electrophoresis and eluted from the gel 
and digested by BamH I at 37°C for 3-4 hours and inactivated at 65°C for 20 
minutes.  
 
Digestion: 
 
 
 
 
 
After purification, the digested inserts were ligated with the Bgl II digested and 
purified pACDC entry clone vector with a ratio of 6 : 1. 
 
Ligation mixture: 
 
 
 
 
 
 
 
 
 
 
 
P-5` (100 pmol/ul) 
P-3` (100 pmol/ul) 
dNTP (2 mM) 
MgSO4 (25 mM) 
PCR buffer (10X) 
KOD-Polymerase (1U/μl) 
insert 
DMSO 
DEPC-H2O 
1 μl 
1 μl 
5 μl 
3 μl 
5 μl 
1 μl 
1 μl 
2.5 μl 
to 50 μl 
PCR-program;   1. initial denaturation 
2. denaturation 
3. annealing l 
4. elongation 
5. terminal elongation 
6. cooling 
35 cycles form step 2 to step4 
 
94°C  2 min 
94°C  30 sec 
72°C  30 sec 
72°C  4 min 
72°C  10 min 
4°C 
4
. elongation 
5
. terminal 
elongation 
6
. cooling 
FMNL1ΔDAD or G2TA4TΔDAD 
BamH I buffer with BSA (10X) 
BamH I (10 U/ml) 
DEPC-H2O 
100 μg 
10 μl 
3 μl 
to 100 μl 
pACDC-FMNL1ΔDAD 
FMNL1ΔDAD (BamH I) 
pACDC(Bgl II) 
Ligation buffer (10X) 
T4 ligase 
DEPC-H2O 
 
 
 
0.35 μl (1034 ng/μl) 
0.5 ul (220 ng/μl) 
1 μl 
1 μl 
to 10 μl 
 
 
P-5` (100 pmol/ul) 
P-3` (100 pmol/ul) 
dNTP (2 mM) 
MgSO4 (25 mM) 
PCR buffer (10X) 
KOD-Polymerase (1U/μl) 
G2TA4T insert 
DMSO 
DEPC-H2O 
1 μl 
1 μl 
5 μl 
3 μl 
5 μl 
1 μl 
1 μl 
2.5 μl 
to 50 μl 
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Bacteria were transformed by ligation products. After DNA extraction, the 
plasmids with correct insert were selected by double digestion.  
 
Plasmid                    Sbf I (ins)/Mfe I (vec)  EcoR I (ins)/Kpn I (vec) 
pACDC-Kozak-FMNL1ΔDAD   5572 bp/2756 bp     5286 bp/3042 bp 
pACDC-Kozak-G2TA4TΔDAD  5572 bp/2756 bp     5286 bp/3042 bp 
 
Plasmid with the fragments of the correct size had been sequenced by the 
company Sequiserve or MWG. The corresponding starter culture was 
expanded and the maxi preparation was performed with the "Jetstar Plasmid 
Purification Maxi Kit". The DNA quantity was measured on the spectrometer 
and the plasmid was stocked at -20°C. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
pACDC-G2TA4TΔDAD 
GTA4TΔDAD (BamH I) 
pACDC(Bgl II) 
Ligation buffer (10X) 
T4 ligase 
DEPC-H2O 
 
1.3 μl (289 ng/μl) 
0.5 ul (220 ng/μl) 
1 μl 
1 μl 
to 10 μl 
 
Reaction: 
Inactivation: 
Cooling: 
Stock: 
16°C  overnight 
65°C  10 min 
4°C     
-20°C 
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5  Results 
 
5.1   Expression and localization of endogenous FMNL1 in 
hematopoietic lineage-derived cells and tumor cells 
FMNL1 has been previously shown to be selectively expressed in PBMCs 
and overexpressed in CLL samples as well as in malignant cell lines (Figure 
2.1) (Krackhardt, Witzens et al. 2002), suggesting FMNL1 to be an attractive 
target antigen for tumor immune responses. The expression of FMNL1 in was 
now investigated more in detail by western blot and confocal microscopy. 
 
5.1.1  FMNL1 expression in tumor cell lines and in malignant cells 
derived from patients with acute lymphatic leukaemia 
High protein expression of FMNL1 has been reported in native malignant cells 
from patients with lymphatic as well as myeloid leukemias and 
EBV-transformed B cells. FMNL1 protein expression has been also detected in 
lymphoma-derived cell lines and aberrant protein expression was found in 
renal cell carcinoma lines compared to normal embryonal kidney cells 
(Schuster, Busch et al. 2007).  
 
 
Figure 5.1 FMNL1 expression in transformed cells, tumor cell lines and in 
malignant cells derived from patients with acute lymphatic B cell leukaemia. 50 
μg of total protein was used for SDS/PAGE. Probing with anti-actin antibody served 
as equal loading control.  
 
In this study, analysis was extended in more lymphoma cells and carcinoma 
5 Results 
                                                                           59 
cells. The expression of FMNL1 was observed by western blot in B lymphoma 
cell lines as BJAB, DG75, T2, Namalwa, Daudi and Raji cells but not in Ramos 
cells. The T lymphoma cell line Molt-4 had an enhanced expression. FMNL1 is 
highly expressed in malignant cells derived from the selected patient with 
acute lymphatic leukaemia (ALL) and in diverse EBV-transformed B cells. The 
expression of FMNL1 is not detectable in carcinoma cells like the melanoma 
cell line G361, the breast carcinoma cell line Maca A2+ /A2- and cell lines 
dericved from embryonal and normal renal cells like NN26 AND 293T. However, 
FMNL1 is clearly expressed in diverse renal carcinoma cells as RCC26, 
RCC53 and KT195 (Figure 5.1). 
 
5.1.2  Expression and localization of endogenous FMNL1 in different 
subtypes of unstimulated and stimulated PBLs 
To investigate the expression of endogenous FMNL1 in unstimulated and 
stimulated T cells, T cells were unspecificlly stimulated by LPS, TNFα, PMA 
combined with ionomycine and IL 2 combined with OKT-3. LPS from the outer 
membrane of Gram-negative bacteria is an endotoxin, and induces activation 
of B cells, macrophages and other APC. LPS could also stimulate 
proliferation of human T cell by accessory of LPS-primed monocytes and the 
costimulatory signals via the interaction between CD28 on T cells and it ligand 
CD80 on monocytes (Mattern, Flad et al. 1998). TNFα stimulates T cells 
through their receptors on the cell surface. PMA could activate the signal 
transduction enzyme protein kinase C (PKC), which triggers calcium release 
and mobilization resulting in the activation of T cells. Ionomycin is an 
ionophore which is usually used to raise the intracellular level of calcium in 
conjunction with PMA. IL-2 and the CD3-specific antibody OKT3 are T cell 
mitogens, responsible for T cell activation and proliferation. However, 
unspecific stimulation of T cells by OKT3 requires signals provided by 
accessory cells and is IL 2 dependent.  
 
 
Figure 5.2 FMNL1 is naturally expressed in unstimulated T cells and the 
expression is up-regulated after stimulation with different stimuli. 50 μg of total 
protein was used for SDS/PAGE. Probing with anti-actin antibody served as equal 
loading control.  
5 Results 
                                                                           60 
The most effective up-regulation of FMNL1 was induced by PMA combined 
with ionomycine and IL-2 combined with OKT-3 as shown by western blot for 
three different donors (Figure 5.2) 
 
The localization of endogenous FMNL1 in different subtypes of PBLs was 
further investigated by confocal microscopy. FMNL1 showed a dot-like 
expression pattern in the cytoplasma of unstimulated and unspecifically 
stimulated T cells, B cells and malignant B cells from patients with CLL 
(Figure 5.3). 
 
T cell      B cell    CLL cell 
 
 
Figure 5.3 FMNL1 is expressed in diverse hematopoietic lineage-derived cells. 
FMNL1 was visualized in unstimulated and stimulated PBL subtypes as T cells, B 
cells and malignant B cells from patients with CLL by immunofluorescence staining 
with the rat FMNL1-specific antibody 6F2 followed by Cy3-labeled goat anti-rat 
antibody. T cells were stimulated with IL-2 and OKT3 and B cells as well as CLL cells 
were activated using soluble CD40-Ligand. Scale bars represent 2 μm. 
 
5.1.3  The function-associated localization of endogenous FMNL1  
In T cells, FMNL1 has been reported to be involved in reorientation of the 
MTOC towards the immunological synapse (Gomez, Kumar et al. 2007). 
Similar polarization of FMNL1 towards the immunological synapse was 
observed after targeting of FMNL1-PP2-specific T cells (Schuster, Busch et al. 
2007) with peptide-pulsed T2 cells (Figure 5.4). 
 
Peptide-pulsed T2 cell + T cell 
 
CD3       FMNL1     -tubulin    Overlay 
 
Figure 5.4 Polarization of FMNL1 towards the immunological synapse. To 
investigate FMNL1 expression in polarized T cells, the FMNL2-PP2-specific T cell 
Unstimulated 
Stimulated 
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clone SK22 was incubated for 15 minutes with T2 cells pulsed with the peptide 
FMNL1-PP2 at 10 μmol. Cells were then fixed and stained with DAPI for nuclear 
staining (blue), rabbit anti-human CD3 antibody followed by Cy5-labeled goat anti 
rabbit antibody (yellow) for T cell identification and rat FMNL1-specific antibody 6F2 
followed by Cy3-labeled goat anti-rat antibody (red). The MTOC was stained with 
mouse anti-human -tubulin antibody followed by Alexa Fluor 488-labeled goat anti 
mouse antibody (green). Enrichment of FMNL1 and CD3 was observed around the 
MTOC. Scale bars represent 2 μm.  
 
Moreover, dividing T cells were investigated by confocal microscopy after 
unspecific stimulation with IL-2 combined with OKT-3. Colocalization of 
endogenous FMNL1 with -tubulin at the cortex and mitotic spindles was 
observed in dividing T cells during metaphase, anaphase and especially 
telophase (Figure 5.5), suggesting an involvement of FMNL1 in mitosis and 
cytokinesis. 
     
              -tubulin  FMNL1  Overlay    ROI 
 
Figure 5.5 Colocalization of endogenous FMNL1 with -tubulin at the cortex 
and mitotic spindles of dividing T cells. T cells were unspecifically stimulated with 
OKT3 and IL-2. Colocalization was observed at different time points of mitosis as 
metaphase, anaphase and telophase. FMNL1 was stained as described before (red), 
-tubulin was stained with mouse anti-human -tubulin followed by Alexa Fluor 
488-labeled goat anti-mouse antibody (green), nuclei were stained with DAPI (blue). 
Colocalization was quantified and displayed as histograms using the Leica 
microsystems confocal software. ROI = region of interest. 
 
In addition, the murine homologue FRL, which has 85% homology to the 
human counterpart, has been shown to be involved in Fc receptor-mediated 
phagocytosis (Yayoshi-Yamamoto, Taniuchi et al. 2000; Seth, Otomo et al. 
2006). Function-associated localization of endogenous FMNL1 at the 
phagocytic cup of monocytes was also observed during phagocytosis of cells 
and platelets (Figure 5.6). 
metaphase 
anaphase 
telophase 
Dividing T cells 
5 Results 
                                                                           62 
Monocytes 
 
Phalloidin     FMNL1     Overlay 
   
Figure 5.6 FMNL1 is localized at the phagocytic cup (white arrows) of 
monocytes during phagocytosis of cells and platelets. FMNL1 (red) was stained 
as figure 5.4, actin was stained by Alexa 488-conjugated Phalloidin (green) and 
nuclei were stained with DAPI (blue). Scale bars represent 2 μm.  
 
5.2 FMNL1 splice variants and mutant investigated in this 
study 
DRFs including FRL have been previously described to be regulated by 
autoinhibition which is dependent on the C-terminal DAD (Seth, Otomo et al. 
2006). Using exon-specific primers for the C-terminal end of FMNL1, three 
different FMNL1 splice variants derived from cDNA of CLL cells and human 
lung carcinoma have been cloned by Elfriede Eppenger (in the research 
group of Angela Krackhardt) which result in varying C-terminal amino acid 
sequences (Figure 5.7a). Two splice variants are corresponding to the 
previously described murine splice variants, FRL and FRL 
(Yayoshi-Yamamoto, Taniuchi et al. 2000; Harris, Li et al. 2004). An 
additional C-terminal splice variant FMNL1 was identified which contains an 
intron retention but shares the final C-terminal end with FMNL1 (Figure 
5.7b). To further investigate the DAD dependent autoinhibition mechanism, 
an FMNL1 mutant lacking the C-terminal DAD (FMNL1ΔDAD) was generated 
(Figure 5.7a).  
 
 
 
Cell 
phagocytosis 
 
Platelet 
phagocytosis 
 
(a) 
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Figure 5.7 Identification of a novel FMNL1 splice variant (FMNL1) containing 
an intron retention at the C-terminal end. (a) Schematic diagrams of FMNL1, 
FMNL1, FMNL1 and FMNL1ΔDAD constructs used in this study. (b) Amino acid 
sequences of the C-termini of FMNL1 and  corresponding to murine FRL and , 
as well as of the novel isoform FMNL1 containing an C-terminal intron retention but 
sharing the final C-terminal amino acids with FMNL1. The identical C-terminal 
amino acids in FMNL1 and FMNL1 are underlined. 
 
5.3  Function associated localization of FMNL1 and 
FMNL1ΔDAD  
5.3.1  FMNL1 and FMNL1ΔDAD are located at the cell membrane and 
induce membrane blebbing 
All three different FMNL1 splice variants were transfected into 293T cells and 
investigated by confocal microscopy. 293T cells transfected with FMNL1 
and FMNL1 showed mainly intracellular cytoplasmatic distribution of FMNL1, 
whereas cells transfected with FMNL1 showed a distinct membranous 
FMNL1 localization as well as extensive polarized membrane protrusions and 
blebs (Figure 5.8a). Similar membrane protrusions were observed after 
adenoviral transduction of K562 cells with FMNL1 but not with the other 
splice variants. However, in these cells the shape of the blebs was different 
and a more prominent enrichment of FMNL1 at the cell cortex has been 
observed (Figure 5.8b). Similarly, 293T cells and K562 cells transfected or 
transduced with FMNL1ΔDAD showed similar membranous localization of 
FMNL1 and extensive polarized membrane protrusions and blebs (Figure 5.8 
a,b) indicating that deregulation of autoinhibition is responsible for membrane 
localization and blebbing observed in cells overexpressing the splice variant 
FMNL1. Increase of blebbing was less obvious in HT1080 and MDA-MB 231 
cells after adenoviral transduction of FMNL1. However, these cell lines also 
demonstrated FMNL1 localization at the cell membrane and especially 
enrichment of FMNL1 at intracellular vesicles whereas cells transduced with 
the other two splice variants had a more dispersed distribution within the 
cytoplasma (Figure 5.8c). Similar localization was also observed in HT1080 
and MDA-MB 231 cells after adenoviral transduction of FMNL1ΔDAD. 
(b) 
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(a)        293T 
 
 
 
(b)       K562 
 
 
(c) 
 
 
Figure 5.8 FMNL1 and FMNL1ΔDAD are located at the cell membrane and 
cortex and induce extensive cell blebbing.  (a) FMNL1 and FMNL1ΔDAD 
induce extensive blebbing in 293T cells. 293T cells were transfected with the 
pcDNA3.1 vector containing different isoforms of FMNL1 and analyzed by confocal 
microscopy after immunofluorescence staining with the rat FMNL1-specific antibody 
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6F2 followed by Cy3-labeled goat anti-rat antibody (red). Nuclei were stained with 
DAPI (blue). Scale bars represent 2 μm. DIC = differential interference contrast. (b) 
FMNL1 and FMNL1ΔDAD induce blebbing in K562 cells. FMNL1 isoforms were 
adenovirally transduced into K562 cells and analyzed by confocal microscopy as 
described above. Scale bars represent 2 μm. (c) FMNL1 and FMNL1ΔDAD are 
enhanced in intracellular vesicles of HT1080 and MDA-MB 231 cells. FMNL1 
isoforms were adenovirally transduced into HT1080 and MDA-MB 231 cells and 
analyzed by confocal microscopy as described above. Scale bars represent 2 μm. 
 
Significant increase of membrane blebbing in 293T and K562 cells after 
transduction with FMNL1 and FMNL1ΔDAD in comparison to the other 
splice variants was quantified by independent counting experiments (Figure 
5.9).  
 
 
 
Figure 5.9 Cell blebbing was quantified by counting hundred 
FMNL1-transduced cells in 293T cells and K562 cells. By independent counting 
experiments (n ≥ 3), the results indicate a significant increase of blebbing in cells 
expressing FMNL1 and FMNL1ΔDAD (*** p < 0.001). 
 
5.3.2  FMNL1 co-localizes with actin, ezrin and myosin IIb on the cell 
membrane and cortex 
FMNL1γ colocalized with actin in FMNL1γ-transfected 293T cells as shown 
by Phalloidin staining demonstrating actin assembly activity of FMNL1 
(Figure 5.10).  
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293T-FMNL1 
 
                    FMNL1    Phalloidin   Overlay 
 
Figure 5.10 FMNL1 colocalizes with actin in 293T cells. 293T cells were 
transfected with the pcDNA3.1 vector containing FMNL1 and stained with Alexa 
488-conjugated Phalloidin (green) as well as with the FMNL1-specific antibody 
FMNL1 6F2 followed by rat Cy3-labeled goat anti-rat secondary antibody (red). Nuclei 
were stained with DAPI (blue). Scale bars represent 2 μm.  
 
Bleb expansion is driven by intracellular pressure transiently generated by 
myosin II contraction at the actin cortex (Charras 2008). Ezrin links the actin 
cytoskeleton to the membrane and localizes to bleb membrane when bleb 
expansion slows (Charras, Hu et al. 2006). We have investigated if Ezrin and 
myosin IIb colocalzes with FMNL at the membrane of blebbing cells. In fact, 
we observed colocalization of FMNL1 with ezrin and myosin IIb especially at 
the cortex of blebbing K562 cells by confocal microscopy (Figure 5.11). 
Moreover, K562 cells transduced with FMNL1 often demonstrated a 
polarized circular accumulation of FMNL1γ at one pole of the cell showing 
also small blebbing. FMNL1 colocalizes especially with ezrin and myosin IIb 
in this area (Figure 5.11). 
 
          K562-FMNL1K562-FMNL1
      
FMNL1      Ezrin     Overlay          FMNL1    Myosin IIb   Overlay  
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Figure 5.11 FMNL1 colocalizes with ezrin and myosin IIb particularly at the 
cortex of blebbing K562 cells. K562 cells were transduced with adenoviral vector 
containing the FMNL1 isoform. Cells were then stained with the FMNL1-specific 
antibody 6F2 followed by rat Cy3-labeled goat anti-rat (red), as well as with rabbit 
anti-human ezrin and rabbit anti-human myosin IIb followed by Cy5-conjugated goat 
anti-rabbit (yellow). Nuclei were stained with DAPI (blue). Scale bars represent 2 
μm. 
 
5.3.3  FMNL1 does not induce apoptosis in K562 cell 
Plasma membrane blebbing has long been observed as an early event in 
apoptosis. More recently, non-apoptotic blebbing was identified to play roles 
in distinct cellular processes such as cytokine release, cytokinesis or cancer 
cell invasion (Charras, Yarrow et al. 2005; Fackler and Grosse 2008). As 
blebbing may occur during apoptosis, I investigated if FMNL1 expression 
increases apoptosis by Annexin V and propidium iodide staining. K562 cells 
were adenovirally transduced with FMNL1 isoforms as well as vector control. 
Vincristine was added to cells to induce cell apoptosis as a positive control. 
Three days later, cells were harvested and stained with Annexin V and 
propidium iodide to analyze apoptotic cell death. The result demonstrated 
that FMNL1 does not induce apoptosis in K562 cell compared to wild type 
cells, vector control and other isoforms of FMNL1 (Figure 5.12).  
 
 
 
Figure 5.12 FMNL1 does not induce apoptosis in K562 cell. Non-treated K562 
cells, K562 cells incubated with vincristine and K562 cells transduced with vector 
alone or FMNL1 isoforms were stained with APC conjugated to annexin V together 
with propidium iodide. Vincristine was used to induce cell apoptosis as a positive 
control.  
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5.3.4  Blebbing induced by FMNL1 or FMNL1ΔDAD is independent of 
Src and ROCK but depends on myosin, actin and tubulin 
integrity 
Plasma membrane blebbing has been previously shown to be induced by 
FHOD1 when co-expressed with ROCK1 (Hannemann, Madrid et al. 2008). 
Moreover, blebbing induced by FHOD1 requires Src activity (Hannemann, 
Madrid et al. 2008). Our former results demonstrated the association of 
blebbing induced by FMNL1 with F-actin and myosin IIb. It has also been 
previously reported that tubulins were involved in blebbing and associated in 
formin-associated functions. Nocodazole has been previously described to 
inhibit leishmania-derived HASPB induced blebbing although no colocalization 
of microtubuli and HASPB was observed (Tournaviti, Hannemann et al. 2007). 
However, the formin mDia has been demonstrated to be involved in 
organization of microtubules (Ishizaki, Morishima et al. 2001) and to interact 
with the microtubule binding protein CLIP-170 (Lewkowicz, Herit et al. 2008).  
 
To further investigate components involved in plasma membrane blebbing 
induced by FMNL1, 293T cells were transfected with FMNL1 and different 
substances were added which are known to inhibit membrane blebbing. 
According to previous publications, concentrations of inhibitors were selected 
as follows: 50 μM Src inhibitor PP1, 90 μM ROCK inhibitor Y-27632, 100 μM 
myosin II inhibitor Blebbistatin, 25 μM F-actin inhibitor Latrunculin B and 200 
μM tubulin inhibitor Nocodazole (Eisenmann, Harris et al. 2007; Tournaviti, 
Hannemann et al. 2007; Hannemann, Madrid et al. 2008). PP1 and Y-27632 
had only minimal effects on membrane blebbing as investigated by confocal 
microscopy. However, membrane blebbing was grossly reduced by addition of 
Latrunculin B, Blebbistatin and Nocodazole (Figure 5.13a,b), demonstrating 
that the mechanism of blebbing induced by FMNL1 was not mediated by Src 
and ROCK but dependent on actin, myosin and tubulin integrity. Similar data 
were obtained by FMNL1ΔDAD-transfected 293T cells (Figure 5.13a,b).  
 
(a) 293T 
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(b) 293T- FMNL1

 
Figure 5.13 Blebbing induced by FMNL1 or FMNL1ΔDAD is independent of 
ROCK and Src but depends on actin, myosin and microtubules. 293T cells were 
transfected with the pcDNA3.1 vector containing FMNL1 or FMNL1ΔDAD and 
treated with different inhibitors of blebbing as well as solvent controls. After 2 days 
cells were stained with the rat FMNL1-specific antibody 6F2 followed by Cy3-labeled 
goat anti-rat antibody (red). Nuclei were stained with DAPI (blue). Scale bars 
represent 2 μm. Blebbing cells were analyzed by confocal microscopy as previously 
described (a). Cell blebbing was quantified by counting hundred FMNL1-transduced 
cells in three independent experiments (b) classifying them as cells exhibiting 
extensive blebs (white bars), limited blebs (black bars) or none (grey bars). Standard 
deviation of independent counting experiments is shown (n=3, *** p<0.001). 
 
Furthermore, FMNL1 transduced 293T cells were treated with Latrubulin B, 
Blebbistatin and Nocodazole of gradient concentrations demonstrating that 
blebbing induced by FMNL1 could be inhibited at very low concentration 
(Figure 5.14 a,b). 
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(b)  
 
 
Figure 5.14 Inhibition of blebbing induced by FMNL1 by Latrubulin B,   
Blebbistatin and Nocodazole was analyzed using gradient concentrations of 
inhibitors. 293T cells were transfected with the pcDNA3.1 vector containing 
FMNL1 and treated with different bleb-inhibitors at gradient concentrations as well 
as DMSO controls. After 2 days cells were stained with the rat FMNL1-specific 
antibody 6F2 followed by Cy3-labeled goat anti-rat antibody (red). Myosin IIb was 
stained with a rabbit anti-myosin IIb antibody followed by Cy5-labeled goat 
anti-rabbit antibody (yellow). F-actin was stained with Alexa 488-conjugated 
Phalloidin (green) and -tubulin was stained with a mouse anti- -tubulin antibody 
followed by Alexa 488-conjugated goat anti-mouse antibody (green). Nuclei were 
stained with DAPI (blue). Scale bars represent 2 μm (a). Cell blebbing was quantified 
by counting hundred FMNL1-transduced cells (b), classifying them as cells 
exhibiting extensive blebs (white bars), limited blebs (black bars) or none (grey 
bars).  
 
5.4   Identification of the mechanism of membranous 
localization induced by FMNL1 and FMNL1ΔDAD 
Membrane localization of FMNL1 was a predominant feature in 293T cells 
transfected with the splice variant FMNL1 and FMNL1ΔDAD. The 
mechanism how FMNL1 is located to the cell membrane remains elusive. 
Investigation of the FMNL1 amino acid sequence by prediction analyses 
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revealed a potential N-terminal myristoylation site (http://elm.eu.org). This 
N-terminal myristoylation motif is highly specific for the leukocyte-specific 
formins FMNL1, 2 and 3 in man and mouse but not present in other formin 
proteins. To investigate whether FMNL1 is indeed a myristoylated protein, 
glycine (G) at position 2 and alanine (A) at position 4 were mutated to 
threonine (T) within FMNL1 (Figure 5.15).  
 
 
Figure 5.15 Schematic view of the N-terminus of FMNL1. The predicted 
N-terminal myristoylation site was mutated on position 2 and 4, glycine and alanine 
to threonine (red), respectively. 
 
5.4.1  FMNL1 contains an N-terminal myristoylation site 
To further confirm that FMNL1 contains a myristoylation site, 293T cells were 
transfected with FMNL1 or G2TA4T mutant and then metabolically labeled 
with [3H]-myristic acid. Total proteins were immunoprecipitated with the 
FMNL1-specific antibody 8A8 detecting an N-terminal epitope not including 
the N-terminal myristoylation site. Immunoprecipitated probes were 
investigated by immunoblot using the FMNL1-specific antibody 6F2 to 
examine for expression of FMNL1 or G2TA4T mutant (Figure 5.16a) as well 
as autoradiography to analyze incorporation of [3H]-myristic acid (Figure 
5.16b). Both FMNL1 protein and G2TA4T mutant were sufficiently 
immunprecipitated by FMNL1-specific antibody 8A8, however only FMNL1, 
but not G2TA4T, was myristoylated in 293T cells. These results provide clear 
evidence that FMNL1 is indeed a myristoylated protein.  
 
(a) (b) 
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Figure 5.16 FMNL1 contains an N-terminal myristoylation site. Metabolic labelling 
of FMNL1 with [3H]-myristic acid. 293T cells transfected with FMNL1 or G2TA4T 
were cultured for 16 h with [3H]-myristic acid. FMNL1 proteins were 
immunoprecipitated with 8A8 antibody or the isotype control, analysed by SDS/PAGE, 
followed by immunoblotting with anti-FMNL1 mAb 6F2 (a) or autoradiography (b). 
Molecular mass sizes are indicated in kDa. 
 
5.4.2  Membrane localization and blebbing of FMNL1 is mediated by 
N-terminal myristoylation 
To investigate if N-terminal myristoylation plays a role in FMNL1 function and 
membrane localization, cells were transfected with FMNL1 or the G2TA4T 
mutant. The mutant G2TA4T, in fact, abolished membranous and cortical 
localization of FMNL1 after transfection of the mutant splice variant in 293T 
cells as well as after genetic transfer of this mutant in other cell lines (Figure 
5.17a). Similarly, mutation of the N-myristoylation site in the FMNL1ΔDAD 
(G2TA4TΔDAD) also abrogated membranous localization of FMNL1ΔDAD 
(Figure 5.17b). Membrane localization of FMNL1 and FMNL1ΔDAD could be 
also inhibited by adding 2-Hydroxymyristate, a potent inhibitor of protein 
myristoylation (Paige, Zheng et al. 1990), further confirming that plasma 
membrane localization of FMNL1 is dependent on N-terminal myristoylation 
(Figure 5.18).  
 
 
Figure 5.17 Mutation of the N-myristoylation site abrogated membranous 
localization of FMNL1 and FMNL1ΔDAD. (a) Localization of FMNL at the 
membrane or intracellular vesicles is abrogated by mutation of the N-terminal 
myristoylation motif. Different cell lines were transfected or adenovirally transduced 
with either FMNL1 or the mutant G2TA4T followed by staining with the rat 
FMNL1-specific antibody 6F2 and Cy3-labeled goat anti-rat antibody (red). Nuclei 
were stained with DAPI (blue). Scale bars represent 2 μm. (b) Localization of 
FMNL1ΔDAD at the membrane is abrogated by mutation of the N-terminal 
myristoylation motif. 293T cell lines were transfected with either FMNL1ΔDAD or the 
mutant G2TA4TΔDAD followed by staining with the rat FMNL1-specific antibody 6F2 
and Cy3-labeled goat anti-rat antibody (red). Nuclei were stained with DAPI (blue). 
Scale bars represent 2 μm.  
(a)
 
(b)
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Figure 5.18 Membrane localization of FMNL1 and FMNL1ΔDAD could be 
inhibited by adding 2-Hydroxymyristate. 293T cells transfected with the isoform 
FMNL1 and FMNL1ΔDAD were treated with the inhibitor 2-hydroxy-myristic acid, a 
potent inhibitor of protein myristoylation and stained as described in Figure 5.17. 
Scale bars represent 2 μm.  
 
Blebbing was significantly reduced in 293T cells after transfection with 
G2TA4T or G2TA4TΔDAD in comparison to FMNL1 or FMNL1ΔDAD (Figure 
5.19), indicating that membrane or cortical localization mediated by 
N-terminal myristoylation is important for membrane blebbing induced by 
FMNL1. Furthermore, we observed an increase in multinucleated cells in 
T293 cells transduced with the mutated FMNL1 (Figure 5.20). 
 
 
Figure 5.19 Mutation of the N-terminal myristoylation motif reduced membrane 
blebbing induced by FMNL1 or FMNL1ΔDAD in 293T cells. Hundred transduced 
cells were analyzed for investigation of cell blebbing. The bars show the standard 
deviation of independent counting experiments (n=3; *** p< 0.001).  
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Figure 5.20 Mutation of the N-terminal myristoylation motif increased cells with 
multiple nuclei. (a) 293T cells were transfected with pcDNA vector contiaing FMNL 
or G2TA4T mutant. Cells were stained with the rat FMNL1-specific antibody 6F2 
followed with Cy3-labeled goat anti-rat antibody (red). Nuclei were stained with DAPI 
(blue). Scale bars represent 2 μm. (b) For investigation of cells with multiple nuclei, 
hundred transfected cells were analyzed. The bars show the standard deviation of 
independent counting experiments (n=3; *** p< 0.001).  
 
5.5  Expression of FMNL1 moderately increases cell 
proliferation  
Blebbing has been previously shown to be associated to cytokinesis (Charras 
2008). By analyzing cell numbers after transfection of 293T cells or 
transduction of K562, MDA-MB 231 and HT1080 cells with different splice 
variants of FMNL1, moderately increased cell counts were observed in cells 
transfected or transduced with FMNL1 in comparison to the other isoforms or 
the GFP mock control (Figure 5.21).  
     
(a)
 
(b)
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Figure 5.21 Cell counts after transfection of 293T cells or transduction of K562, 
MDA-MB 231 and HT1080 cells with different splice variants of FMNL1. Counting 
of cells after transduction with different FMNL1 isoforms revealed a moderate 
increase in cell proliferation after transfection or transduction with FMNL1γ in 
comparison to FMNL1α, FMNL1β and GFP. All single counting experiments showed 
an increase in cell counts after transduction of this isoform in different cell lines as 
293T, K562, HT1080 and MDA-MB 231. The multiplication factor (MF) of cell counts 
after transduction in comparison to day -1 or day 0, when adenoviral transduction was 
performed, is shown.  
 
As HT1080 and MDA-MB 231 cells are highly genetically transducible by 
adenoviral infection as seen by GFP expression (> 90%), we used these cell 
lines for further investigation of proliferation by seminaphtorhodafluor-1 
carboxylic acid, acetate and succinimidyl ester (SNARF-1) staining. SNARF-1 
worked similarly as Carboxyfluorescein diacetate succinimidyl ester (CFSE), 
but conjugated with fluorescence PE instead of Fitc. SNARF-1 is retained by 
the cells and is shared by the daughter cells at each division, resulting in 
multimodal flow cytometric SNARF-1 histograms, with each cell generation 
clustering around half the fluorescence intensity of the previous one. Cells 
transduced with FMNL1γ demonstrated an enhanced decrease of SNARF-1 
stain correlating with increased cell proliferation (Figure 5.21a). Similar results 
were obtained after 5`-bromo-2`-deoxyuridine (BrdU) incorporation followed 
by anti-BrdU and 7-amino-Actinomycin D (7-AAD) staining of HT1080 cells 
transduced with different splice variants (Figure 5.22b). In these experiments 
we did not observe major differences in single cell cycle phases. However, 
despite of a reduced number of cells entering the cell cycle after adenoviral 
infection similar for all conditions, we repeatedly observed a significant BrdU 
positive population at G0/G1 phase 3 days after transduction with FMNL1γ in 
comparison to the other isoforms or GFP control indicating an accelerated 
passage through the cell cycle (Figure 5.22b).  
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(b)   HT1080 
 
 
 
Figure 5.22 FMNL1 moderately enhances cell proliferation in transduced cell 
lines. (a) Increase of proliferation was confirmed by SNARF-1 staining using 
MDA-MB 231 and HT1080. Cells were stained by SNARF-1 and then adenovirally 
transduced with the three different FMNL1 isoforms as well as GFP control. The filled 
grey curves show the fluorescence at 620 nm at day 0 and the black transparent 
curves at day 4 after transduction. The mean fluorescence of SNARF-1 after 4 days is 
indicated within the graph. One of three similar experiments is shown. (b) Accelerated 
proliferation in HT1080 cells after transduction of FMNL1γ was additionally confirmed 
by BrdU uptake without significant differences in single cell cycle phases analyzed by 
DNA-staining with 7-AAD. HT1080 cells were seeded overnight and transduced the 
next day with different FMNL1 isoforms and GFP vector control. After 24 hours 10 μM 
BrdU was added and 48 hours later cells were harvested fixed and stained with 
APC-conjugated anti-BrdU antibody and 7-AAD. R1: life gate within forward and side 
scatter (not shown), R2: apoptotic cells, R3: cells in G0/G1 without BrdU uptake, R4: 
cells in S phase without BrdU uptake, R5 cells in G2/M with BrdU uptake, R6: cells in 
G0/G1 with BrdU uptake after cycling.  
(a) 
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Investigation by confocal microscopy has demonstrated that, like the 
endogenous FMNL1 in T cells, FMNL1 located at contractile ring and cortex 
of mitotic FMNL1 transfected 293T cells (Figure 5.23). This result suggested 
that the involvement of FMNL1 in acceleration of cell proliferation may be 
associated to the involvement of FMNL1 in cytokinesis. 
 
293T-FMNL1 
 
 
Figure 5.23 FMNL1 was located at contractile ring and cortex of mitotic cells. 
293T cells were transfected with FMNL and stained with the rat FMNL1-specific 
antibody 6F2 followed by Cy3-labeled goat anti-rat antibody (red). Nuclei were 
stained with DAPI (blue). Scale bars represent 2 μm. 
 
5.6  FMNL1 increases free intracellular Calcium after 
stimulation  
By matrix-assisted laser desorption/ionization (MALDI), several candidates 
have been isolated in the group of Angela Krackhardt (unpublished data) as 
interaction partners of FMNL1 including the protein AHNAK. AHNAK is a 
scaffold protein which has been reported to be critical for calcium signaling 
during T cell activation. AHNAK deficiency in CD4+ T cells resulted in a 
reduced calcium influx upon TCR crosslinking and subsequent poor 
activation of the transcription factor NFAT (Matza, Badou et al. 2008). We 
therefore transfected or transduced different cell lines with FMNL1 isoforms 
and measured the calcium influx after activating these cells with ionomycine 
or A23187 (Figure 5.24a-c).  
 
293T cells were transfected with FMNL1 isoforms as well as the vector 
control and activated by 10 μg/ml ionomycine. In two experiments, FMNL1 
isoforms increased free intracellular calcium level compared to the vector 
control. Two additional cell lines MDA-MB 231 cells and HT1080 cells were 
adenovirally transduced with FMNL1 isoforms as well as vector conrol. 
MDA-MB 231 cells were activated by 10 μg/ml ionomycine while HT1080 
cells were activated with 10μg/ml A23187, which is also known as calcium 
ionophore used to increase intracellular Ca2+ levels. Similar results have been 
obtained indicating that all splice variants of FMNL1 induced an increase of 
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free intracellular calcium compared to vector and WT controls. At the same 
time, immunoblotting was performed to confirm expression of FMNL1. These 
experiments suggested that N-terminal myristoylation may not play a role in 
increasing intracellular calcium as no difference between cell transfected with 
FMNL1 isoforms or G2TA4T mutant was observed in all experiments 
performed. 
 
 
 
 
 
(a) 
(b) 
Exp2: 
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Figure 5.24 FMNL1 induces increased calcium influx after cell activation. 293T 
cells (a) were transfected with pcDNA vector containing FMNL1 isoforms as well as 
the vector control. MDA-MB 231 cells (b) and HT1080 cells (c) were adenovirally 
transduced with FMNL1 isoforms as well as vector conrol. 2 days later, cells were 
harvested and activated by 10 μg/ml ionomycine (a,b) or 10μg/ml A23187 (c). 
Calcium concentration was measured by a ratiometric method using indo-1 as probe. 
MF= mean fluorescence. The expression of FMNL1 isoforms was investigated by 
immunoblotting using the FMNL1 specific antibody 6F2. 
 
 
 
 
 
 
 
 
 
 
 
 
(c) 
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6 Discussion 
Immunotherapies against cancer using T cells or antibodies specific for tumor 
antigens are attractive alternative and complementary treatment modalities of 
malignant diseases. One major advantage is the high specificity and limited 
toxicity of these agents. Several therapeutic monoclonal antibodies have been 
already approved by the US Food and Drug Administration (FDA) for use in 
oncology (Adams and Weiner 2005; Weiner, Dhodapkar et al. 2009). Adoptive 
cell therapy (ACT) using autologous tumor-infiltrating lymphocytes has been 
considered as the most effective treatment for patients with metastatic 
melanoma since it can induce approximate 50% regression in patients with 
target cancer (Rosenberg, Restifo et al. 2008). The emphasis of the 
development of immunotherapies has shifted from discovery and identification 
of tumor antigens to the utilizating these antigens to mediate the destruction of 
tumor in humans (Rosenberg 1999). However, it might be also important to 
carefully investigate expression and function of tumor-associated antigens in 
order to estimate potential side effect when targeting them (Theoret et. 
al.2008). 
 
The hematopoietic lineage-specific formin FMNL1 is a tumor-associated 
antigen which has been previously identified using the SEREX technology.  
FMNL1 is overexpressed in malignant cells derived from patients with CLL 
and other lymphomas as well as some solid tumors. In healthy tissue, it is 
almost exclusively expressed in hematopoietic cells suggesting this TAA to 
be a suitable target antigen for immune-mediated therapies in a transplant 
setting. However, function and role of FMNL1 have not been well 
characterized. Formin proteins have been described to promote the formation 
of actin networks and to be involved in regulation of essential cellular 
functions as cell division, migration, adhesion and intracellular trafficking.  
 
In this work, we first investigated the expression of FMNL1 by western blot and 
confirmed the previous data that FMNL1 could be detected in native malignant 
cells from patients with lymphatic as well as myeloid leukemias and 
EBV-transformed B cells. FMNL1 is also expressed in lymphoma-derived cells 
and renal carcinoma cells (Schuster, Busch et al. 2007). Moreover, we 
continued to investigate the localization of FMNL1 by confocal microscopy. We 
found a dot-like cytoplasmic localization of native human FMNL1 in different 
hematopoietic lineage-derived cells and observed stimulation-specific 
polarization of endogenous FMNL1 to the immunological synapse of T cells 
and to the phagocytotic cup of monocytes which is in common with previous 
observations for human FMNL1 and the murine counterpart 
(Yayoshi-Yamamoto, Taniuchi et al. 2000; Seth, Otomo et al. 2006; Gomez, 
Kumar et al. 2007). We additionally noticed colocalization of FMNL1 at the 
mitotic spindle and cortex of dividing T cells, especially at the telephase, 
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suggesting involvement of FMNL1 involved in mitosis and cytokinesis 
(discussed in Chapter 6.4). 
 
To further investigate the functional role of FMNL1, we have isolated three 
different FMNL1 splice variants from cDNA of CLL cells and human lung 
carcinoma, which result in varying C-terminal amino acid sequences (Figure 
5.7a). FMNL1 and FMNL1 are corresponding to the previously described 
murine splice variants, FRL and FRL (Yayoshi-Yamamoto, Taniuchi et 
al. 2000; Harris, Li et al. 2004). However, the novel identified splice variant 
(FMNL1) contains an intron retention of 58 amino acids at the C-terminal end 
affecting the DAD but sharing the last 30 amino acids of C-terminal end with 
FMNL1 (Figure 5.7b). FMNL1 showed increased mRNA-expression in bone 
marrow, thymus, fetal brain and diverse hematopoietic lineage-derived cells. 
We also observed a high expression of FMNL1 in malignant cells of a subset 
of CLL patients. Detailed analyses of systematically isolated and processed 
patient samples need to be performed in order to clarify if overexpression of 
FMNL1 in CLL samples is associated with an activated malignant cell status 
and/or patient prognosis and will be a focus of further studies.  
 
Overexpression of FMNL1 shows that it is specifically located at the cell 
membrane and cortex in diverse cell lines which is similar as observed for a 
mutant lacking the DAD domain (FMNL1∆DAD) indicating that deregulation of 
autoinhibition is effective in FMNL1. Both expression of FMNL1 and 
FMNL1∆DAD induces polarized non-apoptotic blebbing which is dependent on 
actin, tubulin and myosin integrity but independent of Src and ROCK activity, 
which are reported to be crucial for bleb formation induced by other formins 
(discussed in Chapter 6.2). Moreover, we described N-terminal myristoylation 
as a regulative mechanism of FMNL1 responsible for membrane trafficking 
potentially involved in a diversity of polarized processes of cells including 
proliferation.  
 
6.1  Deregulation of autoinhibition in FMNL1 
Although a role of the novel isolated splice variant FMNL1 in malignant 
transformation could not be ascertained in this study, it showed distinct 
functional properties similar to the FMNL1 mutant missing the DAD sequence 
with deregulated autoinhibition. Both of them showed membrane localization 
and distinct functional properties as actin assembly activity and blebbing. This 
is in common with a previous publication demonstrating that deregulation of 
autoinhibition by deletion of the DAD region induces membrane localization 
and actin assembly activity in FRLα (Seth, Otomo et al. 2006).  
 
A complex regulation network seems to be responsible for activation and 
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different functions of formin proteins. A central regulative tool for DRFs is 
autoregulation which can be released by interaction with active Rho-GTPases 
and potentially additional factors (Faix and Grosse 2006). Splicing has been 
also shown to result in differential functionality of formin proteins (Gasman, 
Kalaidzidis et al. 2003). The protein autoinhibition is induced by binding of the 
DAD peptide region to the DID armadillo repeat structure which has been 
reported to be mainly dependent of hydrophobic interaction (Nezami, Poy et al. 
2006; Lammers, Meyer et al. 2008). The core of the DAD segment is an 
amphipathic helix. As described for mDia1 by Nezami et al, the Gly1180 at its 
N terminus and Gly1192 at its C terminus bind to the concave surface of DID 
which is formed by the central B helices of the five armadillo repeats. The 
hydrophobic face of the DAD helix, defined by Val1181, Met1182, Leu1185, 
and Leu1189, packs in a shallow groove on the DID. DAD residue Met1182 
makes particularly extensive contact; it inserts into a pocket formed by a ring of 
hydrophobic residues on DID (Nezami, Poy et al. 2006).  
 
The DAD binding surface on the DID domain is highly conserved among most 
Diaphanous related formins. 5 surface residues (Asn217, Asn218, Ala256, 
Asn310, and Gln352) were demonstrated to be most conserved participating in 
DAD recognition. This is based on mapping of conserved residues on the 
surface of the DID domain of DRFs (Nezami, Poy et al. 2006). Moreover, The 
DAD residues in the binding interface are also conserved among most DRFs, 
including the residues of Met 1182, Leu1185, Leu1186 and Leu1189 (Figure 
6.1) (Alberts 2001; Nezami, Poy et al. 2006).   
 
 
Figure 6.1 Conservation at the DID/DAD Interface. Highly conserved residues of 
DID interacting with DAD are shown in pink. Previous structure/function analysis 
(Alberts, 2001) of the DAD segment reveals that residues Met1182, Leu1185 and 
Leu1189 (red side chains) are required for autoinhibition, but Ser1183, Glu1187, and 
Gln1190 are not required (green side chains). (Nezami, Poy et al. 2006) 
 
In figure 6.2, we have compared the conserved DAD residues of FMNL1, 
FMNL1 and FMNL1 with mammalian formins mDia, Daam1 
(Dishevelledassociated activator of morphogenesis-1), the yeast formin Bnr1p, 
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the mammalian formin FRL1, FRL2, and FRL3 (Higgs and Peterson 2005; 
Nezami, Poy et al. 2006). It shows that Ile1059, Ile1062 and Ile1066 in 
FMNL1 and Ile1059, Ile1062 and Leu1066 in FMNL1 are corresponding to 
Met1182, Leu1185, and Leu1189 in mDia, which are considered to be 
responsible for protein autoinhibition. However, FMNL1 contains an intron 
retention of 58 amino acids at the C-terminus but shares the last 30 amino 
acids with FMNL1. This intron retention affects the DAD sequence and 
results in a positive charged polar amino acid Lys1066 instead of the non polar 
amino acids Ile1066 or Leu1066 present in FMNL1 or FMNL1. This polar 
lysine could be responsible for release of hydrophobic reaction between DID 
and DAD and further release of autoinhibition of FMNL1 resulting in a 
constitutively activated form.  
 
 
 
Figure 6.2 Multiple sequence alignment of residues at the DAD interface in DRF 
formins. Residues involved in the autoinhibitory interaction are indicated in red. High 
conservation of these residues in all mDia formins as well as mammalian Daam1, 
FRL1, FRL2, FRL3, FMNL1 splice variants and yeast Bnr1p points to a similar 
mechanism of autoinhibition in these formins. However, FMNL1 contains an intron 
retention affecting the DAD sequence and resulting in a positive charged polar amino 
acid Lys1066 instead (in blue), which may be responsible for the release of 
autoinhibition in FMNL1. 
 
In fact, the splice variant FMNL1, in common with FMNL1ΔDAD, was 
specifically located at the membrane and cortex of different cell lines and 
induced bleb formation. It points to the fact that the incapability of DID binding 
to DAD is responsible for deregulation of autoinhibition and membrane 
localization and bleb formation by FMNL1. It is very interesting that FRL2 has 
been also reported to be a constitutively activated formin protein because of its 
capability to accumulate actin stress fibers. However, FRL2 is located in the 
cytoplasma as its autoinhibited counterpart FRL3. The DAD of FRL2 could still 
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bind to the DID without any inhibition (Vaillant, Copeland et al. 2008). It could 
be explained by the presence of only non polar amino acids at the highly 
conserved position of DAD in FRL2, which insures the interaction between the 
two domains. However, this interaction failed to inhibit FRL2 activity suggesting 
an additional regulator for formin autoinhibition. 
 
6.2  Regulation of blebbing induced by FMNL1 
Blebbing is a common feature of cell physiology during cell movement, 
cytokinesis, cell spreading and apoptosis. Blebs are spherical protrusions of 
the cell membrane which form and disappear in seconds (Charras, Yarrow et 
al. 2005). Usually, the blebs induced by apoptosis are larger and more 
transparent and their growth is independent of actomyosin contractions 
(Barros, Kanaseki et al. 2003). Unlike them, other blebs depend on actomyosin 
contractions of the cortex, which cause either detachment of the cell 
membrane from the actin cortex (Charras, Yarrow et al. 2005) or a local 
rupture in the actin cortex (Paluch, Piel et al. 2005) to form blebbs. In the 
former way, a local shortening of the actin cortex caused by myosin contraction 
gives rises to a centripetal compression of the cytoplasm and induces a 
transient increase in intra-cellular pressure. This high local intra-cellular 
pressure tears the membrane from the actin cortex and pushed cytosol from 
cell body by into blebs. Alternatively, myosin contraction stretchs the actin 
cortex and increases local tension, leading to the final rupture of actin cortex 
and the expelling of cytosol which inflates the cell membrane. During growth, 
the plasma membrane is transiently devoid of an actin cytoskeleton and lipids 
flow into the bleb through the neck of blebs. Furthermore, after growth has 
stalled, an actin cortex is reconstituted under the plasma membrane (Charras 
2008). During the blebs expansion and cortex regrowth, regulatory proteins of 
the actin cytoskeleton are present at the cell membrane, the first of which is the 
ERM protein ezrin, which links the actin cytoskeleton to the cell membrane. 
Shortly after the recruitment of ezrin, actin appeared at the bleb membrane 
forming a cage-like structure underneath the bleb membrane. Finally, myosin II 
motors powered bleb retraction (Charras, Hu et al. 2006; Charras 2008).  
 
In this work, we have observed that FMNL1 could induce non-apoptotic cell 
blebbing in 293T cells and K562 cells. Moreover, FMNL1 colocalized with the 
indicated regulatory proteins such as actin, ezrin and myosin IIb on cell 
membrane and cortex to blebs. The colocalization FMNL1 with F-actin in bleb 
protrusions suggests the property of FMNL1 to induce actin assembly. 
Blebbing but not membrane localization of FMNL1 was totally abrogated by 
Latrunculin B further confirming regulation of actin assembly and 
actin-mediated polarized bleb formation by FMNL1. To further investigate the 
mechanism of bleb formation induced by FMNL1, FMNL1 transduced 293T 
cells were incubated in medium containing Myosin II-ATPase inhibitor 
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Blebbistatin and microtubuli inhibitor Nocodazole. Bleb formation was 
significantly inhibited by these inhibitors confirming a substantial role of myosin 
and microtubules in FMNL1-induced blebbing. These results are in common 
with previous reports demonstrating that bleb induction by the Leishmania 
parasite virulence factor HASPB depends on the integrity of F-actin and 
requires myosin II function as well as microtubule networks (Tournaviti, 
Hannemann et al. 2007). Tournaviti also demonstrated that although blebbing 
induced by HASPB is dependent on the integrity of microtubule, no specific 
association of microtubule with the blebs was observed (Tournaviti, 
Hannemann et al. 2007). In contrast, we additionally observed colacolization of 
-tubulin with FMNL1 to FMNL1-induced blebs in 293T cells. It suggested 
that, unlike HASPB, FMNL1 may directly associate with microtubule to induce 
bleb formation. However, it needs to be confirmed by protein 
immunoprecipitation. 
 
Moreover, the formins FHOD1, mDia1 and mDia2 have been also associated 
to blebbing (Eisenmann, Harris et al. 2007; Kitzing, Sahadevan et al. 2007; 
Hannemann, Madrid et al. 2008). Bleb formation induced by these formins 
required Rho-kinase (ROCK) and Src activity. It has been previously reported 
that the small GTPase Rho and its downstream effector ROCK play an 
essential role in governing cell cortex contraction (Coleman, Sahai et al. 2001; 
Etienne-Manneville and Hall 2002). The activation of GTPase Rho and ROCK 
leads to both actin polymerization and myosin II recruitment during cytokinesis 
and chemotaxis (Lee, Katakai et al. 2004; Bement, Benink et al. 2005; Kamijo, 
Ohara et al. 2006). Rho directly activates formins, which as an actin-nucleating 
protein hold onto growing barbed ends (Higashida, Miyoshi et al. 2004), and 
activates myosin II by regulation of its phosphorylation state through 
Rho-kinase (Totsukawa, Yamakita et al. 2000).  How might Src signalling 
regulate blebbing? Ezrin which is a membrane-actin crosslinks protein, is 
subject to regulation by Src (Elliott, Qiao et al. 2004; Srivastava, Elliott et al. 
2005). Additionally, Src functionally cooperates with formin protein family 
which might also govern bleb retraction (Tominaga, Sahai et al. 2000; Gasman, 
Kalaidzidis et al. 2003; Koka, Minick et al. 2005). However, in contrast to 
former publications, blebbing induced by FMNL1 is independent of Src and 
ROCK as the Src inhibitor PP1 and the ROCK inhibitor Y-27632 did not reduce 
blebbing in our experiments. This might be explained by the constitutive 
activation of FMNL1 and suggest a novel regulation of blebbing induced by 
formin proteins beside the activation of Rho GTPase, ROCK and Src. 
 
Futrthermore, the shape and extent of blebs varied in different cell lines. 
FMNL1-induced blebbing was less obvious in HT1080 and MDA-MB 231 cells. 
However, these cell lines especially demonstrated enrichment of FMNL1 at 
intracellular vesicles beside the localization at the cell membrane. HT1080 has 
mesenchymal characteristics and MDA-MB 231 cells are epithelial cells, 
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indicating that cell type-specific interaction partners additionally play an 
important role in function and bleb shape. In these cell lines, FMNL1 could play 
a role in vesicles transferring and autophagocytosis. Unlike them, the K562 
cells are hematopoietic origin, which could probably represent a more natural 
recipient cell for investigation of FMNL1. K562 cells transduced with FMNL1 
often demonstrated a polarized uropod-like circular. Uropod formation of 
leukocytes has been reported to be involved in cell migration, activation and 
cell-cell interaction. This polarized structure has distinct function in the immune 
response as it could help T cell to form the immunological synapse when 
interacting with target cells (Fais and Malorni 2003). The involvement of 
FMNL1 in the cell polarization is in common with the investigation of 
endogenous FMNL1 in specific targeted T cell. 
 
6.3  N-terminal myristoylation 
To further evaluate the mechanism of membrane localization and 
bleb-induction by FMNL1, we analyzed the protein sequence motifs of FMNL1 
and identified a myristoylation site at the N-terminus of human FMNL1 and 
murine FRL with glycine at position 2 representing an essential requirement for 
myristoylation.  
 
N-terminal myristoylation of proteins stand for the covalent attachment of 
myristate, a 14-carbon saturated fatty acid, to the N-terminal glycine of 
eukaryotic and viral proteins (Farazi, Waksman et al. 2001). This transfer is 
catalyzed by myristoyl-CoA:protein N-myristoyltransferase (Nmt) (Towler, 
Adams et al. 1987). N-terminal myristoylation sites have been reported to 
direct membrane association by interaction with negatively charged 
phospholipids enriched in the cytoplasmic leaflet of cellular membranes 
(Peitzsch and McLaughlin 1993). The model of how the N-terminal 
myristoylated protein, tyrosine kinase c-Src, anchors to the membrane is 
shown in Figure 6.3 (Murray, Ben-Tal et al. 1997): 10 carbon fatty acids 
penetrate the hydrocarbon core of the membrane while the other four insert 
into the polar head group region. The N-terminal glycine is located just outside 
the envelope of the polar head group region.  
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Figure 6.3 Schematic view of interaction of N-myristoalated protein Src with 
membrane. (a) The N-terminal portion of Src which contains the two motifs required 
for membrane association: the myristate (colored green) and a cluster of basic 
residues (blue plus signs), which are shown in more detail in (b) The myristate of Src 
protein is colored green, basic residues blue and acidic residues red. In the 
membrane, the acidic lipid, phosphatidylserine, is identified by its exposed nitrogen, 
colored blue. (Murray, Ben-Tal et al. 1997) 
 
Some proteins containing an N-termial glycine at position two are not 
myristoylated, probably because of some sequence requirements that are not 
fulfilled by those proteins. The sequence at the N-terminal myristoylatrion site 
of the protein substrates should contain more than the glycine at the 
N-terminus (Boutin 1997). The most important sequence might be the second 
and sixth residue (Boutin 1997). A serine or a threonine residue at the sixth 
position favours the myristoylation (Johnson, Bhatnagar et al. 1994). FMNL1 
does have a glycine at N-terminus at position two and the favourable 
asparagines at position three, however lacks the serine or threonine at position 
six (Figure 5.15). FMNL1contains another glycine at position s, which is also 
common in some myristoylated proteins like ARF3, c-abl and Rat lipase 
(Boutin 1997). To confirm if FMNL1is an N-myristoylated protein, a myristic 
acid uptake assay was performed. Cells transfected with FMNL1 or G2TA4T 
mutant were metabolically labeled with [3H]-myristic acid and 
immunoprecipitated by FMNL1-specific antibody. Autoradiography analysis 
demonstrated that FMNL1, but not G2TA4T, was myristoylated in 293T cells 
which provides direct evidence that FMNL1 is indeed an N-terminal 
myristoylated protein. FMNL1 and FMNL1ΔDAD but not the mutant G2TA4T 
was shown to be located to the plasma membrane. Moreover, myristoylation 
could be inhibited by 2-Hydroxymyristate, a potent inhibitor of myristoylation 
(Paige, Zheng et al. 1990), resulting in loss of membrane localization. As 
described before, FMNL1 splice variants just differ at the C-terminus. 
Therefore, FMNL1 and FMNL1 also contain N-terminal myristoylation site. 
However, the complex formed by the interaction between DID and DAD in the 
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autoinhibited state may impede membrane localization regulated by N-terminal 
myristoylation.
 
N-terminal myristoylated proteins have diverse functions and intracellular 
destinations. They are crucial in signal transduction, cellular transformation, 
and oncogenesis (Shrivastav, Varma et al. 2008). This motif is typically 
present in the SH4 domain of Src tyrosine kinases and myristoylation has been 
shown to be critical for malignant transformation of v-Src (Cross, Garber et al. 
1984; Kamps, Buss et al. 1985). Myristate is required for Src membrane 
binding which, in turn, is required for Src to function, since nonmyristoylated 
v-Src mutants are found in the cytoplasm but do not transform cells, even 
though the kinase activity of the protein is unaffected. It may because some 
critical targets for Src activity are located at or near the cell membrane (Kamps, 
Buss et al. 1985; Buss, Kamps et al. 1986). In this work, we investigated that 
blebbing induced by FMNL1γ is dependent on N-terminal myristoylation   
since the mutation of glycine at position 2 significantly reduced blebbing. We 
therefore propose that activation of FMNL1 is regulated not only by binding of 
a Rho-GTPase but additionally by an increase of intracellular Ca2+ or a specific 
ligand binding. This may cause a myristoyl switch and therefore induces 
extrusion of the myristoyl group enabling it to quickly and reversibly interact 
with lipid bilayer membranes as previously described for other myristoylated 
proteins (Seykora, Myat et al. 1996; Ames, Ishima et al. 1997). It was proposed 
that the myristoyl group is sequestered in the calcium-free form of the protein 
and becomes exposed in the calcium-bound form, enabling it to insert into a 
lipid bilayer of membrane or a hydrophobic site of a target protein (Zozulya and 
Stryer 1992; Ames, Ishima et al. 1997). These data suggested that myristoyl 
groups are not simply hydrophobic anchors, but can serve as dynamic 
partners in signaling (Ames, Ishima et al. 1997). We have observed that 
calcium binding slightly increases the membrane localization of the 
autoinhibited FMNL1 and FMNL1(preliminary data) suggesting that FMNL1 
could also be activated through the calcium- myristoyl switch. Furthermore, 
stimulation of ionomycine will induce higher concentration of intracellular 
calcium in FMNL1 transduced cells potentially reprtesenting a self-activating 
loop, which will be discussed later in chapter 6.5. 
 
6.4  Acceleration of cell proliferation induced by FMNL1 
As we have shown by Annexin V and propidium iodide staining that blebbing 
induced by FMNL1 was not associated to apoptosis (Figure 5.12). We 
continued to investigate other cellular processes which have been described 
to be involved in cell blebbing such as cytokinesis. By analyzing cell numbers 
in independent counting experiments, we observed that cells derived from 
different cell lines transfected or transduced with FMNL1γ revealed slightly 
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enhanced cell numbers compared to the other splice variants and the mock 
control. Moderately accelerated cell proliferation induced by FMNL1 was 
confirmed by SNARF-1 staining in two cell lines, HT1080 and MDA-MB 231, 
which are highly genetically transducible by adenoviral infection as seen by 
GFP expression (> 90%). Similar results were obtained through a cell cycle 
experiment by BrdU incorporation followed by anti-BrdU and 7-AAD staining 
of HT1080 cells transduced with different FMNL1 splice variants 
demonstrating a significant BrdU positive population at G0/G1 phase 3 days 
after transduction with FMNL1γ which was not present in the other isoforms 
or GFP control. This experiment did not show major differences in single cell 
cycle phases, however indicated an accelerated passage of cells transduced 
by FMNL through the cell cycle.  
 
Murine formin FRL has been shown to be involved in regulation of cell 
survival (Yayoshi-Yamamoto et al., 2000). This group demonstrated that 
macrophages overexpressing the FRL-FH3 truncated protein (only contains 
N-terminal FH3 domain but not FH1 and FH2 domians) were inhibited in cell 
growth and were prone to cell apoptosis. This may be explained by the direct 
binding of FRL-FH3 truncated protein to Rho GTPase Rac, which interfered 
with the Rac binding to endogenous FRL; thus, the normal function of FRL 
was inhibited. However, a direct effect on proliferation has not been 
demonstrated so far. In this work, we have observed by confocal microscopy 
that FMNL1 located at contractile ring and cortex of mitotic FMNL1 
transfected 293T cells. Futhermore, proliferation of cells transduced with 
G2TA4T was still enhanced although slightly reduced in comparison to the 
non-mutated FMNL1 (data not shown). Meanwhile, cells transduced with 
G2TA4T showed an enhancement of multinucleated cells compared to cells 
transduced with non-mutated FMNL1. Multinucleation was also observed in 
spermatids of male flies, when the formin diaphanous mutants resulted in a 
failure in cell division during spermatogenesis (Goode and Eck 2007). Our 
relsults give rise for the hypothsis that the accelerated cell proliferation 
induced by FMNL1 may because of its involvement in cell cytokinesis and 
N-terminal myristoylation may play a role in cell seperation. 
 
The effect on cell proliferation induced by FMNL1 was moderate but 
constantly observed. This may correlate with the slow increase in malignant 
cell burden often observed in patients with CLL and highly encourages the 
further investigation of the role of FMNL1 in CLL cells. In addition, we 
observed colocalization of endogenous FMNL1 to the microtubules and 
midzone cortex of dividing T cells pointing to a possible involvement of 
FMNL1 in mitosis of T cells.  
 
To further confirm the involvement of FMNL1 in cell proliferation, a FMNL1 
specific siRNA would be required to knockdown the endogenous FMNL1 in 
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hematopoietic lineage-derived cells, for example T cells, and then analyzes 
cell proliferation. A FMNL1 specific antiboby would also be required to detect 
the colocalization of endogenous FMNL1 to the microtubuli at the cortex and 
mitotic spindles in dividing cells. On the other hand, the endogenous FMNL1 
may be generally involved in enhanced cell proliferation since knock down of 
FMNL1 in T cells showed slight inhibition of T cell proliferation (unpublished 
data of the group of Dr. Angela Krackhardt). Furthermore, FMNL1 could 
increase intracellular calcium concentration after stimulation which is a 
sufficient signal for cell activation and subsequent gene expression and 
proliferation through the nuclear factor-B (NF-B) pattway (Dolmetsch, 
Lewis et al. 1997). Analysis of interaction partners of FMNL1 could also be 
required to characterize the complete sigaling pathway. 
 
6.5  Intracellular calcium concentration 
The intracellular calcium is one of the most fundamental signalling substances 
which controls diverse cell functions, including adhesion, motility, gene 
expression and proliferation. It has also been reported to be involved in cell 
morphological oscillations such as blebbing (Pletjushkina, Rajfur et al. 2001; 
Blaser, Reichman-Fried et al. 2006). Cyclic intra-cellular calcium changes are 
accompanied with cortical contractility, but whether these calcium oscillations 
are the cause or a consequence of the enhanced contractility is unclear. 
Chelation of extracellular calcium could inhibit blebbing. Therefore elevated 
intra-cellular calcium may cause the myosin contractions that give rise to blebs. 
Conversely, calcium could also enter the cells as a consequence of increased 
membrane tension in blebs. 
 
On the other hand, a cooperation partner of FMNL1, AHNAK, which has been 
identified as an interaction partner of FMNL1 by our group, has been reported 
to be critical for calcium signaling during T cell activation. AHNAK deficiency in 
CD4+ T cells resulted in a reduced calcium influx upon TCR crosslinking and 
subsequent poor activation of the transcription factor NFAT (Matza, Badou et al. 
2008). In our preliminary experiments, AHNAK, like FMNL1, was polarized at 
the immunosynapse in specifically stimulated T cells and colocalized with CD3. 
Moreover, AHNAK was colocalized with FMNL1 at cell membrane and blebs 
in FMNL1 transduced cells. 
 
In this work, different cell lines were transfected or transduced with FMNL1 
isoforms and stained with indo-1 AM. Immediately after activation with 
ionomycine or A23187, the intracellular calcium concentrations in these cells 
were measured during a time of 10 minutes. The results demonstrated a 
higher intracellular calcium concentration in cells transfected or transduced 
with different isoforms of FMNL1 compared to vector and wildtype control. 
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However, there is no difference of enhancement of intracellular calcium 
concentration among different isoforms of FMNL1 including the mutant 
G2TA4T. Thus, the increase of intracellular calcium concentration seems to be 
independent of N-terminal myristoylation. Further experiments need to be 
performed to investigate the role of FMNL1 in calcium signaling pathways.  
 
In conclusion, this project provides novel information about expression and 
specific localization of human endogenous FMNL1 in a diversity of polarized 
processes of hematopoietic lineage-derived cells suggesting FMNL1 to be a 
pluripotent effector protein. Moreover, the newly identified splice variant 
FMNL1 represents a constitutively active form of FMNL1 which localizes at 
the membrane and induces bleb formation. FMNL1 also associates FMNL1 
to mitosis and cell growth. We identified N-terminal myristoylation as an 
important regulatory tool for FMNL1 necessary for bleb formation, enabling 
fast and reversible membrane localization compatible with diverse functions 
of hematopoietic lineage-derived cells. Thus our results suggest FMNL1 to be 
a promise potential target antigen for anti-tumor immunotherapy as it is 
potentially involved in cellular transformation and tumor progression. The 
identification of interaction partners of FMNL1 in diverse 
hematopoietic-derived cells as well as the further characterization of splice 
variants will be highly interesting to identify key molecules regulating different 
FMNL1 functions potentially revealing possibilities for specific therapeutic 
interaction in malignant and inflammatory disease.
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7- amino-Actinomycin D 
Adoptive cell therapy 
acute lymphatic leukaemia 
antigen-presenting cells 
5`-bromo-2`-deoxyuridine 
cluster of differentiation 
complememtary-DNA 
Carboxyfluorescein diacetate succinimidyl 
ester  
chronic lymphocytic leukemia  
Curie 
cytopathic effect 
cytotoxic T-lymphocyte  
cytotoxic T-lymphocyte–associated  
antigen 4  
Diaphanous autoregulatory domain  
Dendritic cells  
dimerization domain 
Diethylpyrocarbonat 
Diaphanous-inhibitory domain  
Dulbecco‟s modified Eagle‟s medium 
Dimethyl Sulfoxide 
Desoxinucleosidtriphosphate  
diaphanous-related forming 
dithiothreitol 
Epstein-Barr virus 
fluorescence-activated cell sorting 
Fetal calf serum  
formin homology 
formin-like 1 
GTPase binding domain 
Green fluorescent protein 
Granulocyte Macrophage Colony Stimulating 
Factory 
Hanks Balanced Salt Solution 
Hodgkin disease 
Iscove‟s Modified Dulbecco‟s Medium  
Interferone-γ 
Immunoglobulin 
Interleukin 
Lipopolysaccharide 
 
7-AAD 
ACT 
ALL 
APCs 
BrdU 
CD 
cDNA 
CFSE 
 
CLL 
Ci 
CPE 
CTL 
CTLA-4 
 
DAD 
DC 
DD 
DEPC 
DID 
DMEM 
DMSO 
dNTP 
DRF 
DTT 
EBV 
FACS 
FCS 
FH 
FMNL1 
GBD 
GFP 
GM-CSF 
 
HBSS 
HD  
IMDM 
INF  
Ig   
IL   
LPS 
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MALDI 
mDia1 
MHC 
min 
Mio 
MTOC 
NHL 
PBL 
PBMC    
PBS 
PCR    
PFA 
PG 
PI 
PMA 
PMSF 
RCC  
rpm         
SNARF-1 
 
TA 
TAA 
TAE   
TBS 
TILs 
TNF α 
 
matrix-assisted laser desorption/ionization 
mammalian diaphanous 1 
major histocompatibility complex 
minute 
miollion 
microtubule organizing center 
non-Hodgkin lymphoma  
peripheral blood leukocytes  
Peripheral blood mononuclear cells 
Phosphate buffered saline 
polymerase chain reaction 
Paraformaldehyd  
Prostaglandin  
Prodium Iodide  
phorbol 12-myristate 13-acetate  
Pheylmethanesulfonyl 
renal cell carcinoma  
rounds per minute 
Seminaphtorhodafluor-1carboxylic acid, 
acetate and succinimidyl ester  
tumor antigens 
tumor-associated antigens 
Tris-acetat-EDTA buffer 
Tris buffered saline 
tumor-infiltrating lymphocytes  
Tumor necrosis factor α 
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The formin protein formin-like 1 (FMNL1) is highly restrict-
edly expressed in hematopoietic lineage-derived cells and has
been previously identified as a tumor-associated antigen. How-
ever, function and regulation of FMNL1 are not well defined.
We have identified a novel splice variant (FMNL1) containing
an intron retention at the C terminus affecting the diaphanous
autoinhibitory domain (DAD). FMNL1 is specifically located
at the cell membrane and cortex in diverse cell lines. Similar
localization of FMNL1 was observed for a mutant lacking the
DAD domain (FMNL1DAD), indicating that deregulation of
autoinhibition is effective in FMNL1. Expression of both
FMNL1 and FMNL1DAD induces polarized nonapoptotic
blebbing that is dependent on N-terminal myristoylation of
FMNL1 but independent of Src and ROCK activity. Thus, our
results describe N-myristoylation as a regulative mechanism
of FMNL1 responsible for membrane trafficking potentially
involved in a diversity of polarized processes of hematopoietic
lineage-derived cells.
Formins represent a protein family indispensable for
many fundamental actin-dependent processes, including
migration, vesicle trafficking, morphogenesis, and cytokine-
sis (1). Because these polarized processes are also involved in
inflammation, deregulated proliferation, and metastasis,
formins have been suggested to represent attractive drug tar-
gets for inflammatory and malignant diseases. Formin-like 1
(FMNL1)3 is expressed restrictedly in hematopoietic lineage-
derived cells and overexpressed in malignant cells of different
origin. This restricted expression suggests FMNL1 to be an
attractive target for novel immunotherapies in malignant and
inflammatory diseases (2, 3). However, function and regulation
of FMNL1 are less well characterized. Previous work has shown
involvement of FMNL1 in the reorientation of themicrotubule-
organizing center toward the immunological synapse and cyto-
toxicity of T cells (4). Themurine homolog FRL, which has 85%
homology to the human counterpart, has been additionally
shown to be involved in cell adhesion and motility of macro-
phages as well as Fc receptor-mediated phagocytosis (5, 6). To
date, it is not clear how these different membrane-associated
processes are regulated.
Formins are defined by a unique and highly conserved C-ter-
minal formin homology (FH) 2 domain that mediates the
effects on actin (7–11). The FH2 domain is proceeded by a
proline-rich FH1 domain that bindswith lowmicromolar affin-
ity to profilin (12, 13). In a conserved subfamily of formins
known as diaphanous-related formins (DRFs), the FH1 and
FH2 domains are flanked by an array of regulatory domains at
theN terminus and by a single C-terminal diaphanous autoreg-
ulatory domain (DAD) (14). The large N-terminal regulatory
region includes a binding domain for small G proteins like Rho-
GTPase followed by an adjacent diaphanous-inhibitory domain
(DID) and a dimerization domain (13, 15–17). TheDAD,which
comprised only a small stretch of amino acid residues, binds to
the DID. Interaction of DAD and DID is responsible for auto-
inhibition of DRFs. The mammalian diaphanous 1 (Dia1) as
well as the macrophage-enriched murine formin-like protein 1
(FRL) are both regulated by autoinhibition in a DAD-depen-
dent manner (5, 6, 18, 19).
In addition to the domain-specific functions, formin proteins
seem to be intensively regulated by splicing. Splicing at the N
terminus has been demonstrated to be involved in distinct pro-
tein regulation and function of Dia2 (20). The DAD domain is
also a hotspot of splicing. Within this area, two splice variants
have been characterized for FRL, although functional differ-
ences have not been observed (19). In contrast, abrogation of
autoinhibition in mutants lacking the C terminus in Dia1 and
FRL specifically induces peripheral and plasma membrane
localization (5, 21). The exactmechanismof howDRFs locate to
the plasma membrane is, however, currently unknown.
We identified a novel splice variant and constitutively active
form of FMNL1with distinctmembrane localization.We dem-
onstrate that this novel splice variant (FMNL1) directly medi-
ates intensive blebbing that is independent of Src and ROCK
activity. In contrast, FMNL1-mediated membrane trafficking
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KR2305/3-1, the Helmholtz Zentrum Mu¨nchen, and the Life Science
Stiftung.
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and bleb formation are dependent on N-terminal myristoyla-
tion of FMNL1, potentially representing a general mechanism
involved in diverse membrane-associated functions of FMNL.
EXPERIMENTAL PROCEDURES
Cells and Cell Lines—Peripheral blood mononuclear cells
(PBMCs) from healthy donors as well as patients with
chronic lymphocytic leukemia (CLL) were collected with
donors’ and patients’ informed consent following the
requirements of the local ethical board. Patients had diagno-
sis of CLL by morphology, flow cytometric analysis, and
cytogenetics. PBMCs were obtained by density gradient cen-
trifugation on Ficoll/Hypaque (Biochrom). PBMC subpopula-
tions from healthy donors were isolated by negative or positive
magnetic depletion (Invitrogen). A T cell clone (SK22) with
specificity for the FMNL1-derived peptide PP2was used to ana-
lyze polarized T cells (3). For polarization experiments, T2 cells
were pulsed with the specific peptide followed by incubation
with SK22 for 15min before staining. Unspecific stimulation of
PBMCswas induced by interleukin-2 (50 units/ml; ChironVac-
cines International) and OKT3 (30 ng/ml; ATCC) for 3 days. B
cells and CLL cells were activated by soluble CD40-ligand (1
g/ml; Tebu-bio). The following cell lineswere used for expres-
sion and analysis of FMNL1 splice variants after adenoviral
transfer: chronic myelogenous leukemia cell line K562 (ATCC
CCL-243), breast carcinoma cell line MDA-MB 231 (CLS), the
human fibrosarcoma cell line HT1080 (ATCC CCL-121), and
HEK293T embryonal kidney cells (ATCC CRL-1573). In addi-
tion, 293A (Invitrogen) cells were used for production of
adenoviral supernatant.
Detection of FMNL1 Splice Variants and Sequence Analysis—
The DAD region of FMNL1 in CLL cells was analyzed using
the following exon-overlapping primers: forward, GTGCT-
GCAGGAGCTAGACATG, and reverse, CCCTCTAGCCC-
CTCAGATCTG. Gel electrophoresis of PCR amplicons re-
vealed PCR products of two different sizes, 1312 and 1489
(NCBI FJ534522), representing the C termini of FMNL1 and
FMNL1, respectively. The PCR products were cloned into
pCR 2.1 using the Topo cloning kit (Invitrogen) followed by
transformation of Top10 Escherichia coli (Invitrogen). Grow-
ing clones were analyzed by sequencing (Sequiserve) revealing
twodifferentC-terminal sequences. In addition, theC terminus
representing FMNL1 was derived from human lung carci-
noma cDNA clone IMAGp958M162704Q2 (RZPD). The three
splice variants are shown in Fig. 2B.
Quantitative Reverse Transcription-PCR—Toevaluate quan-
titative mRNA expression of FMNL1 compared with overall
FMNL1 expression, total RNA was extracted from normal
PBMCs and malignant cells from patients with CLL and cell
lines (22), and cDNA was synthesized by Superscript II reverse
transcriptase (Invitrogen) according to the manufacturer’s
instructions. In addition, cDNA derived from normal tissues
pooled fromdifferent donors (Clontech)was used. Detection of
splice variant-specific FMNL1mRNAwas conducted using the
Light Cycler PCR Master Mix (Roche Applied Science). The
following exon-overlapping primers were used for overall
FMNL1 detection, resulting in a 299-bp amplicon: 5-CAAG-
AACCCCAGAACCAAGGCTCTGG and 3-CTGCAGGT-
CGTACGCCTCAATGGC. In addition, exon-overlapping
FMNL1 splice variant-specific primers were applied, resulting
in a 254-bp amplicon: 5-GCAGCAGAAGGAGCCACTCAT-
TTATGAGAGC and 3-GCACCGTCTTGATCACTGAGT-
GGGGGTGG. These primers resulted in high cycle threshold
values (26) in 293T cells overexpressing FMNL1 and  (see
Fig. 2D). The amplicons were detected by fluorescence (530
nm) using a double-stranded DNA-binding dye, SYBR Green I
with the Light Cycler instrument. 18 S rRNAwas processed as a
control for relative quantification. Relative quantitative
expression was calculated using the - cycle threshold
method (23). Skeletal muscle was used as reference tissue
because it showed the highest cycle threshold for detection
of FMNL1 and FMNL1 (cycle threshold for overall FMNL1
expression in skeletal muscle, 25; for FMNL1 expression in
skeletal muscle, 30).
Cloning of FMNL1 Splice Variants and Mutants—DNA of
different splice variants was cloned into pcDNA3.1 and a
pEntr11/pACDC-derived entry clone containing the com-
plete FMNL1 sequence using the single SbfI restriction site
within FMNL1 to exchange the C termini with the sequences of
FMNL1 and FMNL1. The pEntr11/pACDC-derived entry
clone additionally contains the green fluorescent protein gene.
This vector was used for recombination into pAD/PL-DEST
adenoviral vector, digested with PacI, and transfected into a
293A adenoviral producer cell line according to the manufac-
turer’s instructions (Invitrogen). Amplification of adenoviral
stocks resulted in titers of 107–109 particles/ml. Virus superna-
tantswere used to transiently infect different cell lines for trans-
duction of FMNL1 splice variants. Transduction efficiency was
analyzed by green fluorescent protein expression of infected
cells andwas 90–100% forHT1080 andMDA-MB 231 but only
20–40% for K562. In addition, pcDNA3.1 vectors containing
different FMNL1 splice variants were transfected into 293T
cells by calcium phosphate transfection as indicated, resulting
in transfection rates of approximately 40–50%.Mutation of the
hypothetical N-terminal myristoylation site was performed
using the QuikChange mutagenesis kit (Stratagene) according
to the manufacturer’s instructions. The G2T/A4T mutations
were performed at the N terminus (see Fig. 5A).
Mutants lacking the DAD were generated for FMNL1 and
themutantG2TA4Tby PCR and cloned in pcDNA3.1 using the
following primers: FMNL1, 5-ATTGCTAGCCACCATGGG-
CAACGCGGCCGGCAGCGCCGAGC; G2T/A4T, 5-ATTG-
CTAGCCACCATGACCAACACGGCCGGCAGCGCCGAG;
and FMNL1DAD, 3-ATTCTAGACTAGCTCTCATAAAT-
GAGTGGCTCCTTCTGCTG. The FMNL1 lacking DAD was
also cloned in pEntr11/pACDC-derived entry clone using the
following primers: FMNL1, 5-ATGGATCCCACCATGGGC-
AACGCGGCCGGCAGCGCCGAGCAGC; and FMNL1DAD,
3-AAGGATCCCTAGCTCTCATAAATGAGTGGCTCCTT-
CTGCTG.
Reagents and Antibodies—The previously described C-ter-
minal FMNL1-specific rat anti-human antibody 6F2 recog-
nizing the peptide KKEAAAQEAGADT was used to detect
FMNL1 by immunofluorescence microscopy and Western
blotting. Specificity for FMNL1 has been demonstrated pre-
viously by immunoprecipitation and mass spectrometry (3).
Regulation of FMNL1 by N-Myristoylation
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We generated an additional N-terminal FMNL1-specific rat
anti-human antibody (8A8) recognizing the peptide PAAPPP-
KQPAPPKQP which was used for immunoprecipitation of
FMNL1. In addition, the following primary and secondary anti-
bodies were used: rabbit anti-human CD3 polyclonal antibody
(Dako), mouse anti-human -tubulin monoclonal antibody
(Santa Cruz Biotechnology), mouse anti-human -tubulin
monoclonal antibody (Sigma), and rabbit anti-human myosin
IIb antibody (Sigma). Appropriate secondary antibodies with
minimal cross-reactivity and conjugation to Cy3, Cy5 (Jack-
son), and Alexa Fluor 488 (Invitrogen) were applied as indi-
cated. Alexa Fluor 488-labeled phalloidin (Invitrogen) was used
to stain actin. For immunoblotting, horseradish peroxidase-
conjugated secondary antibodies to rat and mouse were used.
For inhibition of different targets involved in blebbing the fol-
lowing reagents were used: blebbistatin (Calbiochem) at 1 M,
50 M and 100 M; PP1 (Calbiochem) at 50 M; latrunculin B
(Calbiochem) at 1M, 10M, and 25M; Y-27632 (Sigma) at 90
M; and nocodazole (Calbiochem) at 1 M, 10 M, 100 M, and
200 M. 2-Hydroxymyristic acid (Biozol) was used for inhibi-
tion of N-terminal myristoylation at a concentration of 1 mM.
Immunofluorescence—Nonadherent cells were dropped on
poly-L-lysine-coated coverslips, and adherent cells were set-
tled on sterilized coverslips overnight. Cells were fixed in 3%
paraformaldehyde for 30 min. Cells were then washed (phos-
phate-buffered saline, 0.5% Nonidet P-40, 0.01% NaN3),
blocked with 10% fetal calf serum for 20–30 min and stained
with specific primary and secondary antibodies as indicated.
DAPI (Molecular Probes) was used for nuclear staining.
Glass coverslips were mounted on the cells in mounting
medium (Molecular Probes) and investigated by Leica con-
focal microscopy.
Immunoprecipitation, Immunoblotting, and [3H]Myristic
Acid Uptake Assay—293T cell were transfected with FMNL1
or G2T/A4T and 24 h later biosynthetically labeled with
[3H]myristic acid (0.2mCi/ml) (PerkinElmer) followed by incu-
bation for 16 h in Dulbecco’s modified Eagle’s medium supple-
mented with 5% heat-inactivated fetal bovine serum. Labeled
cells were washed with phosphate-buffered saline and lysed in
lysis buffer (20 mM Tris-HCl, 150 mM NaCl, pH 7.4, 150 mM
Chaps, 1 mM phenylmethylsulfonyl fluoride, 1 mM Na3VO4, 1
mMNaF, 1Complete). FMNL1 andG2T/A4Tproteins were
immunoprecipitated with the FMNL1-specific antibody 8A8
and protein G-Sepharose 4 Fast Flow (Amersham Biosciences).
Eluted proteinswere split and forwarded for SDS-PAGEon two
separated gels. One gel was used for immunoblotting to detect
the presence of FMNL1 using the FMNL1-specific antibody
6F2. The other gel was treated with AmplifyTM fluorographic
reagent (Amersham Biosciences) as indicated by the manufac-
turer and exposed for 12 days to Hyperfilm MP (Amersham
Biosciences) at80 °C using an intensifying screen.
RESULTS
Expression and Localization of Endogenous FMNL1 in
Diverse Hematopoietic Lineage-derived Cells—We have previ-
ously demonstrated protein expression of endogenous human
FMNL1 in different subtypes of PBMCs by Western blotting
using the FMNL1-specific antibody 6F2 (3). Here, we investi-
gated the localization of FMNL1 in these cells by confocal
microscopy. FMNL1 showed a dot-like expression pattern in
the cytoplasma of unstimulated and unspecifically stimulatedT
cells, B cells, andCLL cells (Fig. 1A). InT cells, FMNL1has been
reported to be involved in reorientation of the microtubule-
organizing center toward the immunological synapse (4). We
similarly observed polarization of FMNL1 toward the immuno-
logical synapse after targeting of FMNL1-PP2-specific T cells
FIGURE 1. FMNL1 is expressed in diverse hematopoietic lineage-derived
cells and shows function-specific polarized localization. A, FMNL1 was
visualized in unstimulated and stimulated PBMC subtypes as T cells, B cells,
and malignant B cells from patients with CLL by immunofluorescence stain-
ing with the rat FMNL1-specific antibody 6F2 followed by Cy3-labeled goat
anti-rat antibody. T cells were stimulated with interleukin-2 and OKT3, and B
cells as well as CLL cells were activated using soluble CD40-ligand. Scale bars,
2m. B, to investigate FMNL1 expression in polarized T cells, the FMNL2-PP2-
specific T cell clone SK22 was incubated for 15 min with T2 cells pulsed with
the peptide FMNL1-PP2 at 10 mol. Cells were then fixed and stained with
DAPI for nuclear staining (blue), rabbit anti-human CD3 antibody followed by
Cy5-labeled goat anti-rabbit antibody (yellow) for T cell identification, and rat
FMNL1-specific antibody 6F2 followed by Cy3-labeled goat anti-rat antibody
(red). The microtubule-organizing center was stained with mouse anti-hu-
man-tubulin antibody followedbyAlexa Fluor 488-labeledgoat anti-mouse
antibody (green). Enrichment of FMNL1 and CD3 was observed around the
microtubule-organizing center. Scale bar, 2 m. C, FMNL1 is localized at the
phagocytic cup (white arrows) ofmonocytes during phagocytosis of cells and
platelets. FMNL1 (red) was stained as above, F-actin was stained by Alexa
488-conjugated phalloidin (green), and nuclei were stained with DAPI (blue).
Scale bars, 2 m. Fluorescent images were visualized at room temperature
through a LEICA TCS SP2/405 confocal microscope using the HCX PL APO
objective (63  1.4-0.6 OIL BL) and the LEICA DC 300F camera. The LEICA
confocal software was used for acquisition and analysis (A–C).
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with peptide-pulsed T2 cells (Fig. 1B) (3). Function-associated
localization of endogenous humanFMNL1was also observed at
the phagocytic cup of monocytes during phagocytosis of cells
and platelets (Fig. 1C) being in common with previous investi-
gations of the function of murine FRL. Thus, our results con-
firm expression of human FMNL1 in different hematopoietic
lineage-derived cells as well as involvement in diverse polarized
and membrane-associated processes.
Identification and Cloning of Different FMNL1 Splice Var-
iants—DRFs including FRL have been previously described to
be regulated by autoinhibition, which is dependent on the
C-terminal DAD (5). Using exon-specific primers for the C
FIGURE 2. Identification of a novel FMNL1 splice variant (FMNL1) containing an intron retention at the C terminus. A, schematic diagrams of FMNL1,
FMNL1, FMNL1, and FMNL1DAD constructs used in this study. B, amino acid sequences of the C termini of FMNL1 and , corresponding tomurine FRL
and , as well as of the novel isoform FMNL1 containing a C-terminal intron retention but sharing the final C-terminal amino acids with FMNL1. The DAD
sequence responsible for autoinhibition in themurine homolog is framed, and the identical C-terminal amino acids in FMNL1 and FMNL1 are underlined.AA,
amino acids.C, quantitativemRNAexpression of overall FMNL1 (black bars) and the isoform FMNL1 (gray bars) with specific exon-overlapping primers inwild
type (WT) 293T cells and 293T cells transduced with the different FMNL1 isoforms. The relative quantitative expression compared with skeletal muscle was
calculated using the - cycle threshold method. D–F, quantitative mRNA expression of general FMNL1 (black bars) and isoform-specific FMNL1 (gray bars)
inhealthy tissue (D) and indiverse cell populations isolated fromperipheral bloodofhealthydonors (E) and20patientswithCLL (F). PBMCsubpopulationswere
isolated by negative (CD4, CD8, CD19, and CD14) and positive (CD34) selection. Dendritic cells (DC) were generated by adherence and cytokinematuration (E).
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cDNA of CLL cells and human lung carcinoma, resulting in
varying C-terminal amino acid sequences (Fig. 2A). Two splice
variants are corresponding to the previously described murine
splice variants, FRL and FRL (6, 19). We additionally identi-
fied anotherC-terminal splice variant, FMNL1, containing an
intron retention but sharing the final C terminus with
FMNL1 (Fig. 2B). We selected splice variant-specific exon-
overlapping primers (Fig. 2C) to quantify the mRNA expres-
sion of the novel splice variant FMNL1 in different tissues
and hematopoietic derived cells
by quantitative reverse transcrip-
tion-PCR. FMNL1 shows a similar
tissue-specific mRNA expression
profile compared with the non-
splice-specific expression of FMNL1
(Fig. 2, D and E), although some tis-
sues such as bone marrow, fetal
brain, and thymus show relatively
higher expression of FMNL1 com-
pared with general FMNL1 (3). Of
note, FMNL1 is highly expressed
in malignant cells of a subset of
patients with CLL (Fig. 2F).
FMNL1 and FMNL1 Lacking the
C-terminal DAD Are Located at the
Cell Membrane and Induce Mem-
branous Bleb Formation—Because
FMNL1 differed in the DAD se-
quence representing an important
region for FMNL1 regulation, we
cloned all three different FMNL1
splice variants and investigated
transfected 293T cells by confocal
microscopy. 293T cells transfected
with FMNL1 and FMNL1 showed
mainly intracellular cytoplasmic dis-
tribution of FMNL1, whereas cells
transfected with FMNL1 showed a
distinctmembranous FMNL1 local-
ization aswell as extensive polarized
membrane protrusions and blebs
(Fig. 3A). Similarmembrane protru-
sionswere observed after adenoviral
transduction of K562 cells with
FMNL1 but not with the other
splice variants. However, in these
cells the shape of the blebs was dif-
ferent, and a more prominent
enrichment of FMNL1 at the cell
cortex has been observed (Fig. 3B).
Similarly, 293T cells and K562 cells
transfected or transduced with
FMNL1 lacking the DAD domain
(FMNL1DAD, Fig. 2A) showed
membranous and cortical localiza-
tion of FMNL1 and extensive polar-
ized membrane protrusions and
blebs (Fig. 3, A and B), suggesting
that deregulation of autoinhibition is responsible for mem-
brane localization and blebbing observed in cells overexpress-
ing the splice variant FMNL1. Increase of blebbing was less
obvious in HT1080 and MDA-MB 231 cells after adenoviral
transduction of FMNL1. However, these cell lines also dem-
onstrated FMNL1 localization at the cell membrane and espe-
cially enrichment of FMNL1 at intracellular vesicles, whereas
cells transduced with the other two splice variants had a more
dispersed distribution within the cytoplasma (Fig. 3C). Again,
FIGURE 3. FMNL1 and FMNL1DAD show membranous and cortical localization and induce bleb for-
mation.A, FMNL1 andFMNL1DAD induceextensiveblebbing in 293T cells. 293T cellswere transfectedwith
the pcDNA3.1 vector containing three different isoforms of FMNL1 and analyzed by confocal microscopy after
immunofluorescence stainingwith the rat FMNL1-specific antibody 6F2 followed by Cy3-labeled goat anti-rat
antibody (red). Nuclei were stained with DAPI (blue). Scale bars, 2 m. DIC, differential interference contrast.
B, FMNL1 andFMNL1DAD induceblebbing inK562 cells. FMNL1 isoformswere adenovirally transduced into
K562 cells and analyzed by confocal microscopy as described in A. Scale bars, 2 m. C, FMNL1 and
FMNL1DAD are enhanced in intracellular vesicles of HT1080 and MDA-MB 231 cells. FMNL1 isoforms were
adenovirally transduced into HT1080 and MDA-MB 231 cells and analyzed by confocal microscopy as
described above. Scale bars, 2m.D, F-actin,-tubulin, andmyosin IIb showpolarized localization in FMNL1-
induced blebs in 293T cells. 293T cells were transfected with the pcDNA3.1 vector containing FMNL1 and
stained with rat FMNL1-specific antibody 6F2 followed by Cy3-labeled goat anti-rat antibody (red). Myosin IIb
was stained with a rabbit anti-myosin IIb antibody followed by Cy5-labeled goat anti-rabbit antibody (yellow).
F-actin was stained with Alexa Fluor 488-conjugated phalloidin (green), and -tubulin was stained with a
mouse anti--tubulin antibody followed by Alexa Fluor 488-conjugated goat anti-mouse antibody (green).
Nuclei were stained with DAPI (blue). Scale bars, 2 m. E and F, cell blebbing was quantified by counting 100
FMNL1-transduced cells in 293T cells (E) and K562 cells (F) by independent counting experiments (n  3),
indicating a significant increase of blebbing in cells expressing FMNL1 and FMNL1DAD (***, p  0.001).
Fluorescent images (A–D) were investigated as described in Fig. 1.
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similar localizationwas observed inHT1080 andMDA-MB231
cells after adenoviral transduction of FMNL1DAD (Fig. 3C).
We additionally noticed colocalization of FMNL1 with F-ac-
tin in blebs of FMNL1-transfected 293T cells as shown by
phalloidin staining pointing to an induction of actin assembly
activity by FMNL (Fig. 3D). Myosin IIb and -tubulin were
also polarized to the FMNL1-induced blebs (Fig. 3D). A
significant increase of membrane blebbing in 293T and K562
cells after transduction with FMNL1 and FMNL1DAD
compared with the other splice variants was quantified by
independent counting experiments (Fig. 3, E and F).
Blebbing Induced by FMNL1 Is Independent of Src and
ROCK but Depends on Actin, Myosin, and Tubulin Integrity—
Plasma membrane blebbing has been previously shown to be
induced by the formin FHOD1when coexpressed with ROCK1
(24).Moreover, blebbing induced by FHOD1 requires Src activ-
ity (24). To investigate plasma membrane blebbing induced by
FMNL1 further, we transfected 293T cells with FMNL1 and
added different substances previously reported to inhibitmem-
brane blebbing. Whereas the Src inhibitor PP1 and the ROCK
inhibitor Y-27632 had onlyminimal effects onmembrane bleb-
bing, thiswas grossly reduced by addition of latrunculin B, bleb-
bistatin, and nocodazole (Fig. 4, A and B and supplement Fig.
S1), demonstrating that the mechanism of blebbing induced by
FMNL1 is not mediated by Src and ROCK but depends on
actin, myosin, and tubulin integrity. Similar data were obtained
by FMNL1DAD-transfected 293T cells (data not shown).
FMNL1 IsMyristoylated at the N Terminus—Membrane local-
izationof FMNL1was apredominant feature in 293Tcells trans-
fected with the splice variant FMNL1 and FMNL1DAD. The
mechanism of how FMNL1 is located to the cell membrane
remains elusive. Investigation of the FMNL1 structure by pre-
diction analyses revealed a potential N-terminal myristoylation
site (see the Eukaryotic Linear Motif (ELM) resource on the
Internet). This N-terminal myristoylation motif is highly spe-
cific for the leukocyte-specific formins FMNL1, 2, and 3 inman
andmouse but is not present in other formin proteins. To prove
whether FMNL1 is myristoylated at the N terminus, we
mutated glycine at position 2 and alanine at position 4 to thre-
onine within FMNL1 (G2T/A4T) (Fig. 5A). 293T cells were
transfected with FMNL1 or the G2T/A4T mutant form and
thenmetabolically labeledwith [3H]myristic acid. Total protein
of transfected 293T cells was immunoprecipitated by the
FMNL1-specific antibody 8A8 detecting anN-terminal epitope
not including the N-terminal myristoylation site. Immunopre-
cipitated probes were investigated by immunoblotting using
the FMNL1-specific antibody 6F2 (Fig. 5B) as well as autora-
diography to analyze incorporation of [3H]myristic acid (Fig.
5C). Both proteins, FMNL1 and G2T/A4T, were sufficiently
immunoprecipitated by the FMNL1-specific antibody 8A8 (Fig.
5B). However, only FMNL1, but not G2T/A4T, wasmyristoy-
lated after transfection in 293T cells.
Membrane Localization and Blebbing of FMNL1 Are Medi-
ated by N-terminal Myristoylation—To investigate whether
N-terminal myristoylation plays a role in FMNL1 function and
membrane localization, cells were transfectedwith FMNL1 or
G2T/A4T. The mutant G2T/A4T, in fact, abolished membra-
nous and cortical localization of FMNL1 after transfection of
the mutant splice variant in 293T cells as well as after genetic
transfer of this mutant in other cell lines (Fig. 6A). Similarly,
mutation of the N-myristoylation site in the FMNL1DAD
(G2T/A4TDAD) also abrogated membranous localization of
FMNL1DAD (Fig. 6B). Membrane localization of FMNL1
and FMNL1DAD could be also inhibited by adding 2-hy-
droxymyristate, a potent inhibitor of protein myristoylation
(25), further confirming that plasma membrane localization of
FMNL1 is dependent on N-terminal myristoylation (Fig. 6C).
Blebbing was significantly reduced in 293T cells transfected
withG2T/A4TorG2T/A4TDADcomparedwith FMNL1 or
FMNL1DAD(Fig. 6D), indicating thatmembrane localization
mediated by N-terminal myristoylation is important for bleb
formation induced by FMNL1.
DISCUSSION
Formin proteins have been described to promote the forma-
tion of actin networks and to be involved in regulation of essen-
tial cellular functions such as cell division, migration, adhesion,
and intracellular trafficking. So far, little is known about the
hematopoietic lineage-specific formin FMNL1. Here, we show
expression and polarized localization of native human FMNL1
in different hematopoietic lineage-derived cells, confirming
FIGURE 4. Blebbing induced by FMNL1 is independent of ROCK and Src
but depends on actin, myosin, andmicrotubules. A and B, 293T cells were
transfected with the pcDNA3.1 vector containing FMNL1 and treated with
different bleb inhibitors and solvent controls. Cells were stained after 2 days
with the rat FMNL1-specific antibody 6F2 followed by Cy3-labeled goat anti-
rat antibody (red). Nuclei were stained with DAPI (blue). Scale bars, 2 m.
Blebbing cells were analyzed by confocal microscopy as described in A. Cell
blebbing was quantified by counting 100 FMNL1-transduced cells in three
independent experiments (B), classifying them as cells exhibiting extended
blebs (white bars), limited blebs (black bars), or none (gray bars). DMSO, di-
methyl sulfoxide. The S.D. of independent counting experiments is shown
(n 3; ***, p 0.001).
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previous reports about different functional aspects of human
FMNL1 and murine FRL (4–6).
A complex regulation network seems to be responsible for
activation and different functions of formin proteins. A central
regulative tool for DRFs is autoregulation, which can be
released by interaction with active Rho-GTPases and poten-
tially additional factors (1). Splicing has been also shown to
result in differential functionality of forming proteins (20). We
isolated a novel FMNL1 splice variant (FMNL1) from malig-
nant cells of patients with CLL. This splice variant showed
increased mRNA expression in bone marrow, thymus, fetal
brain, and diverse hematopoietic lineage-derived cells. More-
over, we observed a high expression in malignant cells of a sub-
set of CLL patients. Detailed analyses of systematically isolated
and processed patient samples need to be performed to clarify
whether overexpression of FMNL1 in CLL samples is associ-
ated with an activated malignant cell status and/or patient
prognosis and will be a focus of further studies. However,
although a role of FMNL1 in malignant transformation
could not be ascertained in this study, this splice variant
showed distinct functional properties similar to cells ex-
pressing a mutant of FMNL1 with deregulated autoinhibi-
tion caused by the lack of the autoinhibitory DAD sequence
(FMNL1DAD). FMNL1 contains an intron retention of 58
amino acids at the C terminus but shares the last 30 amino
acids with the previously described FMNL1. This intron
retention affects the DAD sequence
and results in a positive charged
polar amino acid lysine at position
1062 instead of the nonpolar
amino acids leucine or isoleucine
present in FMNL1 and FMNL1.
Because binding of the DAD pep-
tide region to the DID armadillo
repeat structure is mainly depen-
dent on hydrophobic interactions as
described for Dia1 (17, 26), this
polar lysine may be responsible for
release of autoinhibition of FMNL1,
resulting in a constitutively acti-
vated form. In fact, the splice variant
FMNL1 was specifically located at
the membrane and cortex and
induced bleb formation. The shape
and extent of blebs varied in differ-
ent cell lines, indicating that cell
type-specific interaction partners
additionally play an important role
in function and bleb shape. How-
ever, a similar effect on FMNL1
localization and function in diverse
cell lines was observed in cells trans-
fected with a FMNL1 mutant miss-
ing the DAD sequence, confirming
that deregulation of autoinhibition
is responsible for membrane local-
ization and blebbing in FMNL1-
transfected cells. FMNL1 colocal-
ized with F-actin in bleb protrusions, suggesting FMNL1
induced actin assembly. Blebbing but not membrane localiza-
tion of FMNL1was totally abrogated by latrunculin B, further
confirming regulation of actin assembly and actin-mediated
polarized bleb formation by FMNL. We additionally observed
polarization of myosin IIb and -tubulin to FMNL1-induced
blebs in 293T cells. Moreover, bleb formation was significantly
inhibited by blebbistatin and nocodazole, confirming a sub-
stantial role of myosin and microtubules in FMNL1-induced
blebbing. These results are in common with previous reports
demonstrating that bleb induction by the Leishmania parasite
virulence factor HASPB depends on the integrity of F-actin and
requires myosin II function as well as microtubule networks
(27). Moreover, the formins FHOD1, mDia1, and mDia2 have
been also previously associatedwith blebbing (24, 28, 29). How-
ever, in contrast to bleb formation induced by HASPB and
FHOD1 (24, 27), blebbing induced by FMNL1 is independent
of Src and ROCK because the Src inhibitor PP1 and the ROCK
inhibitor Y-27632 did not reduce blebbing in our experiments.
To evaluate the mechanism of membrane localization and
bleb induction by FMNL1 further, we analyzed the protein
sequence motifs of FMNL1 and identified a myristoylation site
at the N terminus of human FMNL1 and murine FRL with
glycine at position 2 representing an essential requirement for
myristoylation. In fact, N-terminal myristoylation of FMNL1
but not the mutant G2T/A4T could be directly proved by
FIGURE 5. FMNL1 contains an N-terminal myristoylation site. A, schematic view of the N terminus of
FMNL1. The predicted N-terminal myristoylation site wasmutated on positions 2 and 4, glycine and alanine to
threonine (gray), respectively.AA, aminoacid.BandC, immunoprecipitationandmetabolic labelingof FMNL1
with [3H]myristic acid. 293T cells transfectedwith FMNL1 or G2T/A4Twere cultured for 16 hwith [3H]myristic
acid. The indicated proteins were immunoprecipitated with the FMNL1-specific monoclonal antibody 8A8 as
well as the isotype control (iso), separated by SDS-PAGE followed by immunoblotting with anti-FMNL1mono-
clonal antibody 6F2 (B) or fluorography (C). Molecular mass sizes are indicated in kDa.
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[3H]myristic acid uptake. Moreover, myristoylation could be
inhibited by 2-hydroxymyristate, a potent inhibitor of myr-
istoylation (25), resulting in loss of membrane localization
and confirming the significance of N-terminal myristoylation
for the specific membranous localization of FMNL1. Loss of
myristoylation by mutation of glycine at position 2 additionally
significantly reduced blebbing induced by FMNL1 and
FMNL1DAD, demonstrating that the induction of blebbing
was dependent on N-terminal myristoylation of FMNL1.
N-terminal myristoylation can facilitate anchoring of proteins
to lipid membranes by hydrophobic interaction of myristate
with themembrane bilayer. Thismotif is typically present in the
SH4 domain of Src kinases, andmyristoylation has been shown
to be critical for malignant transformation of v-Src (30, 31).
Moreover, it has been reported previously that expression of
active SH4 domains is associated with cell blebbing (27). We
therefore propose that activation of FMNL1 is regulated not
only by binding of a Rho-GTPase but additionally by an
increase of intracellular Ca2 or a specific ligand binding. This
may cause a myristoyl switch and therefore induces extrusion
of the myristoyl group, enabling it to interact quickly and
reversibly with lipid bilayermembranes as described previously
for other myristoylated proteins (32, 33). Thus, by its N-termi-
nal myristoylation site, FMNL1, in contrast to other formin
proteins, may be able to perform expeditious cytoskeletal
changes independent of Src and ROCK.
In conclusion, the newly identified splice variant FMNL1
represents a constitutively active form of FMNL1 that local-
izes at the membrane and induces bleb formation. We iden-
tified N-terminal myristoylation as an important regulatory
tool for FMNL1 necessary for bleb formation, enabling fast
and reversible membrane localization compatible with di-
verse functions of hematopoietic lineage-derived cells. The
identification of interaction partners of FMNL1 in diverse
hematopoietic derived cells as well as the further characteriza-
tion of splice variants will be highly interesting to identify key
molecules regulating different FMNL1 functions, potentially
revealing possibilities for specific therapeutic interaction in
malignant and inflammatory diseases.
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